INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1, 128, 'Ketorolac', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (2, 171, 'Ketorolac', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (3, 172, 'Ketorolac', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (4, 173, 'Ketorolac', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5, 3795, 'Ketorolac', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (6, 4624, 'Ketorolac', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (7, 4627, 'Ketorolac', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (8, 6885, 'Ketorolac', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (9, 6886, 'Ketorolac', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (10, 6905, 'Ketorolac', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (11, 6908, 'Ketorolac', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (12, 6909, 'Ketorolac', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (13, 6910, 'Ketorolac', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (14, 17786, 'Ketorolac', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (15, 18780, 'Ketorolac', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (16, 21403, 'Ketorolac', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (17, 25046, 'Ketorolac', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (18, 26490, 'Ketorolac', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (19, 260, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (20, 261, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (21, 262, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (22, 264, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (23, 1498, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (24, 1507, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (25, 1587, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (26, 3793, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (27, 4729, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (28, 4730, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (29, 4731, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (30, 4910, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (31, 6803, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (32, 6870, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (33, 6871, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (34, 6875, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (35, 6876, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (36, 6877, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (37, 6878, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (38, 6879, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (39, 6880, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (40, 6881, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (41, 6884, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (42, 6887, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (43, 6888, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (44, 6889, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (45, 6890, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (46, 6891, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (47, 6893, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (48, 6897, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (49, 6900, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (50, 6901, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (51, 7002, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (52, 7004, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (53, 7005, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (54, 14936, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (55, 17784, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (56, 18250, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (57, 19090, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (58, 19759, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (59, 21357, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (60, 21363, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (61, 21366, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (62, 21367, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (63, 21368, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (64, 21372, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (65, 21386, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (66, 21387, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (67, 21389, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (68, 21391, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (69, 21394, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (70, 21436, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (71, 21437, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (72, 21493, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (73, 22554, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (74, 22555, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (75, 22557, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (76, 25307, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (77, 25308, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (78, 25309, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (79, 25310, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (80, 25311, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (81, 28285, 'Ketoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (82, 728, 'Lacosamide', 'Alcohol may potentiate some of the pharmacologic effects of central nervous system (CNS)-active agents.  Use in combination may result in additive CNS depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (83, 2676, 'Lacosamide', 'Alcohol may potentiate some of the pharmacologic effects of central nervous system (CNS)-active agents.  Use in combination may result in additive CNS depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (84, 4068, 'Lacosamide', 'Alcohol may potentiate some of the pharmacologic effects of central nervous system (CNS)-active agents.  Use in combination may result in additive CNS depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (85, 12338, 'Lacosamide', 'Alcohol may potentiate some of the pharmacologic effects of central nervous system (CNS)-active agents.  Use in combination may result in additive CNS depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (86, 13694, 'Lacosamide', 'Alcohol may potentiate some of the pharmacologic effects of central nervous system (CNS)-active agents.  Use in combination may result in additive CNS depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (87, 14137, 'Lacosamide', 'Alcohol may potentiate some of the pharmacologic effects of central nervous system (CNS)-active agents.  Use in combination may result in additive CNS depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (88, 14138, 'Lacosamide', 'Alcohol may potentiate some of the pharmacologic effects of central nervous system (CNS)-active agents.  Use in combination may result in additive CNS depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (89, 14139, 'Lacosamide', 'Alcohol may potentiate some of the pharmacologic effects of central nervous system (CNS)-active agents.  Use in combination may result in additive CNS depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (90, 14140, 'Lacosamide', 'Alcohol may potentiate some of the pharmacologic effects of central nervous system (CNS)-active agents.  Use in combination may result in additive CNS depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (91, 14141, 'Lacosamide', 'Alcohol may potentiate some of the pharmacologic effects of central nervous system (CNS)-active agents.  Use in combination may result in additive CNS depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (92, 14142, 'Lacosamide', 'Alcohol may potentiate some of the pharmacologic effects of central nervous system (CNS)-active agents.  Use in combination may result in additive CNS depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (93, 21519, 'Lacosamide', 'Alcohol may potentiate some of the pharmacologic effects of central nervous system (CNS)-active agents.  Use in combination may result in additive CNS depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (94, 21520, 'Lacosamide', 'Alcohol may potentiate some of the pharmacologic effects of central nervous system (CNS)-active agents.  Use in combination may result in additive CNS depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (95, 21521, 'Lacosamide', 'Alcohol may potentiate some of the pharmacologic effects of central nervous system (CNS)-active agents.  Use in combination may result in additive CNS depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (96, 21522, 'Lacosamide', 'Alcohol may potentiate some of the pharmacologic effects of central nervous system (CNS)-active agents.  Use in combination may result in additive CNS depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (97, 21523, 'Lacosamide', 'Alcohol may potentiate some of the pharmacologic effects of central nervous system (CNS)-active agents.  Use in combination may result in additive CNS depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (98, 21524, 'Lacosamide', 'Alcohol may potentiate some of the pharmacologic effects of central nervous system (CNS)-active agents.  Use in combination may result in additive CNS depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (99, 30778, 'Lacosamide', 'Alcohol may potentiate some of the pharmacologic effects of central nervous system (CNS)-active agents.  Use in combination may result in additive CNS depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (100, 30779, 'Lacosamide', 'Alcohol may potentiate some of the pharmacologic effects of central nervous system (CNS)-active agents.  Use in combination may result in additive CNS depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (101, 30780, 'Lacosamide', 'Alcohol may potentiate some of the pharmacologic effects of central nervous system (CNS)-active agents.  Use in combination may result in additive CNS depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (102, 30782, 'Lacosamide', 'Alcohol may potentiate some of the pharmacologic effects of central nervous system (CNS)-active agents.  Use in combination may result in additive CNS depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (103, 32258, 'Lacosamide', 'Alcohol may potentiate some of the pharmacologic effects of central nervous system (CNS)-active agents.  Use in combination may result in additive CNS depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (104, 21268, 'Kava', 'The combination of kava and alcohol poses a theoretical risk of additive hepatotoxicity during chronic concomitant use.  Studies in mice also suggest that the hypnotic effects of kava and alcohol may be synergistically increased when taken together, and that alcohol can markedly potentiate the toxicity of kava.', 'alcohol', 'Moderate', 'In general, patients should consult a healthcare provider before taking any herbal or alternative medicine.  Use of kava-containing products with alcohol should be avoided.  Patients using kava should be instructed to discontinue the drug promptly and seek medical attention if signs and symptoms of hepatic injury develop, including fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, and jaundice.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (105, 25736, 'Kava', 'The combination of kava and alcohol poses a theoretical risk of additive hepatotoxicity during chronic concomitant use.  Studies in mice also suggest that the hypnotic effects of kava and alcohol may be synergistically increased when taken together, and that alcohol can markedly potentiate the toxicity of kava.', 'alcohol', 'Moderate', 'In general, patients should consult a healthcare provider before taking any herbal or alternative medicine.  Use of kava-containing products with alcohol should be avoided.  Patients using kava should be instructed to discontinue the drug promptly and seek medical attention if signs and symptoms of hepatic injury develop, including fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, and jaundice.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (106, 4696, 'Labetalol', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (107, 7023, 'Labetalol', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (108, 21511, 'Labetalol', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (109, 21513, 'Labetalol', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (110, 6795, 'Ketamine', 'Alcohol may potentiate some of the pharmacologic effects of ketamine.  Use in combination may result in additive central nervous system (CNS) depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving ketamine should not drink alcohol.  Caution is advised when ketamine is used in patients with acute alcohol intoxication or a history of chronic alcoholism.  Following anesthesia with ketamine, patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination, such as driving or operating hazardous machinery, for at least 24 hours and until they know how the medication affects them.  Patients treated with oral ketamine should also avoid consumption of grapefruit and grapefruit juice during treatment.  Otherwise, dosage reductions of oral ketamine should be considered.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (111, 6864, 'Ketamine', 'Alcohol may potentiate some of the pharmacologic effects of ketamine.  Use in combination may result in additive central nervous system (CNS) depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving ketamine should not drink alcohol.  Caution is advised when ketamine is used in patients with acute alcohol intoxication or a history of chronic alcoholism.  Following anesthesia with ketamine, patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination, such as driving or operating hazardous machinery, for at least 24 hours and until they know how the medication affects them.  Patients treated with oral ketamine should also avoid consumption of grapefruit and grapefruit juice during treatment.  Otherwise, dosage reductions of oral ketamine should be considered.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (112, 6865, 'Ketamine', 'Alcohol may potentiate some of the pharmacologic effects of ketamine.  Use in combination may result in additive central nervous system (CNS) depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving ketamine should not drink alcohol.  Caution is advised when ketamine is used in patients with acute alcohol intoxication or a history of chronic alcoholism.  Following anesthesia with ketamine, patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination, such as driving or operating hazardous machinery, for at least 24 hours and until they know how the medication affects them.  Patients treated with oral ketamine should also avoid consumption of grapefruit and grapefruit juice during treatment.  Otherwise, dosage reductions of oral ketamine should be considered.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (113, 7331, 'Ketamine', 'Alcohol may potentiate some of the pharmacologic effects of ketamine.  Use in combination may result in additive central nervous system (CNS) depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving ketamine should not drink alcohol.  Caution is advised when ketamine is used in patients with acute alcohol intoxication or a history of chronic alcoholism.  Following anesthesia with ketamine, patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination, such as driving or operating hazardous machinery, for at least 24 hours and until they know how the medication affects them.  Patients treated with oral ketamine should also avoid consumption of grapefruit and grapefruit juice during treatment.  Otherwise, dosage reductions of oral ketamine should be considered.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (114, 21359, 'Ketamine', 'Alcohol may potentiate some of the pharmacologic effects of ketamine.  Use in combination may result in additive central nervous system (CNS) depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving ketamine should not drink alcohol.  Caution is advised when ketamine is used in patients with acute alcohol intoxication or a history of chronic alcoholism.  Following anesthesia with ketamine, patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination, such as driving or operating hazardous machinery, for at least 24 hours and until they know how the medication affects them.  Patients treated with oral ketamine should also avoid consumption of grapefruit and grapefruit juice during treatment.  Otherwise, dosage reductions of oral ketamine should be considered.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (115, 23608, 'Ixazomib', 'Food may reduce the oral bioavailability of ixazomib.  A food effect study found that administration of a single 4 mg dose of ixazomib with a high-fat meal decreased ixazomib peak plasma concentration (Cmax) by 69% and systemic exposure (AUC) by 28%.', 'high-fat foods', 'Moderate', 'Ixazomib should be taken at least one hour before or two hours after eating.  On days when both ixazomib and dexamethasone are administered, advise patients to separate dosing times, since dexamethasone should be taken with food while ixazomib should be taken on an empty stomach.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (116, 23609, 'Ixazomib', 'Food may reduce the oral bioavailability of ixazomib.  A food effect study found that administration of a single 4 mg dose of ixazomib with a high-fat meal decreased ixazomib peak plasma concentration (Cmax) by 69% and systemic exposure (AUC) by 28%.', 'high-fat foods', 'Moderate', 'Ixazomib should be taken at least one hour before or two hours after eating.  On days when both ixazomib and dexamethasone are administered, advise patients to separate dosing times, since dexamethasone should be taken with food while ixazomib should be taken on an empty stomach.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (117, 23610, 'Ixazomib', 'Food may reduce the oral bioavailability of ixazomib.  A food effect study found that administration of a single 4 mg dose of ixazomib with a high-fat meal decreased ixazomib peak plasma concentration (Cmax) by 69% and systemic exposure (AUC) by 28%.', 'high-fat foods', 'Moderate', 'Ixazomib should be taken at least one hour before or two hours after eating.  On days when both ixazomib and dexamethasone are administered, advise patients to separate dosing times, since dexamethasone should be taken with food while ixazomib should be taken on an empty stomach.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (118, 3182, 'Ketoconazole', 'Excessive use of alcohol or products containing alcohol together with ketoconazole or levoketoconazole may potentiate the risk of liver injury.  Serious hepatotoxicity has been reported with levoketoconazole.  Fatal hepatotoxicity or requiring liver transplantation have been reported with the use of oral ketoconazole, of which levoketoconazole is an enantiomer.', 'alcohol', 'Moderate', 'Excessive consumption of alcohol should generally be avoided during ketoconazole or levoketoconazole therapy.  Patients receiving ketoconazole or levoketoconazole should be instructed to contact their doctor immediately if they experience swelling, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, abdominal pain, dark colored urine, light colored stools, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (119, 6867, 'Ketoconazole', 'Excessive use of alcohol or products containing alcohol together with ketoconazole or levoketoconazole may potentiate the risk of liver injury.  Serious hepatotoxicity has been reported with levoketoconazole.  Fatal hepatotoxicity or requiring liver transplantation have been reported with the use of oral ketoconazole, of which levoketoconazole is an enantiomer.', 'alcohol', 'Moderate', 'Excessive consumption of alcohol should generally be avoided during ketoconazole or levoketoconazole therapy.  Patients receiving ketoconazole or levoketoconazole should be instructed to contact their doctor immediately if they experience swelling, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, abdominal pain, dark colored urine, light colored stools, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (120, 6868, 'Ketoconazole', 'Excessive use of alcohol or products containing alcohol together with ketoconazole or levoketoconazole may potentiate the risk of liver injury.  Serious hepatotoxicity has been reported with levoketoconazole.  Fatal hepatotoxicity or requiring liver transplantation have been reported with the use of oral ketoconazole, of which levoketoconazole is an enantiomer.', 'alcohol', 'Moderate', 'Excessive consumption of alcohol should generally be avoided during ketoconazole or levoketoconazole therapy.  Patients receiving ketoconazole or levoketoconazole should be instructed to contact their doctor immediately if they experience swelling, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, abdominal pain, dark colored urine, light colored stools, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (121, 6869, 'Ketoconazole', 'Excessive use of alcohol or products containing alcohol together with ketoconazole or levoketoconazole may potentiate the risk of liver injury.  Serious hepatotoxicity has been reported with levoketoconazole.  Fatal hepatotoxicity or requiring liver transplantation have been reported with the use of oral ketoconazole, of which levoketoconazole is an enantiomer.', 'alcohol', 'Moderate', 'Excessive consumption of alcohol should generally be avoided during ketoconazole or levoketoconazole therapy.  Patients receiving ketoconazole or levoketoconazole should be instructed to contact their doctor immediately if they experience swelling, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, abdominal pain, dark colored urine, light colored stools, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (122, 8908, 'Ketoconazole', 'Excessive use of alcohol or products containing alcohol together with ketoconazole or levoketoconazole may potentiate the risk of liver injury.  Serious hepatotoxicity has been reported with levoketoconazole.  Fatal hepatotoxicity or requiring liver transplantation have been reported with the use of oral ketoconazole, of which levoketoconazole is an enantiomer.', 'alcohol', 'Moderate', 'Excessive consumption of alcohol should generally be avoided during ketoconazole or levoketoconazole therapy.  Patients receiving ketoconazole or levoketoconazole should be instructed to contact their doctor immediately if they experience swelling, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, abdominal pain, dark colored urine, light colored stools, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (123, 8914, 'Ketoconazole', 'Excessive use of alcohol or products containing alcohol together with ketoconazole or levoketoconazole may potentiate the risk of liver injury.  Serious hepatotoxicity has been reported with levoketoconazole.  Fatal hepatotoxicity or requiring liver transplantation have been reported with the use of oral ketoconazole, of which levoketoconazole is an enantiomer.', 'alcohol', 'Moderate', 'Excessive consumption of alcohol should generally be avoided during ketoconazole or levoketoconazole therapy.  Patients receiving ketoconazole or levoketoconazole should be instructed to contact their doctor immediately if they experience swelling, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, abdominal pain, dark colored urine, light colored stools, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (124, 8916, 'Ketoconazole', 'Excessive use of alcohol or products containing alcohol together with ketoconazole or levoketoconazole may potentiate the risk of liver injury.  Serious hepatotoxicity has been reported with levoketoconazole.  Fatal hepatotoxicity or requiring liver transplantation have been reported with the use of oral ketoconazole, of which levoketoconazole is an enantiomer.', 'alcohol', 'Moderate', 'Excessive consumption of alcohol should generally be avoided during ketoconazole or levoketoconazole therapy.  Patients receiving ketoconazole or levoketoconazole should be instructed to contact their doctor immediately if they experience swelling, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, abdominal pain, dark colored urine, light colored stools, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (125, 8919, 'Ketoconazole', 'Excessive use of alcohol or products containing alcohol together with ketoconazole or levoketoconazole may potentiate the risk of liver injury.  Serious hepatotoxicity has been reported with levoketoconazole.  Fatal hepatotoxicity or requiring liver transplantation have been reported with the use of oral ketoconazole, of which levoketoconazole is an enantiomer.', 'alcohol', 'Moderate', 'Excessive consumption of alcohol should generally be avoided during ketoconazole or levoketoconazole therapy.  Patients receiving ketoconazole or levoketoconazole should be instructed to contact their doctor immediately if they experience swelling, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, abdominal pain, dark colored urine, light colored stools, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (126, 12764, 'Ketoconazole', 'Excessive use of alcohol or products containing alcohol together with ketoconazole or levoketoconazole may potentiate the risk of liver injury.  Serious hepatotoxicity has been reported with levoketoconazole.  Fatal hepatotoxicity or requiring liver transplantation have been reported with the use of oral ketoconazole, of which levoketoconazole is an enantiomer.', 'alcohol', 'Moderate', 'Excessive consumption of alcohol should generally be avoided during ketoconazole or levoketoconazole therapy.  Patients receiving ketoconazole or levoketoconazole should be instructed to contact their doctor immediately if they experience swelling, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, abdominal pain, dark colored urine, light colored stools, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (127, 12765, 'Ketoconazole', 'Excessive use of alcohol or products containing alcohol together with ketoconazole or levoketoconazole may potentiate the risk of liver injury.  Serious hepatotoxicity has been reported with levoketoconazole.  Fatal hepatotoxicity or requiring liver transplantation have been reported with the use of oral ketoconazole, of which levoketoconazole is an enantiomer.', 'alcohol', 'Moderate', 'Excessive consumption of alcohol should generally be avoided during ketoconazole or levoketoconazole therapy.  Patients receiving ketoconazole or levoketoconazole should be instructed to contact their doctor immediately if they experience swelling, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, abdominal pain, dark colored urine, light colored stools, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (128, 21326, 'Ketoconazole', 'Excessive use of alcohol or products containing alcohol together with ketoconazole or levoketoconazole may potentiate the risk of liver injury.  Serious hepatotoxicity has been reported with levoketoconazole.  Fatal hepatotoxicity or requiring liver transplantation have been reported with the use of oral ketoconazole, of which levoketoconazole is an enantiomer.', 'alcohol', 'Moderate', 'Excessive consumption of alcohol should generally be avoided during ketoconazole or levoketoconazole therapy.  Patients receiving ketoconazole or levoketoconazole should be instructed to contact their doctor immediately if they experience swelling, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, abdominal pain, dark colored urine, light colored stools, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (129, 21481, 'Ketoconazole', 'Excessive use of alcohol or products containing alcohol together with ketoconazole or levoketoconazole may potentiate the risk of liver injury.  Serious hepatotoxicity has been reported with levoketoconazole.  Fatal hepatotoxicity or requiring liver transplantation have been reported with the use of oral ketoconazole, of which levoketoconazole is an enantiomer.', 'alcohol', 'Moderate', 'Excessive consumption of alcohol should generally be avoided during ketoconazole or levoketoconazole therapy.  Patients receiving ketoconazole or levoketoconazole should be instructed to contact their doctor immediately if they experience swelling, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, abdominal pain, dark colored urine, light colored stools, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (130, 21482, 'Ketoconazole', 'Excessive use of alcohol or products containing alcohol together with ketoconazole or levoketoconazole may potentiate the risk of liver injury.  Serious hepatotoxicity has been reported with levoketoconazole.  Fatal hepatotoxicity or requiring liver transplantation have been reported with the use of oral ketoconazole, of which levoketoconazole is an enantiomer.', 'alcohol', 'Moderate', 'Excessive consumption of alcohol should generally be avoided during ketoconazole or levoketoconazole therapy.  Patients receiving ketoconazole or levoketoconazole should be instructed to contact their doctor immediately if they experience swelling, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, abdominal pain, dark colored urine, light colored stools, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (131, 21483, 'Ketoconazole', 'Excessive use of alcohol or products containing alcohol together with ketoconazole or levoketoconazole may potentiate the risk of liver injury.  Serious hepatotoxicity has been reported with levoketoconazole.  Fatal hepatotoxicity or requiring liver transplantation have been reported with the use of oral ketoconazole, of which levoketoconazole is an enantiomer.', 'alcohol', 'Moderate', 'Excessive consumption of alcohol should generally be avoided during ketoconazole or levoketoconazole therapy.  Patients receiving ketoconazole or levoketoconazole should be instructed to contact their doctor immediately if they experience swelling, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, abdominal pain, dark colored urine, light colored stools, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (132, 29644, 'Ketoconazole', 'Excessive use of alcohol or products containing alcohol together with ketoconazole or levoketoconazole may potentiate the risk of liver injury.  Serious hepatotoxicity has been reported with levoketoconazole.  Fatal hepatotoxicity or requiring liver transplantation have been reported with the use of oral ketoconazole, of which levoketoconazole is an enantiomer.', 'alcohol', 'Moderate', 'Excessive consumption of alcohol should generally be avoided during ketoconazole or levoketoconazole therapy.  Patients receiving ketoconazole or levoketoconazole should be instructed to contact their doctor immediately if they experience swelling, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, abdominal pain, dark colored urine, light colored stools, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (133, 0, 'Ivosidenib', 'Grapefruit juice may increase the plasma concentrations of ivosidenib.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.Inhibition of hepatic CYP450 3A4 may also contribute.  The interaction has not been studied with grapefruit juice.', 'grapefruit juice', 'Major', 'Ivosidenib may be administered with or without food, but should not be administered with a high-fat meal.  Patients should avoid consumption of grapefruit and grapefruit juice during treatment with ivosidenib.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (134, 0, 'Abacavir', 'Consumption of ethanol during treatment with abacavir results in a decrease in elimination of abacavir due to the inhibition of alcohol dehydrogenase.', 'alcohol', 'Minor', 'Consumption of ethanol during treatment with abacavir results in a decrease in elimination of abacavir due to the inhibition of alcohol dehydrogenase.  Coadministration of alcohol 0.7 g/kg (equivalent to 5 drinks) and abacavir resulted in a 41% increase in the area under the time concentration curve and a 26% increase in elimination half life.  The clinical significance of this interaction is unknown.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (135, 3008, 'Lamotrigine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (136, 3010, 'Lamotrigine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (137, 3011, 'Lamotrigine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (138, 4022, 'Lamotrigine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (139, 4024, 'Lamotrigine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (140, 4032, 'Lamotrigine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (141, 7074, 'Lamotrigine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (142, 7075, 'Lamotrigine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (143, 7088, 'Lamotrigine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (144, 7089, 'Lamotrigine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (145, 7090, 'Lamotrigine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (146, 7091, 'Lamotrigine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (147, 7114, 'Lamotrigine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (148, 7206, 'Lamotrigine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (149, 21509, 'Lamotrigine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (150, 21510, 'Lamotrigine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (151, 21560, 'Lamotrigine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (152, 21561, 'Lamotrigine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (153, 21583, 'Lamotrigine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (154, 21616, 'Lamotrigine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (155, 21710, 'Lamotrigine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (156, 26360, 'Lamotrigine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (157, 0, 'Ixabepilone', 'Grapefruit juice may increase the plasma concentrations of ixabepilone.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Moderate', 'Patients treated with ixabepilone should avoid the consumption of grapefruit or grapefruit juice.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (158, 21596, 'Lanthanum carbonate', 'Lanthanum carbonate should be administered with food for therapeutic efficacy.  However, it is insoluble in water (<0.01 mg/mL at pH 7.5) and therefore cannot be dissolved in liquid for administration through an enteral feeding tube, because it may result in blockage of the tube.', 'food', 'Moderate', 'Administration of lanthanum carbonate with enteral feedings is not recommended.  Alternative medications such as calcium carbonate suspension should be considered.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (159, 11771, 'Lapatinib', 'Grapefruit juice may increase the plasma concentrations of lapatinib.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Moderate', 'Patients treated with lapatinib should preferably avoid the consumption of grapefruit or grapefruit juice.  The manufacturer recommends that lapatinib be administered at least one hour before or one hour after a meal.  The lapatinib dose is administered once daily and should not be divided.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (160, 0, 'Lanreotide', 'Due to their gastrointestinal pharmacologic effects, somatostatin analogs (e.g., octreotide, lanreotide) may variously affect the absorption of dietary nutrients and concomitantly administered oral medications.  Somatostatin analogs have been shown to prolong gastrointestinal transit time and inhibit intestinal absorption of some nutrients such as fat.', 'food', 'Moderate', 'Clinicians should be aware of the potential for altered absorption of concomitantly administered oral medications during treatment with somatostatin analogs.  Blood levels and clinical response should be monitored, particularly for drugs that have a narrow therapeutic index, and the dosages adjusted as necessary.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (161, 0, 'Larotrectinib', 'Grapefruit juice may increase the plasma concentrations of larotrectinib.  The proposed mechanism is inhibition of CYP450 3A4-mediated metabolism of larotrectinib by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Larotrectinib may be taken with or without food.  Patients should avoid the consumption of grapefruit and grapefruit juice during treatment.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (162, 832, 'Leflunomide', 'The consumption of alcohol during therapy with leflunomide may potentiate the risk of liver injury.', 'alcohol', 'Moderate', 'Patients should be advised to avoid excessive alcohol use during leflunomide treatment.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (163, 978, 'Leflunomide', 'The consumption of alcohol during therapy with leflunomide may potentiate the risk of liver injury.', 'alcohol', 'Moderate', 'Patients should be advised to avoid excessive alcohol use during leflunomide treatment.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (164, 979, 'Leflunomide', 'The consumption of alcohol during therapy with leflunomide may potentiate the risk of liver injury.', 'alcohol', 'Moderate', 'Patients should be advised to avoid excessive alcohol use during leflunomide treatment.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (165, 1149, 'Leflunomide', 'The consumption of alcohol during therapy with leflunomide may potentiate the risk of liver injury.', 'alcohol', 'Moderate', 'Patients should be advised to avoid excessive alcohol use during leflunomide treatment.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (166, 1150, 'Leflunomide', 'The consumption of alcohol during therapy with leflunomide may potentiate the risk of liver injury.', 'alcohol', 'Moderate', 'Patients should be advised to avoid excessive alcohol use during leflunomide treatment.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (167, 1151, 'Leflunomide', 'The consumption of alcohol during therapy with leflunomide may potentiate the risk of liver injury.', 'alcohol', 'Moderate', 'Patients should be advised to avoid excessive alcohol use during leflunomide treatment.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (168, 7176, 'Leflunomide', 'The consumption of alcohol during therapy with leflunomide may potentiate the risk of liver injury.', 'alcohol', 'Moderate', 'Patients should be advised to avoid excessive alcohol use during leflunomide treatment.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (169, 12066, 'Leflunomide', 'The consumption of alcohol during therapy with leflunomide may potentiate the risk of liver injury.', 'alcohol', 'Moderate', 'Patients should be advised to avoid excessive alcohol use during leflunomide treatment.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (170, 13039, 'Leflunomide', 'The consumption of alcohol during therapy with leflunomide may potentiate the risk of liver injury.', 'alcohol', 'Moderate', 'Patients should be advised to avoid excessive alcohol use during leflunomide treatment.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (171, 21678, 'Leflunomide', 'The consumption of alcohol during therapy with leflunomide may potentiate the risk of liver injury.', 'alcohol', 'Moderate', 'Patients should be advised to avoid excessive alcohol use during leflunomide treatment.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (172, 21679, 'Leflunomide', 'The consumption of alcohol during therapy with leflunomide may potentiate the risk of liver injury.', 'alcohol', 'Moderate', 'Patients should be advised to avoid excessive alcohol use during leflunomide treatment.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (173, 25621, 'Leflunomide', 'The consumption of alcohol during therapy with leflunomide may potentiate the risk of liver injury.', 'alcohol', 'Moderate', 'Patients should be advised to avoid excessive alcohol use during leflunomide treatment.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (174, 25622, 'Leflunomide', 'The consumption of alcohol during therapy with leflunomide may potentiate the risk of liver injury.', 'alcohol', 'Moderate', 'Patients should be advised to avoid excessive alcohol use during leflunomide treatment.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (175, 28954, 'Leflunomide', 'The consumption of alcohol during therapy with leflunomide may potentiate the risk of liver injury.', 'alcohol', 'Moderate', 'Patients should be advised to avoid excessive alcohol use during leflunomide treatment.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (176, 28955, 'Leflunomide', 'The consumption of alcohol during therapy with leflunomide may potentiate the risk of liver injury.', 'alcohol', 'Moderate', 'Patients should be advised to avoid excessive alcohol use during leflunomide treatment.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (177, 0, 'Lefamulin', 'Food may reduce the oral bioavailability of lefamulin.  When a single 600 mg oral dose of lefamulin was administered with a high-calorie, high-fat breakfast (800 to 1000 calories; approximately 50% from fat), lefamulin peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by approximately 23% and 18%, respectively.', 'high-fat foods', 'Moderate', 'Lefamulin tablets should be taken at least one hour before or two hours after a meal.  Patients should preferably avoid or limit the consumption of grapefruit and grapefruit juice during treatment with lefamulin.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (178, 0, 'Lefamulin', 'Food may reduce the oral bioavailability of lefamulin.', 'grapefruit juice', 'Moderate', 'Lefamulin tablets should be taken at least one hour before or two hours after a meal.  Patients should preferably avoid or limit the consumption of grapefruit and grapefruit juice during treatment with lefamulin.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (179, 0, 'Lemborexant', 'Alcohol may increase the plasma concentrations and potentiate some of the pharmacologic effects of the central nervous system (CNS)-active agent, lemborexant.  Coadministration with alcohol increased the peak plasma concentration (Cmax) and systemic exposure (AUC) of lemborexant by 35% and 70%, respectively; however, the mechanism of the interaction has not been established.  Use in combination may result in additive CNS depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Major', 'According to the manufacturer, due to their potentially additive effects, the concomitant use of lemborexant with alcohol should be avoided.  Patients should be advised to avoid consumption of alcohol.  Ambulatory patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their doctor if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (180, 0, 'Lemborexant', 'Grapefruit juice may increase the plasma concentrations of lemborexant, which is primarily metabolized by CYP450 3A4.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  Inhibition of hepatic CYP450 3A4 may also contribute.  The interaction has not been studied with grapefruit juice but has been reported for other CYP450 3A4 inhibitors.', 'grapefruit juice', 'Major', 'The manufacturer makes no recommendation regarding administration with food; however, the time to sleep onset may be delayed if taken with or soon after a meal.  Patients should avoid consumption of grapefruit, grapefruit juice, or supplements that contain grapefruit during treatment with lemborexant.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (181, 6796, 'Levamisole', 'Case histories have suggested that levamisole is associated with some side effects (including headache, fever, shivers, and dizziness) that suggest an disulfiram-like interaction with alcohol.  These side effects could be alleviated by total abstinence from alcohol.  No mechanism has been established for this interaction.', 'alcohol', 'Moderate', 'Patients receiving levamisole should avoid alcohol.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (182, 6797, 'Levamisole', 'Case histories have suggested that levamisole is associated with some side effects (including headache, fever, shivers, and dizziness) that suggest an disulfiram-like interaction with alcohol.  These side effects could be alleviated by total abstinence from alcohol.  No mechanism has been established for this interaction.', 'alcohol', 'Moderate', 'Patients receiving levamisole should avoid alcohol.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (183, 21728, 'Levamisole', 'Case histories have suggested that levamisole is associated with some side effects (including headache, fever, shivers, and dizziness) that suggest an disulfiram-like interaction with alcohol.  These side effects could be alleviated by total abstinence from alcohol.  No mechanism has been established for this interaction.', 'alcohol', 'Moderate', 'Patients receiving levamisole should avoid alcohol.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (184, 29690, 'Levamisole', 'Case histories have suggested that levamisole is associated with some side effects (including headache, fever, shivers, and dizziness) that suggest an disulfiram-like interaction with alcohol.  These side effects could be alleviated by total abstinence from alcohol.  No mechanism has been established for this interaction.', 'alcohol', 'Moderate', 'Patients receiving levamisole should avoid alcohol.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (185, 353, 'Levamlodipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (186, 534, 'Levamlodipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (187, 537, 'Levamlodipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (188, 593, 'Levamlodipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (189, 695, 'Levamlodipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (190, 696, 'Levamlodipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (191, 8507, 'Levamlodipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (192, 8508, 'Levamlodipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (193, 9016, 'Levamlodipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (194, 9017, 'Levamlodipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (195, 12101, 'Levamlodipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (196, 12626, 'Levamlodipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (197, 12628, 'Levamlodipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (198, 13749, 'Levamlodipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (199, 13962, 'Levamlodipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (200, 13974, 'Levamlodipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (201, 15854, 'Levamlodipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (202, 16807, 'Levamlodipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (203, 17565, 'Levamlodipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (204, 17700, 'Levamlodipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (205, 23747, 'Levamlodipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (206, 24942, 'Levamlodipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (207, 25793, 'Levamlodipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (208, 25794, 'Levamlodipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (209, 29025, 'Levamlodipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (210, 29026, 'Levamlodipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (211, 29417, 'Levamlodipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (212, 32142, 'Levamlodipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (213, 4666, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (214, 5258, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (215, 6847, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (216, 6848, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (217, 6850, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (218, 6851, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (219, 6852, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (220, 6853, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (221, 6854, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (222, 6965, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (223, 7246, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (224, 7248, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (225, 7250, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (226, 7251, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (227, 7252, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (228, 10584, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (229, 11094, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (230, 11095, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (231, 11096, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (232, 11352, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (233, 11452, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (234, 11456, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (235, 13677, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (236, 19518, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (237, 19519, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (238, 19520, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (239, 19521, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (240, 21226, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (241, 21328, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (242, 21329, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (243, 21330, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (244, 21331, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (245, 21332, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (246, 21339, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (247, 21340, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (248, 21737, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (249, 21738, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (250, 21739, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (251, 21746, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (252, 21920, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (253, 21921, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (254, 21922, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (255, 25687, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (256, 26115, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (257, 26704, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (258, 26705, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (259, 26706, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (260, 27789, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (261, 28215, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (262, 28216, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (263, 28217, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (264, 28218, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (265, 28219, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (266, 28220, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (267, 28221, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (268, 28223, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (269, 28224, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (270, 28225, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (271, 28518, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (272, 28519, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (273, 31324, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (274, 31325, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (275, 31400, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (276, 31493, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (277, 31495, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (278, 32988, 'Levetiracetam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (279, 154, 'Levocetirizine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (280, 375, 'Levocetirizine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (281, 400, 'Levocetirizine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (282, 7207, 'Levocetirizine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (283, 7242, 'Levocetirizine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (284, 7243, 'Levocetirizine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (285, 7261, 'Levocetirizine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (286, 7270, 'Levocetirizine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (287, 12654, 'Levocetirizine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (288, 12655, 'Levocetirizine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (289, 13769, 'Levocetirizine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (290, 13786, 'Levocetirizine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (291, 16227, 'Levocetirizine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (292, 21090, 'Levocetirizine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (293, 21717, 'Levocetirizine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (294, 21735, 'Levocetirizine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (295, 21754, 'Levocetirizine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (296, 21756, 'Levocetirizine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (297, 21767, 'Levocetirizine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (298, 21768, 'Levocetirizine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (299, 21769, 'Levocetirizine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (300, 21836, 'Levocetirizine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (301, 22609, 'Levocetirizine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (302, 22881, 'Levocetirizine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (303, 24258, 'Levocetirizine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (304, 24259, 'Levocetirizine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (305, 28607, 'Levocetirizine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (306, 28608, 'Levocetirizine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (307, 29825, 'Levocetirizine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (308, 31862, 'Levocetirizine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (309, 33460, 'Levocetirizine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (310, 6309, 'Levodopa', 'Alcohol may potentiate some of the pharmacologic effects of levodopa.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'In general, alcohol consumption should be avoided or limited during treatment with CNS-depressant agents.  Until more data are available, it is advisable to avoid large fluctuations in daily protein intake and to monitor patients for altered effects of levodopa if the protein content of the diet is increased.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (311, 10850, 'Levodopa', 'Alcohol may potentiate some of the pharmacologic effects of levodopa.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'In general, alcohol consumption should be avoided or limited during treatment with CNS-depressant agents.  Until more data are available, it is advisable to avoid large fluctuations in daily protein intake and to monitor patients for altered effects of levodopa if the protein content of the diet is increased.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (312, 27442, 'Levodopa', 'Alcohol may potentiate some of the pharmacologic effects of levodopa.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'In general, alcohol consumption should be avoided or limited during treatment with CNS-depressant agents.  Until more data are available, it is advisable to avoid large fluctuations in daily protein intake and to monitor patients for altered effects of levodopa if the protein content of the diet is increased.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (313, 27443, 'Levodopa', 'Alcohol may potentiate some of the pharmacologic effects of levodopa.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'In general, alcohol consumption should be avoided or limited during treatment with CNS-depressant agents.  Until more data are available, it is advisable to avoid large fluctuations in daily protein intake and to monitor patients for altered effects of levodopa if the protein content of the diet is increased.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (314, 27444, 'Levodopa', 'Alcohol may potentiate some of the pharmacologic effects of levodopa.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'In general, alcohol consumption should be avoided or limited during treatment with CNS-depressant agents.  Until more data are available, it is advisable to avoid large fluctuations in daily protein intake and to monitor patients for altered effects of levodopa if the protein content of the diet is increased.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (315, 30279, 'Levodopa', 'Alcohol may potentiate some of the pharmacologic effects of levodopa.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'In general, alcohol consumption should be avoided or limited during treatment with CNS-depressant agents.  Until more data are available, it is advisable to avoid large fluctuations in daily protein intake and to monitor patients for altered effects of levodopa if the protein content of the diet is increased.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (316, 31402, 'Levodopa', 'Alcohol may potentiate some of the pharmacologic effects of levodopa.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'In general, alcohol consumption should be avoided or limited during treatment with CNS-depressant agents.  Until more data are available, it is advisable to avoid large fluctuations in daily protein intake and to monitor patients for altered effects of levodopa if the protein content of the diet is increased.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (317, 33042, 'Levodopa', 'Alcohol may potentiate some of the pharmacologic effects of levodopa.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'In general, alcohol consumption should be avoided or limited during treatment with CNS-depressant agents.  Until more data are available, it is advisable to avoid large fluctuations in daily protein intake and to monitor patients for altered effects of levodopa if the protein content of the diet is increased.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (318, 326, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (319, 327, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (320, 2863, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (321, 4510, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (322, 4967, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (323, 5022, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (324, 5760, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (325, 6679, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (326, 6918, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (327, 6919, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (328, 7113, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (329, 7172, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (330, 7173, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (331, 7174, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (332, 7175, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (333, 7234, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (334, 7235, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (335, 7236, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (336, 7262, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (337, 7263, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (338, 7264, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (339, 7267, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (340, 7268, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (341, 7271, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (342, 7275, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (343, 7277, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (344, 8000, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (345, 8302, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (346, 11185, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (347, 11201, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (348, 11202, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (349, 11203, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (350, 11204, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (351, 11205, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (352, 11209, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (353, 11210, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (354, 11894, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (355, 12162, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (356, 12163, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (357, 12810, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (358, 13106, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (359, 13430, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (360, 13685, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (361, 15307, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (362, 15308, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (363, 16345, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (364, 17139, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (365, 17140, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (366, 18676, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (367, 21404, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (368, 21405, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (369, 21761, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (370, 21762, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (371, 21764, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (372, 21765, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (373, 21772, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (374, 21773, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (375, 21774, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (376, 21776, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (377, 22464, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (378, 22465, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (379, 22932, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (380, 23178, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (381, 23216, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (382, 25557, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (383, 25920, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (384, 26371, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (385, 27931, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (386, 28717, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (387, 28733, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (388, 28734, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (389, 31459, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (390, 32857, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (391, 33578, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (392, 33889, 'Levofloxacin', 'Food may reduce the oral absorption and bioavailability of levofloxacin.  According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.', 'food', 'Moderate', 'To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals.  For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin.  The oral tablets may be taken without regard to food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (393, 16758, 'Levonorgestrel', 'The central nervous system effects and blood levels of ethanol may be increased in patients taking oral contraceptives, although data are lacking and reports are contradictory.  The mechanism may be due to enzyme inhibition.', 'alcohol', 'Minor', 'Consider counseling women about this interaction which is unpredictable.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (394, 21534, 'Levonorgestrel', 'The central nervous system effects and blood levels of ethanol may be increased in patients taking oral contraceptives, although data are lacking and reports are contradictory.  The mechanism may be due to enzyme inhibition.', 'alcohol', 'Minor', 'Consider counseling women about this interaction which is unpredictable.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (395, 22725, 'Levonorgestrel', 'The central nervous system effects and blood levels of ethanol may be increased in patients taking oral contraceptives, although data are lacking and reports are contradictory.  The mechanism may be due to enzyme inhibition.', 'alcohol', 'Minor', 'Consider counseling women about this interaction which is unpredictable.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (396, 22836, 'Levonorgestrel', 'The central nervous system effects and blood levels of ethanol may be increased in patients taking oral contraceptives, although data are lacking and reports are contradictory.  The mechanism may be due to enzyme inhibition.', 'alcohol', 'Minor', 'Consider counseling women about this interaction which is unpredictable.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (397, 25073, 'Levonorgestrel', 'The central nervous system effects and blood levels of ethanol may be increased in patients taking oral contraceptives, although data are lacking and reports are contradictory.  The mechanism may be due to enzyme inhibition.', 'alcohol', 'Minor', 'Consider counseling women about this interaction which is unpredictable.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (398, 16758, 'Levonorgestrel', 'Grapefruit juice may increase the plasma concentrations of orally administered drugs that are substrates of the CYP450 3A4 isoenzyme.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients who regularly consume grapefruit or grapefruit juice should be monitored for adverse effects and altered plasma concentrations of drugs that undergo significant presystemic metabolism by CYP450 3A4.  Grapefruit and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact with these drugs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (399, 21534, 'Levonorgestrel', 'Grapefruit juice may increase the plasma concentrations of orally administered drugs that are substrates of the CYP450 3A4 isoenzyme.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients who regularly consume grapefruit or grapefruit juice should be monitored for adverse effects and altered plasma concentrations of drugs that undergo significant presystemic metabolism by CYP450 3A4.  Grapefruit and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact with these drugs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (400, 22725, 'Levonorgestrel', 'Grapefruit juice may increase the plasma concentrations of orally administered drugs that are substrates of the CYP450 3A4 isoenzyme.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients who regularly consume grapefruit or grapefruit juice should be monitored for adverse effects and altered plasma concentrations of drugs that undergo significant presystemic metabolism by CYP450 3A4.  Grapefruit and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact with these drugs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (401, 22836, 'Levonorgestrel', 'Grapefruit juice may increase the plasma concentrations of orally administered drugs that are substrates of the CYP450 3A4 isoenzyme.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients who regularly consume grapefruit or grapefruit juice should be monitored for adverse effects and altered plasma concentrations of drugs that undergo significant presystemic metabolism by CYP450 3A4.  Grapefruit and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact with these drugs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (402, 25073, 'Levonorgestrel', 'Grapefruit juice may increase the plasma concentrations of orally administered drugs that are substrates of the CYP450 3A4 isoenzyme.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients who regularly consume grapefruit or grapefruit juice should be monitored for adverse effects and altered plasma concentrations of drugs that undergo significant presystemic metabolism by CYP450 3A4.  Grapefruit and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact with these drugs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (403, 4490, 'Levothyroxine', 'Consumption of certain foods as well as the timing of meals relative to dosing may affect the absorption of T4 thyroid hormone (i.e., levothyroxine).  T4 absorption is increased by fasting and decreased by foods such as soybean flour (e.g., infant formula), cotton seed meal, walnuts, dietary fiber, calcium, and calcium fortified juices.', 'dietary fiber', 'Moderate', 'Preparations containing T4 thyroid hormone should be administered on a consistent schedule with regard to time of day and relation to meals so as to avoid large fluctuations in serum levels.  Foods that may affect T4 absorption should be avoided within several hours of dosing if possible.  When administered to patients receiving continuous enteral nutrition for more than 7 days, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of levothyroxine is given and to monitor patients'' thyroid function.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (404, 4491, 'Levothyroxine', 'Consumption of certain foods as well as the timing of meals relative to dosing may affect the absorption of T4 thyroid hormone (i.e., levothyroxine).  T4 absorption is increased by fasting and decreased by foods such as soybean flour (e.g., infant formula), cotton seed meal, walnuts, dietary fiber, calcium, and calcium fortified juices.', 'dietary fiber', 'Moderate', 'Preparations containing T4 thyroid hormone should be administered on a consistent schedule with regard to time of day and relation to meals so as to avoid large fluctuations in serum levels.  Foods that may affect T4 absorption should be avoided within several hours of dosing if possible.  When administered to patients receiving continuous enteral nutrition for more than 7 days, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of levothyroxine is given and to monitor patients'' thyroid function.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (405, 4492, 'Levothyroxine', 'Consumption of certain foods as well as the timing of meals relative to dosing may affect the absorption of T4 thyroid hormone (i.e., levothyroxine).  T4 absorption is increased by fasting and decreased by foods such as soybean flour (e.g., infant formula), cotton seed meal, walnuts, dietary fiber, calcium, and calcium fortified juices.', 'dietary fiber', 'Moderate', 'Preparations containing T4 thyroid hormone should be administered on a consistent schedule with regard to time of day and relation to meals so as to avoid large fluctuations in serum levels.  Foods that may affect T4 absorption should be avoided within several hours of dosing if possible.  When administered to patients receiving continuous enteral nutrition for more than 7 days, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of levothyroxine is given and to monitor patients'' thyroid function.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (406, 11401, 'Levothyroxine', 'Consumption of certain foods as well as the timing of meals relative to dosing may affect the absorption of T4 thyroid hormone (i.e., levothyroxine).  T4 absorption is increased by fasting and decreased by foods such as soybean flour (e.g., infant formula), cotton seed meal, walnuts, dietary fiber, calcium, and calcium fortified juices.', 'dietary fiber', 'Moderate', 'Preparations containing T4 thyroid hormone should be administered on a consistent schedule with regard to time of day and relation to meals so as to avoid large fluctuations in serum levels.  Foods that may affect T4 absorption should be avoided within several hours of dosing if possible.  When administered to patients receiving continuous enteral nutrition for more than 7 days, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of levothyroxine is given and to monitor patients'' thyroid function.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (407, 18658, 'Levothyroxine', 'Consumption of certain foods as well as the timing of meals relative to dosing may affect the absorption of T4 thyroid hormone (i.e., levothyroxine).  T4 absorption is increased by fasting and decreased by foods such as soybean flour (e.g., infant formula), cotton seed meal, walnuts, dietary fiber, calcium, and calcium fortified juices.', 'dietary fiber', 'Moderate', 'Preparations containing T4 thyroid hormone should be administered on a consistent schedule with regard to time of day and relation to meals so as to avoid large fluctuations in serum levels.  Foods that may affect T4 absorption should be avoided within several hours of dosing if possible.  When administered to patients receiving continuous enteral nutrition for more than 7 days, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of levothyroxine is given and to monitor patients'' thyroid function.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (408, 18659, 'Levothyroxine', 'Consumption of certain foods as well as the timing of meals relative to dosing may affect the absorption of T4 thyroid hormone (i.e., levothyroxine).  T4 absorption is increased by fasting and decreased by foods such as soybean flour (e.g., infant formula), cotton seed meal, walnuts, dietary fiber, calcium, and calcium fortified juices.', 'dietary fiber', 'Moderate', 'Preparations containing T4 thyroid hormone should be administered on a consistent schedule with regard to time of day and relation to meals so as to avoid large fluctuations in serum levels.  Foods that may affect T4 absorption should be avoided within several hours of dosing if possible.  When administered to patients receiving continuous enteral nutrition for more than 7 days, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of levothyroxine is given and to monitor patients'' thyroid function.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (409, 27846, 'Levothyroxine', 'Consumption of certain foods as well as the timing of meals relative to dosing may affect the absorption of T4 thyroid hormone (i.e., levothyroxine).  T4 absorption is increased by fasting and decreased by foods such as soybean flour (e.g., infant formula), cotton seed meal, walnuts, dietary fiber, calcium, and calcium fortified juices.', 'dietary fiber', 'Moderate', 'Preparations containing T4 thyroid hormone should be administered on a consistent schedule with regard to time of day and relation to meals so as to avoid large fluctuations in serum levels.  Foods that may affect T4 absorption should be avoided within several hours of dosing if possible.  When administered to patients receiving continuous enteral nutrition for more than 7 days, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of levothyroxine is given and to monitor patients'' thyroid function.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (410, 27847, 'Levothyroxine', 'Consumption of certain foods as well as the timing of meals relative to dosing may affect the absorption of T4 thyroid hormone (i.e., levothyroxine).  T4 absorption is increased by fasting and decreased by foods such as soybean flour (e.g., infant formula), cotton seed meal, walnuts, dietary fiber, calcium, and calcium fortified juices.', 'dietary fiber', 'Moderate', 'Preparations containing T4 thyroid hormone should be administered on a consistent schedule with regard to time of day and relation to meals so as to avoid large fluctuations in serum levels.  Foods that may affect T4 absorption should be avoided within several hours of dosing if possible.  When administered to patients receiving continuous enteral nutrition for more than 7 days, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of levothyroxine is given and to monitor patients'' thyroid function.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (411, 28165, 'Levothyroxine', 'Consumption of certain foods as well as the timing of meals relative to dosing may affect the absorption of T4 thyroid hormone (i.e., levothyroxine).  T4 absorption is increased by fasting and decreased by foods such as soybean flour (e.g., infant formula), cotton seed meal, walnuts, dietary fiber, calcium, and calcium fortified juices.', 'dietary fiber', 'Moderate', 'Preparations containing T4 thyroid hormone should be administered on a consistent schedule with regard to time of day and relation to meals so as to avoid large fluctuations in serum levels.  Foods that may affect T4 absorption should be avoided within several hours of dosing if possible.  When administered to patients receiving continuous enteral nutrition for more than 7 days, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of levothyroxine is given and to monitor patients'' thyroid function.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (412, 28633, 'Levothyroxine', 'Consumption of certain foods as well as the timing of meals relative to dosing may affect the absorption of T4 thyroid hormone (i.e., levothyroxine).  T4 absorption is increased by fasting and decreased by foods such as soybean flour (e.g., infant formula), cotton seed meal, walnuts, dietary fiber, calcium, and calcium fortified juices.', 'dietary fiber', 'Moderate', 'Preparations containing T4 thyroid hormone should be administered on a consistent schedule with regard to time of day and relation to meals so as to avoid large fluctuations in serum levels.  Foods that may affect T4 absorption should be avoided within several hours of dosing if possible.  When administered to patients receiving continuous enteral nutrition for more than 7 days, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of levothyroxine is given and to monitor patients'' thyroid function.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (413, 4490, 'Levothyroxine', 'Consumption of certain foods as well as the timing of meals relative to dosing may affect the absorption of T4 thyroid hormone (i.e., levothyroxine).  T4 absorption is increased by fasting and decreased by foods such as soybean flour (e.g., infant formula), cotton seed meal, walnuts, dietary fiber, calcium, and calcium fortified juices.', 'soybean', 'Moderate', 'Preparations containing T4 thyroid hormone should be administered on a consistent schedule with regard to time of day and relation to meals so as to avoid large fluctuations in serum levels.  Foods that may affect T4 absorption should be avoided within several hours of dosing if possible.  When administered to patients receiving continuous enteral nutrition for more than 7 days, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of levothyroxine is given and to monitor patients'' thyroid function.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (414, 4491, 'Levothyroxine', 'Consumption of certain foods as well as the timing of meals relative to dosing may affect the absorption of T4 thyroid hormone (i.e., levothyroxine).  T4 absorption is increased by fasting and decreased by foods such as soybean flour (e.g., infant formula), cotton seed meal, walnuts, dietary fiber, calcium, and calcium fortified juices.', 'soybean', 'Moderate', 'Preparations containing T4 thyroid hormone should be administered on a consistent schedule with regard to time of day and relation to meals so as to avoid large fluctuations in serum levels.  Foods that may affect T4 absorption should be avoided within several hours of dosing if possible.  When administered to patients receiving continuous enteral nutrition for more than 7 days, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of levothyroxine is given and to monitor patients'' thyroid function.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (415, 4492, 'Levothyroxine', 'Consumption of certain foods as well as the timing of meals relative to dosing may affect the absorption of T4 thyroid hormone (i.e., levothyroxine).  T4 absorption is increased by fasting and decreased by foods such as soybean flour (e.g., infant formula), cotton seed meal, walnuts, dietary fiber, calcium, and calcium fortified juices.', 'soybean', 'Moderate', 'Preparations containing T4 thyroid hormone should be administered on a consistent schedule with regard to time of day and relation to meals so as to avoid large fluctuations in serum levels.  Foods that may affect T4 absorption should be avoided within several hours of dosing if possible.  When administered to patients receiving continuous enteral nutrition for more than 7 days, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of levothyroxine is given and to monitor patients'' thyroid function.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (416, 11401, 'Levothyroxine', 'Consumption of certain foods as well as the timing of meals relative to dosing may affect the absorption of T4 thyroid hormone (i.e., levothyroxine).  T4 absorption is increased by fasting and decreased by foods such as soybean flour (e.g., infant formula), cotton seed meal, walnuts, dietary fiber, calcium, and calcium fortified juices.', 'soybean', 'Moderate', 'Preparations containing T4 thyroid hormone should be administered on a consistent schedule with regard to time of day and relation to meals so as to avoid large fluctuations in serum levels.  Foods that may affect T4 absorption should be avoided within several hours of dosing if possible.  When administered to patients receiving continuous enteral nutrition for more than 7 days, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of levothyroxine is given and to monitor patients'' thyroid function.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (417, 18658, 'Levothyroxine', 'Consumption of certain foods as well as the timing of meals relative to dosing may affect the absorption of T4 thyroid hormone (i.e., levothyroxine).  T4 absorption is increased by fasting and decreased by foods such as soybean flour (e.g., infant formula), cotton seed meal, walnuts, dietary fiber, calcium, and calcium fortified juices.', 'soybean', 'Moderate', 'Preparations containing T4 thyroid hormone should be administered on a consistent schedule with regard to time of day and relation to meals so as to avoid large fluctuations in serum levels.  Foods that may affect T4 absorption should be avoided within several hours of dosing if possible.  When administered to patients receiving continuous enteral nutrition for more than 7 days, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of levothyroxine is given and to monitor patients'' thyroid function.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (418, 18659, 'Levothyroxine', 'Consumption of certain foods as well as the timing of meals relative to dosing may affect the absorption of T4 thyroid hormone (i.e., levothyroxine).  T4 absorption is increased by fasting and decreased by foods such as soybean flour (e.g., infant formula), cotton seed meal, walnuts, dietary fiber, calcium, and calcium fortified juices.', 'soybean', 'Moderate', 'Preparations containing T4 thyroid hormone should be administered on a consistent schedule with regard to time of day and relation to meals so as to avoid large fluctuations in serum levels.  Foods that may affect T4 absorption should be avoided within several hours of dosing if possible.  When administered to patients receiving continuous enteral nutrition for more than 7 days, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of levothyroxine is given and to monitor patients'' thyroid function.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (419, 27846, 'Levothyroxine', 'Consumption of certain foods as well as the timing of meals relative to dosing may affect the absorption of T4 thyroid hormone (i.e., levothyroxine).  T4 absorption is increased by fasting and decreased by foods such as soybean flour (e.g., infant formula), cotton seed meal, walnuts, dietary fiber, calcium, and calcium fortified juices.', 'soybean', 'Moderate', 'Preparations containing T4 thyroid hormone should be administered on a consistent schedule with regard to time of day and relation to meals so as to avoid large fluctuations in serum levels.  Foods that may affect T4 absorption should be avoided within several hours of dosing if possible.  When administered to patients receiving continuous enteral nutrition for more than 7 days, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of levothyroxine is given and to monitor patients'' thyroid function.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (420, 27847, 'Levothyroxine', 'Consumption of certain foods as well as the timing of meals relative to dosing may affect the absorption of T4 thyroid hormone (i.e., levothyroxine).  T4 absorption is increased by fasting and decreased by foods such as soybean flour (e.g., infant formula), cotton seed meal, walnuts, dietary fiber, calcium, and calcium fortified juices.', 'soybean', 'Moderate', 'Preparations containing T4 thyroid hormone should be administered on a consistent schedule with regard to time of day and relation to meals so as to avoid large fluctuations in serum levels.  Foods that may affect T4 absorption should be avoided within several hours of dosing if possible.  When administered to patients receiving continuous enteral nutrition for more than 7 days, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of levothyroxine is given and to monitor patients'' thyroid function.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (421, 28165, 'Levothyroxine', 'Consumption of certain foods as well as the timing of meals relative to dosing may affect the absorption of T4 thyroid hormone (i.e., levothyroxine).  T4 absorption is increased by fasting and decreased by foods such as soybean flour (e.g., infant formula), cotton seed meal, walnuts, dietary fiber, calcium, and calcium fortified juices.', 'soybean', 'Moderate', 'Preparations containing T4 thyroid hormone should be administered on a consistent schedule with regard to time of day and relation to meals so as to avoid large fluctuations in serum levels.  Foods that may affect T4 absorption should be avoided within several hours of dosing if possible.  When administered to patients receiving continuous enteral nutrition for more than 7 days, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of levothyroxine is given and to monitor patients'' thyroid function.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (422, 28633, 'Levothyroxine', 'Consumption of certain foods as well as the timing of meals relative to dosing may affect the absorption of T4 thyroid hormone (i.e., levothyroxine).  T4 absorption is increased by fasting and decreased by foods such as soybean flour (e.g., infant formula), cotton seed meal, walnuts, dietary fiber, calcium, and calcium fortified juices.', 'soybean', 'Moderate', 'Preparations containing T4 thyroid hormone should be administered on a consistent schedule with regard to time of day and relation to meals so as to avoid large fluctuations in serum levels.  Foods that may affect T4 absorption should be avoided within several hours of dosing if possible.  When administered to patients receiving continuous enteral nutrition for more than 7 days, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of levothyroxine is given and to monitor patients'' thyroid function.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (423, 0, 'Levorphanol', 'Ethanol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Moderate', 'Concomitant use of opioid analgesics with ethanol should be avoided.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (424, 6693, 'Levomilnacipran', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (425, 14737, 'Levomilnacipran', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (426, 22757, 'Levomilnacipran', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (427, 22758, 'Levomilnacipran', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (428, 22759, 'Levomilnacipran', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (429, 22760, 'Levomilnacipran', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (430, 22761, 'Levomilnacipran', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (431, 22762, 'Levomilnacipran', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (432, 23184, 'Levomilnacipran', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (433, 5730, 'Linagliptin', 'Alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Hypoglycemia most frequently occurs during acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.  Episodes of hypoglycemia may last for 8 to 12 hours after ethanol ingestion.  By contrast, chronic alcohol abuse can cause impaired glucose tolerance and hyperglycemia.  Moderate alcohol consumption generally does not affect blood glucose levels in patients with well controlled diabetes.  A disulfiram-like reaction (e.g., flushing, headache, and nausea) to alcohol has been reported frequently with the use of chlorpropamide and very rarely with other sulfonylureas.', 'alcohol', 'Moderate', 'Patients with diabetes should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Patients with well controlled diabetes should limit their alcohol intake to one drink daily for women and two drinks daily for men (1 drink = 5 oz wine, 12 oz beer, or 1.5 oz distilled spirits) in conjunction with their normal meal plan.  Alcohol should not be consumed on an empty stomach or following exercise.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (434, 21837, 'Linagliptin', 'Alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Hypoglycemia most frequently occurs during acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.  Episodes of hypoglycemia may last for 8 to 12 hours after ethanol ingestion.  By contrast, chronic alcohol abuse can cause impaired glucose tolerance and hyperglycemia.  Moderate alcohol consumption generally does not affect blood glucose levels in patients with well controlled diabetes.  A disulfiram-like reaction (e.g., flushing, headache, and nausea) to alcohol has been reported frequently with the use of chlorpropamide and very rarely with other sulfonylureas.', 'alcohol', 'Moderate', 'Patients with diabetes should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Patients with well controlled diabetes should limit their alcohol intake to one drink daily for women and two drinks daily for men (1 drink = 5 oz wine, 12 oz beer, or 1.5 oz distilled spirits) in conjunction with their normal meal plan.  Alcohol should not be consumed on an empty stomach or following exercise.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (435, 24136, 'Linagliptin', 'Alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Hypoglycemia most frequently occurs during acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.  Episodes of hypoglycemia may last for 8 to 12 hours after ethanol ingestion.  By contrast, chronic alcohol abuse can cause impaired glucose tolerance and hyperglycemia.  Moderate alcohol consumption generally does not affect blood glucose levels in patients with well controlled diabetes.  A disulfiram-like reaction (e.g., flushing, headache, and nausea) to alcohol has been reported frequently with the use of chlorpropamide and very rarely with other sulfonylureas.', 'alcohol', 'Moderate', 'Patients with diabetes should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Patients with well controlled diabetes should limit their alcohol intake to one drink daily for women and two drinks daily for men (1 drink = 5 oz wine, 12 oz beer, or 1.5 oz distilled spirits) in conjunction with their normal meal plan.  Alcohol should not be consumed on an empty stomach or following exercise.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (436, 25214, 'Linagliptin', 'Alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Hypoglycemia most frequently occurs during acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.  Episodes of hypoglycemia may last for 8 to 12 hours after ethanol ingestion.  By contrast, chronic alcohol abuse can cause impaired glucose tolerance and hyperglycemia.  Moderate alcohol consumption generally does not affect blood glucose levels in patients with well controlled diabetes.  A disulfiram-like reaction (e.g., flushing, headache, and nausea) to alcohol has been reported frequently with the use of chlorpropamide and very rarely with other sulfonylureas.', 'alcohol', 'Moderate', 'Patients with diabetes should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Patients with well controlled diabetes should limit their alcohol intake to one drink daily for women and two drinks daily for men (1 drink = 5 oz wine, 12 oz beer, or 1.5 oz distilled spirits) in conjunction with their normal meal plan.  Alcohol should not be consumed on an empty stomach or following exercise.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (437, 28383, 'Linagliptin', 'Alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Hypoglycemia most frequently occurs during acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.  Episodes of hypoglycemia may last for 8 to 12 hours after ethanol ingestion.  By contrast, chronic alcohol abuse can cause impaired glucose tolerance and hyperglycemia.  Moderate alcohol consumption generally does not affect blood glucose levels in patients with well controlled diabetes.  A disulfiram-like reaction (e.g., flushing, headache, and nausea) to alcohol has been reported frequently with the use of chlorpropamide and very rarely with other sulfonylureas.', 'alcohol', 'Moderate', 'Patients with diabetes should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Patients with well controlled diabetes should limit their alcohol intake to one drink daily for women and two drinks daily for men (1 drink = 5 oz wine, 12 oz beer, or 1.5 oz distilled spirits) in conjunction with their normal meal plan.  Alcohol should not be consumed on an empty stomach or following exercise.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (438, 0, 'Linaclotide', 'Administration of linaclotide in the fed condition resulted in more gastrointestinal side effects and more frequent and looser stools, than when it was administered under fasting conditions.', 'food', 'Moderate', 'It is recommended to take linaclotide 30 minutes before a meal.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (439, 12971, 'Liraglutide', 'Alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Hypoglycemia most frequently occurs during acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.  Episodes of hypoglycemia may last for 8 to 12 hours after ethanol ingestion.  By contrast, chronic alcohol abuse can cause impaired glucose tolerance and hyperglycemia.  Moderate alcohol consumption generally does not affect blood glucose levels in patients with well controlled diabetes.  A disulfiram-like reaction (e.g., flushing, headache, and nausea) to alcohol has been reported frequently with the use of chlorpropamide and very rarely with other sulfonylureas.', 'alcohol', 'Moderate', 'Patients with diabetes should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Patients with well controlled diabetes should limit their alcohol intake to one drink daily for women and two drinks daily for men (1 drink = 5 oz wine, 12 oz beer, or 1.5 oz distilled spirits) in conjunction with their normal meal plan.  Alcohol should not be consumed on an empty stomach or following exercise.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (440, 12972, 'Liraglutide', 'Alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Hypoglycemia most frequently occurs during acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.  Episodes of hypoglycemia may last for 8 to 12 hours after ethanol ingestion.  By contrast, chronic alcohol abuse can cause impaired glucose tolerance and hyperglycemia.  Moderate alcohol consumption generally does not affect blood glucose levels in patients with well controlled diabetes.  A disulfiram-like reaction (e.g., flushing, headache, and nausea) to alcohol has been reported frequently with the use of chlorpropamide and very rarely with other sulfonylureas.', 'alcohol', 'Moderate', 'Patients with diabetes should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Patients with well controlled diabetes should limit their alcohol intake to one drink daily for women and two drinks daily for men (1 drink = 5 oz wine, 12 oz beer, or 1.5 oz distilled spirits) in conjunction with their normal meal plan.  Alcohol should not be consumed on an empty stomach or following exercise.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (441, 0, 'Lisdexamfetamine', 'Alcohol may potentiate the cardiovascular effects of amphetamines.  The exact mechanism of interaction is unknown.', 'alcohol', 'Moderate', 'Concomitant use of amphetamines and alcohol should be avoided if possible, especially in patients with a history of heart disease.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (442, 27247, 'Lixisenatide', 'Alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Hypoglycemia most frequently occurs during acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.  Episodes of hypoglycemia may last for 8 to 12 hours after ethanol ingestion.  By contrast, chronic alcohol abuse can cause impaired glucose tolerance and hyperglycemia.  Moderate alcohol consumption generally does not affect blood glucose levels in patients with well controlled diabetes.  A disulfiram-like reaction (e.g., flushing, headache, and nausea) to alcohol has been reported frequently with the use of chlorpropamide and very rarely with other sulfonylureas.', 'alcohol', 'Moderate', 'Patients with diabetes should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Patients with well controlled diabetes should limit their alcohol intake to one drink daily for women and two drinks daily for men (1 drink = 5 oz wine, 12 oz beer, or 1.5 oz distilled spirits) in conjunction with their normal meal plan.  Alcohol should not be consumed on an empty stomach or following exercise.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (443, 27248, 'Lixisenatide', 'Alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Hypoglycemia most frequently occurs during acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.  Episodes of hypoglycemia may last for 8 to 12 hours after ethanol ingestion.  By contrast, chronic alcohol abuse can cause impaired glucose tolerance and hyperglycemia.  Moderate alcohol consumption generally does not affect blood glucose levels in patients with well controlled diabetes.  A disulfiram-like reaction (e.g., flushing, headache, and nausea) to alcohol has been reported frequently with the use of chlorpropamide and very rarely with other sulfonylureas.', 'alcohol', 'Moderate', 'Patients with diabetes should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Patients with well controlled diabetes should limit their alcohol intake to one drink daily for women and two drinks daily for men (1 drink = 5 oz wine, 12 oz beer, or 1.5 oz distilled spirits) in conjunction with their normal meal plan.  Alcohol should not be consumed on an empty stomach or following exercise.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (444, 27247, 'Lixisenatide', 'Lixisenatide slows gastric emptying, which may impact the absorption of concomitantly administered oral medications.  The interaction has been studied with various medications, which demonstrated primarily an effect on the rate rather than the overall extent of absorption.', 'food', 'Moderate', 'Caution is advised during concomitant use of lixisenatide with oral medications that have a narrow therapeutic index or that require careful clinical monitoring.  These medications should be administered on a consistent schedule relative to lixisenatide, and blood levels and/or pharmacologic effects should be closely monitored.  In addition, if they are to be administered with food, patients should be advised to take them with a meal or snack when lixisenatide is not administered.  Oral medications that are particularly dependent on threshold concentrations for efficacy, such as antibiotics, or medications for which a delay in effect is undesirable, such as acetaminophen, should be administered at least 1 hour before lixisenatide.  Gastro-resistant formulations containing substances sensitive to stomach degradation should be administered 1 hour before or 4 hours after lixisenatide.  Patients taking oral contraceptives should be advised to take them at least 1 hour before or 11 hours after lixisenatide.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (445, 27248, 'Lixisenatide', 'Lixisenatide slows gastric emptying, which may impact the absorption of concomitantly administered oral medications.  The interaction has been studied with various medications, which demonstrated primarily an effect on the rate rather than the overall extent of absorption.', 'food', 'Moderate', 'Caution is advised during concomitant use of lixisenatide with oral medications that have a narrow therapeutic index or that require careful clinical monitoring.  These medications should be administered on a consistent schedule relative to lixisenatide, and blood levels and/or pharmacologic effects should be closely monitored.  In addition, if they are to be administered with food, patients should be advised to take them with a meal or snack when lixisenatide is not administered.  Oral medications that are particularly dependent on threshold concentrations for efficacy, such as antibiotics, or medications for which a delay in effect is undesirable, such as acetaminophen, should be administered at least 1 hour before lixisenatide.  Gastro-resistant formulations containing substances sensitive to stomach degradation should be administered 1 hour before or 4 hours after lixisenatide.  Patients taking oral contraceptives should be advised to take them at least 1 hour before or 11 hours after lixisenatide.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (446, 6423, 'Loperamide', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (447, 22017, 'Loperamide', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (448, 22019, 'Loperamide', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (449, 27540, 'Loperamide', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (450, 30846, 'Loperamide', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (451, 7430, 'Lisinopril', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (452, 7432, 'Lisinopril', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (453, 10527, 'Lisinopril', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (454, 12818, 'Lisinopril', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (455, 12820, 'Lisinopril', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (456, 22401, 'Lisinopril', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (457, 22402, 'Lisinopril', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (458, 27051, 'Lisinopril', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (459, 27052, 'Lisinopril', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (460, 29893, 'Lisinopril', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (461, 33638, 'Lisinopril', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (462, 7430, 'Lisinopril', 'Moderate-to-high dietary intake of potassium can cause hyperkalemia in some patients who are using angiotensin converting enzyme (ACE) inhibitors.  In some cases, affected patients were using a potassium-rich salt substitute.  ACE inhibitors can promote hyperkalemia through inhibition of the renin-aldosterone-angiotensin (RAA) system.', 'Food High in Potassium', 'Moderate', 'It is recommended that patients who are taking ACE inhibitors be advised to avoid moderately high or high potassium dietary intake.  Particular attention should be paid to the potassium content of salt substitutes.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (463, 7432, 'Lisinopril', 'Moderate-to-high dietary intake of potassium can cause hyperkalemia in some patients who are using angiotensin converting enzyme (ACE) inhibitors.  In some cases, affected patients were using a potassium-rich salt substitute.  ACE inhibitors can promote hyperkalemia through inhibition of the renin-aldosterone-angiotensin (RAA) system.', 'Food High in Potassium', 'Moderate', 'It is recommended that patients who are taking ACE inhibitors be advised to avoid moderately high or high potassium dietary intake.  Particular attention should be paid to the potassium content of salt substitutes.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (464, 10527, 'Lisinopril', 'Moderate-to-high dietary intake of potassium can cause hyperkalemia in some patients who are using angiotensin converting enzyme (ACE) inhibitors.  In some cases, affected patients were using a potassium-rich salt substitute.  ACE inhibitors can promote hyperkalemia through inhibition of the renin-aldosterone-angiotensin (RAA) system.', 'Food High in Potassium', 'Moderate', 'It is recommended that patients who are taking ACE inhibitors be advised to avoid moderately high or high potassium dietary intake.  Particular attention should be paid to the potassium content of salt substitutes.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (465, 12818, 'Lisinopril', 'Moderate-to-high dietary intake of potassium can cause hyperkalemia in some patients who are using angiotensin converting enzyme (ACE) inhibitors.  In some cases, affected patients were using a potassium-rich salt substitute.  ACE inhibitors can promote hyperkalemia through inhibition of the renin-aldosterone-angiotensin (RAA) system.', 'Food High in Potassium', 'Moderate', 'It is recommended that patients who are taking ACE inhibitors be advised to avoid moderately high or high potassium dietary intake.  Particular attention should be paid to the potassium content of salt substitutes.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (466, 12820, 'Lisinopril', 'Moderate-to-high dietary intake of potassium can cause hyperkalemia in some patients who are using angiotensin converting enzyme (ACE) inhibitors.  In some cases, affected patients were using a potassium-rich salt substitute.  ACE inhibitors can promote hyperkalemia through inhibition of the renin-aldosterone-angiotensin (RAA) system.', 'Food High in Potassium', 'Moderate', 'It is recommended that patients who are taking ACE inhibitors be advised to avoid moderately high or high potassium dietary intake.  Particular attention should be paid to the potassium content of salt substitutes.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (467, 22401, 'Lisinopril', 'Moderate-to-high dietary intake of potassium can cause hyperkalemia in some patients who are using angiotensin converting enzyme (ACE) inhibitors.  In some cases, affected patients were using a potassium-rich salt substitute.  ACE inhibitors can promote hyperkalemia through inhibition of the renin-aldosterone-angiotensin (RAA) system.', 'Food High in Potassium', 'Moderate', 'It is recommended that patients who are taking ACE inhibitors be advised to avoid moderately high or high potassium dietary intake.  Particular attention should be paid to the potassium content of salt substitutes.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (468, 22402, 'Lisinopril', 'Moderate-to-high dietary intake of potassium can cause hyperkalemia in some patients who are using angiotensin converting enzyme (ACE) inhibitors.  In some cases, affected patients were using a potassium-rich salt substitute.  ACE inhibitors can promote hyperkalemia through inhibition of the renin-aldosterone-angiotensin (RAA) system.', 'Food High in Potassium', 'Moderate', 'It is recommended that patients who are taking ACE inhibitors be advised to avoid moderately high or high potassium dietary intake.  Particular attention should be paid to the potassium content of salt substitutes.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (469, 27051, 'Lisinopril', 'Moderate-to-high dietary intake of potassium can cause hyperkalemia in some patients who are using angiotensin converting enzyme (ACE) inhibitors.  In some cases, affected patients were using a potassium-rich salt substitute.  ACE inhibitors can promote hyperkalemia through inhibition of the renin-aldosterone-angiotensin (RAA) system.', 'Food High in Potassium', 'Moderate', 'It is recommended that patients who are taking ACE inhibitors be advised to avoid moderately high or high potassium dietary intake.  Particular attention should be paid to the potassium content of salt substitutes.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (470, 27052, 'Lisinopril', 'Moderate-to-high dietary intake of potassium can cause hyperkalemia in some patients who are using angiotensin converting enzyme (ACE) inhibitors.  In some cases, affected patients were using a potassium-rich salt substitute.  ACE inhibitors can promote hyperkalemia through inhibition of the renin-aldosterone-angiotensin (RAA) system.', 'Food High in Potassium', 'Moderate', 'It is recommended that patients who are taking ACE inhibitors be advised to avoid moderately high or high potassium dietary intake.  Particular attention should be paid to the potassium content of salt substitutes.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (471, 29893, 'Lisinopril', 'Moderate-to-high dietary intake of potassium can cause hyperkalemia in some patients who are using angiotensin converting enzyme (ACE) inhibitors.  In some cases, affected patients were using a potassium-rich salt substitute.  ACE inhibitors can promote hyperkalemia through inhibition of the renin-aldosterone-angiotensin (RAA) system.', 'Food High in Potassium', 'Moderate', 'It is recommended that patients who are taking ACE inhibitors be advised to avoid moderately high or high potassium dietary intake.  Particular attention should be paid to the potassium content of salt substitutes.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (472, 33638, 'Lisinopril', 'Moderate-to-high dietary intake of potassium can cause hyperkalemia in some patients who are using angiotensin converting enzyme (ACE) inhibitors.  In some cases, affected patients were using a potassium-rich salt substitute.  ACE inhibitors can promote hyperkalemia through inhibition of the renin-aldosterone-angiotensin (RAA) system.', 'Food High in Potassium', 'Moderate', 'It is recommended that patients who are taking ACE inhibitors be advised to avoid moderately high or high potassium dietary intake.  Particular attention should be paid to the potassium content of salt substitutes.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (473, 5798, 'Lithium carbonate', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (474, 25225, 'Lithium carbonate', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (475, 2702, 'Loratadine', 'Theoretically, grapefruit juice may increase the plasma concentrations of loratadine as it does other drugs that are substrates of the CYP450 3A4 enzymatic pathway.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Minor', 'The clinical significance of this potential interaction is unknown.  Reported interactions with potent CYP450 3A4 inhibitors like clarithromycin, erythromycin and ketoconazole have produced substantial increases in the area under the plasma concentration-time curve (AUC) of loratadine and its active metabolite, descarboethoxyloratadine, without associated changes in the overall safety profile of the drug.Therefore, no additional therapeutic adjustments were required.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (476, 2703, 'Loratadine', 'Theoretically, grapefruit juice may increase the plasma concentrations of loratadine as it does other drugs that are substrates of the CYP450 3A4 enzymatic pathway.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Minor', 'The clinical significance of this potential interaction is unknown.  Reported interactions with potent CYP450 3A4 inhibitors like clarithromycin, erythromycin and ketoconazole have produced substantial increases in the area under the plasma concentration-time curve (AUC) of loratadine and its active metabolite, descarboethoxyloratadine, without associated changes in the overall safety profile of the drug.Therefore, no additional therapeutic adjustments were required.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (477, 7525, 'Loratadine', 'Theoretically, grapefruit juice may increase the plasma concentrations of loratadine as it does other drugs that are substrates of the CYP450 3A4 enzymatic pathway.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Minor', 'The clinical significance of this potential interaction is unknown.  Reported interactions with potent CYP450 3A4 inhibitors like clarithromycin, erythromycin and ketoconazole have produced substantial increases in the area under the plasma concentration-time curve (AUC) of loratadine and its active metabolite, descarboethoxyloratadine, without associated changes in the overall safety profile of the drug.Therefore, no additional therapeutic adjustments were required.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (478, 7530, 'Loratadine', 'Theoretically, grapefruit juice may increase the plasma concentrations of loratadine as it does other drugs that are substrates of the CYP450 3A4 enzymatic pathway.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Minor', 'The clinical significance of this potential interaction is unknown.  Reported interactions with potent CYP450 3A4 inhibitors like clarithromycin, erythromycin and ketoconazole have produced substantial increases in the area under the plasma concentration-time curve (AUC) of loratadine and its active metabolite, descarboethoxyloratadine, without associated changes in the overall safety profile of the drug.Therefore, no additional therapeutic adjustments were required.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (479, 8338, 'Loratadine', 'Theoretically, grapefruit juice may increase the plasma concentrations of loratadine as it does other drugs that are substrates of the CYP450 3A4 enzymatic pathway.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Minor', 'The clinical significance of this potential interaction is unknown.  Reported interactions with potent CYP450 3A4 inhibitors like clarithromycin, erythromycin and ketoconazole have produced substantial increases in the area under the plasma concentration-time curve (AUC) of loratadine and its active metabolite, descarboethoxyloratadine, without associated changes in the overall safety profile of the drug.Therefore, no additional therapeutic adjustments were required.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (480, 13780, 'Loratadine', 'Theoretically, grapefruit juice may increase the plasma concentrations of loratadine as it does other drugs that are substrates of the CYP450 3A4 enzymatic pathway.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Minor', 'The clinical significance of this potential interaction is unknown.  Reported interactions with potent CYP450 3A4 inhibitors like clarithromycin, erythromycin and ketoconazole have produced substantial increases in the area under the plasma concentration-time curve (AUC) of loratadine and its active metabolite, descarboethoxyloratadine, without associated changes in the overall safety profile of the drug.Therefore, no additional therapeutic adjustments were required.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (481, 13784, 'Loratadine', 'Theoretically, grapefruit juice may increase the plasma concentrations of loratadine as it does other drugs that are substrates of the CYP450 3A4 enzymatic pathway.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Minor', 'The clinical significance of this potential interaction is unknown.  Reported interactions with potent CYP450 3A4 inhibitors like clarithromycin, erythromycin and ketoconazole have produced substantial increases in the area under the plasma concentration-time curve (AUC) of loratadine and its active metabolite, descarboethoxyloratadine, without associated changes in the overall safety profile of the drug.Therefore, no additional therapeutic adjustments were required.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (482, 13785, 'Loratadine', 'Theoretically, grapefruit juice may increase the plasma concentrations of loratadine as it does other drugs that are substrates of the CYP450 3A4 enzymatic pathway.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Minor', 'The clinical significance of this potential interaction is unknown.  Reported interactions with potent CYP450 3A4 inhibitors like clarithromycin, erythromycin and ketoconazole have produced substantial increases in the area under the plasma concentration-time curve (AUC) of loratadine and its active metabolite, descarboethoxyloratadine, without associated changes in the overall safety profile of the drug.Therefore, no additional therapeutic adjustments were required.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (483, 20512, 'Loratadine', 'Theoretically, grapefruit juice may increase the plasma concentrations of loratadine as it does other drugs that are substrates of the CYP450 3A4 enzymatic pathway.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Minor', 'The clinical significance of this potential interaction is unknown.  Reported interactions with potent CYP450 3A4 inhibitors like clarithromycin, erythromycin and ketoconazole have produced substantial increases in the area under the plasma concentration-time curve (AUC) of loratadine and its active metabolite, descarboethoxyloratadine, without associated changes in the overall safety profile of the drug.Therefore, no additional therapeutic adjustments were required.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (484, 22027, 'Loratadine', 'Theoretically, grapefruit juice may increase the plasma concentrations of loratadine as it does other drugs that are substrates of the CYP450 3A4 enzymatic pathway.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Minor', 'The clinical significance of this potential interaction is unknown.  Reported interactions with potent CYP450 3A4 inhibitors like clarithromycin, erythromycin and ketoconazole have produced substantial increases in the area under the plasma concentration-time curve (AUC) of loratadine and its active metabolite, descarboethoxyloratadine, without associated changes in the overall safety profile of the drug.Therefore, no additional therapeutic adjustments were required.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (485, 22030, 'Loratadine', 'Theoretically, grapefruit juice may increase the plasma concentrations of loratadine as it does other drugs that are substrates of the CYP450 3A4 enzymatic pathway.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Minor', 'The clinical significance of this potential interaction is unknown.  Reported interactions with potent CYP450 3A4 inhibitors like clarithromycin, erythromycin and ketoconazole have produced substantial increases in the area under the plasma concentration-time curve (AUC) of loratadine and its active metabolite, descarboethoxyloratadine, without associated changes in the overall safety profile of the drug.Therefore, no additional therapeutic adjustments were required.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (486, 22031, 'Loratadine', 'Theoretically, grapefruit juice may increase the plasma concentrations of loratadine as it does other drugs that are substrates of the CYP450 3A4 enzymatic pathway.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Minor', 'The clinical significance of this potential interaction is unknown.  Reported interactions with potent CYP450 3A4 inhibitors like clarithromycin, erythromycin and ketoconazole have produced substantial increases in the area under the plasma concentration-time curve (AUC) of loratadine and its active metabolite, descarboethoxyloratadine, without associated changes in the overall safety profile of the drug.Therefore, no additional therapeutic adjustments were required.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (487, 22032, 'Loratadine', 'Theoretically, grapefruit juice may increase the plasma concentrations of loratadine as it does other drugs that are substrates of the CYP450 3A4 enzymatic pathway.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Minor', 'The clinical significance of this potential interaction is unknown.  Reported interactions with potent CYP450 3A4 inhibitors like clarithromycin, erythromycin and ketoconazole have produced substantial increases in the area under the plasma concentration-time curve (AUC) of loratadine and its active metabolite, descarboethoxyloratadine, without associated changes in the overall safety profile of the drug.Therefore, no additional therapeutic adjustments were required.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (488, 22033, 'Loratadine', 'Theoretically, grapefruit juice may increase the plasma concentrations of loratadine as it does other drugs that are substrates of the CYP450 3A4 enzymatic pathway.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Minor', 'The clinical significance of this potential interaction is unknown.  Reported interactions with potent CYP450 3A4 inhibitors like clarithromycin, erythromycin and ketoconazole have produced substantial increases in the area under the plasma concentration-time curve (AUC) of loratadine and its active metabolite, descarboethoxyloratadine, without associated changes in the overall safety profile of the drug.Therefore, no additional therapeutic adjustments were required.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (489, 22041, 'Loratadine', 'Theoretically, grapefruit juice may increase the plasma concentrations of loratadine as it does other drugs that are substrates of the CYP450 3A4 enzymatic pathway.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Minor', 'The clinical significance of this potential interaction is unknown.  Reported interactions with potent CYP450 3A4 inhibitors like clarithromycin, erythromycin and ketoconazole have produced substantial increases in the area under the plasma concentration-time curve (AUC) of loratadine and its active metabolite, descarboethoxyloratadine, without associated changes in the overall safety profile of the drug.Therefore, no additional therapeutic adjustments were required.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (490, 22993, 'Loratadine', 'Theoretically, grapefruit juice may increase the plasma concentrations of loratadine as it does other drugs that are substrates of the CYP450 3A4 enzymatic pathway.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Minor', 'The clinical significance of this potential interaction is unknown.  Reported interactions with potent CYP450 3A4 inhibitors like clarithromycin, erythromycin and ketoconazole have produced substantial increases in the area under the plasma concentration-time curve (AUC) of loratadine and its active metabolite, descarboethoxyloratadine, without associated changes in the overall safety profile of the drug.Therefore, no additional therapeutic adjustments were required.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (491, 26628, 'Loratadine', 'Theoretically, grapefruit juice may increase the plasma concentrations of loratadine as it does other drugs that are substrates of the CYP450 3A4 enzymatic pathway.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Minor', 'The clinical significance of this potential interaction is unknown.  Reported interactions with potent CYP450 3A4 inhibitors like clarithromycin, erythromycin and ketoconazole have produced substantial increases in the area under the plasma concentration-time curve (AUC) of loratadine and its active metabolite, descarboethoxyloratadine, without associated changes in the overall safety profile of the drug.Therefore, no additional therapeutic adjustments were required.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (492, 26629, 'Loratadine', 'Theoretically, grapefruit juice may increase the plasma concentrations of loratadine as it does other drugs that are substrates of the CYP450 3A4 enzymatic pathway.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Minor', 'The clinical significance of this potential interaction is unknown.  Reported interactions with potent CYP450 3A4 inhibitors like clarithromycin, erythromycin and ketoconazole have produced substantial increases in the area under the plasma concentration-time curve (AUC) of loratadine and its active metabolite, descarboethoxyloratadine, without associated changes in the overall safety profile of the drug.Therefore, no additional therapeutic adjustments were required.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (493, 26681, 'Loratadine', 'Theoretically, grapefruit juice may increase the plasma concentrations of loratadine as it does other drugs that are substrates of the CYP450 3A4 enzymatic pathway.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Minor', 'The clinical significance of this potential interaction is unknown.  Reported interactions with potent CYP450 3A4 inhibitors like clarithromycin, erythromycin and ketoconazole have produced substantial increases in the area under the plasma concentration-time curve (AUC) of loratadine and its active metabolite, descarboethoxyloratadine, without associated changes in the overall safety profile of the drug.Therefore, no additional therapeutic adjustments were required.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (494, 28731, 'Loratadine', 'Theoretically, grapefruit juice may increase the plasma concentrations of loratadine as it does other drugs that are substrates of the CYP450 3A4 enzymatic pathway.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Minor', 'The clinical significance of this potential interaction is unknown.  Reported interactions with potent CYP450 3A4 inhibitors like clarithromycin, erythromycin and ketoconazole have produced substantial increases in the area under the plasma concentration-time curve (AUC) of loratadine and its active metabolite, descarboethoxyloratadine, without associated changes in the overall safety profile of the drug.Therefore, no additional therapeutic adjustments were required.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (495, 28732, 'Loratadine', 'Theoretically, grapefruit juice may increase the plasma concentrations of loratadine as it does other drugs that are substrates of the CYP450 3A4 enzymatic pathway.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Minor', 'The clinical significance of this potential interaction is unknown.  Reported interactions with potent CYP450 3A4 inhibitors like clarithromycin, erythromycin and ketoconazole have produced substantial increases in the area under the plasma concentration-time curve (AUC) of loratadine and its active metabolite, descarboethoxyloratadine, without associated changes in the overall safety profile of the drug.Therefore, no additional therapeutic adjustments were required.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (496, 0, 'Loracarbef', 'Loracarbef may exhibit reduced gastrointestinal absorption in the presence of food.', 'food', 'Moderate', 'Loracarbef should be administered at least one hour before or two hours after eating.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (497, 871, 'Lorazepam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (498, 0, 'Lonafarnib', 'Grapefruit juice may increase the plasma concentrations of lonafarnib.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  Inhibition of hepatic CYP450 3A4 may also contribute.  The interaction has not been studied with grapefruit juice, but has been reported for other CYP450 3A4 inhibitors.', 'grapefruit juice', 'Major', 'Lonafarnib should be administered with the morning and evening meals and an adequate amount of water.  Patients should avoid consumption of grapefruit or grapefruit juice and Seville oranges (also known as bitter or sour oranges).during treatment with lonafarnib.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (499, 0, 'Liotrix', 'Consumption of certain foods as well as the timing of meals relative to dosing may affect the absorption of T4 thyroid hormone (i.e., levothyroxine).  T4 absorption is increased by fasting and decreased by foods such as soybean flour (e.g., infant formula), cotton seed meal, walnuts, dietary fiber, calcium, and calcium fortified juices.', 'soybean', 'Moderate', 'Preparations containing T4 thyroid hormone should be administered on a consistent schedule with regard to time of day and relation to meals so as to avoid large fluctuations in serum levels.  Foods that may affect T4 absorption should be avoided within several hours of dosing if possible.  When administered to patients receiving continuous enteral nutrition for more than 7 days, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of levothyroxine is given and to monitor patients'' thyroid function.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (500, 0, 'Liotrix', 'Consumption of certain foods as well as the timing of meals relative to dosing may affect the absorption of T4 thyroid hormone (i.e., levothyroxine).  T4 absorption is increased by fasting and decreased by foods such as soybean flour (e.g., infant formula), cotton seed meal, walnuts, dietary fiber, calcium, and calcium fortified juices.', 'cotton seed', 'Moderate', 'Preparations containing T4 thyroid hormone should be administered on a consistent schedule with regard to time of day and relation to meals so as to avoid large fluctuations in serum levels.  Foods that may affect T4 absorption should be avoided within several hours of dosing if possible.  When administered to patients receiving continuous enteral nutrition for more than 7 days, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of levothyroxine is given and to monitor patients'' thyroid function.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (501, 0, 'Liotrix', 'Consumption of certain foods as well as the timing of meals relative to dosing may affect the absorption of T4 thyroid hormone (i.e., levothyroxine).  T4 absorption is increased by fasting and decreased by foods such as soybean flour (e.g., infant formula), cotton seed meal, walnuts, dietary fiber, calcium, and calcium fortified juices.', 'walnuts', 'Moderate', 'Preparations containing T4 thyroid hormone should be administered on a consistent schedule with regard to time of day and relation to meals so as to avoid large fluctuations in serum levels.  Foods that may affect T4 absorption should be avoided within several hours of dosing if possible.  When administered to patients receiving continuous enteral nutrition for more than 7 days, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of levothyroxine is given and to monitor patients'' thyroid function.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (502, 0, 'Liotrix', 'Consumption of certain foods as well as the timing of meals relative to dosing may affect the absorption of T4 thyroid hormone (i.e., levothyroxine).  T4 absorption is increased by fasting and decreased by foods such as soybean flour (e.g., infant formula), cotton seed meal, walnuts, dietary fiber, calcium, and calcium fortified juices.', 'dietary fiber', 'Moderate', 'Preparations containing T4 thyroid hormone should be administered on a consistent schedule with regard to time of day and relation to meals so as to avoid large fluctuations in serum levels.  Foods that may affect T4 absorption should be avoided within several hours of dosing if possible.  When administered to patients receiving continuous enteral nutrition for more than 7 days, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of levothyroxine is given and to monitor patients'' thyroid function.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (503, 0, 'Lorcaserin', 'Food does not appear to significantly affect the absorption and oral bioavailability of lurasidone.  In twelve adult volunteers (6 men and 6 women), administration of a single 10 mg oral dose of lorcaserin following a high-fat (approximately 50% of total caloric content of the meal) and high-calorie (approximately 800 to 1000 calories) meal resulted in less than 10% increases in lorcaserin peak plasma concentration (Cmax) and systemic exposure (AUC) compared to administration in the fasted state.  The time to reach peak concentration (Tmax) was delayed by approximately 1 hour in the fed state.', 'food', 'Minor', 'Lorcaserin may be administered with or without food.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (504, 1162, 'Linezolid', 'Foods that contain large amounts of tyramine may precipitate a hypertensive crisis in patients treated with monoamine oxidase inhibitors (MAOIs).  The mechanism is inhibition of MAO-A, the enzyme responsible for metabolizing exogenous amines such as tyramine in the gut and preventing them from being absorbed intact.  Once absorbed, tyramine is metabolized to octopamine, a substance that is believed to displace norepinephrine from storage granules.', 'Tyrosine-rich foods', 'Major', 'In general, patients treated with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should avoid consumption of products that contain large amounts of amines and protein foods in which aging or breakdown of protein is used to increase flavor.  These foods include cheese (particularly strong, aged or processed cheeses), sour cream, wine (particularly red wine), champagne, beer, pickled herring, anchovies, caviar, shrimp paste, liver (particularly chicken liver), dry sausage, salamis, figs, raisins, bananas, avocados, chocolate, soy sauce, bean curd, sauerkraut, yogurt, papaya products, meat tenderizers, fava bean pods, protein extracts, yeast extracts, and dietary supplements.  Caffeine may also precipitate hypertensive crisis so its intake should be minimized as well.  At least 14 days should elapse following discontinuation of MAOI therapy before these foods may be consumed.  Specially designed reference materials and dietary consultation are recommended so that an appropriate and safe diet can be planned.  Patients should be advised to promptly seek medical attention if they experience potential signs and symptoms of a hypertensive crisis such as severe headache, visual disturbances, difficulty thinking, stupor or coma, seizures, chest pain, unexplained nausea or vomiting, and stroke-like symptoms.  Patients should also be counseled not to use MAOIs with alcohol, and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (505, 6221, 'Linezolid', 'Foods that contain large amounts of tyramine may precipitate a hypertensive crisis in patients treated with monoamine oxidase inhibitors (MAOIs).  The mechanism is inhibition of MAO-A, the enzyme responsible for metabolizing exogenous amines such as tyramine in the gut and preventing them from being absorbed intact.  Once absorbed, tyramine is metabolized to octopamine, a substance that is believed to displace norepinephrine from storage granules.', 'Tyrosine-rich foods', 'Major', 'In general, patients treated with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should avoid consumption of products that contain large amounts of amines and protein foods in which aging or breakdown of protein is used to increase flavor.  These foods include cheese (particularly strong, aged or processed cheeses), sour cream, wine (particularly red wine), champagne, beer, pickled herring, anchovies, caviar, shrimp paste, liver (particularly chicken liver), dry sausage, salamis, figs, raisins, bananas, avocados, chocolate, soy sauce, bean curd, sauerkraut, yogurt, papaya products, meat tenderizers, fava bean pods, protein extracts, yeast extracts, and dietary supplements.  Caffeine may also precipitate hypertensive crisis so its intake should be minimized as well.  At least 14 days should elapse following discontinuation of MAOI therapy before these foods may be consumed.  Specially designed reference materials and dietary consultation are recommended so that an appropriate and safe diet can be planned.  Patients should be advised to promptly seek medical attention if they experience potential signs and symptoms of a hypertensive crisis such as severe headache, visual disturbances, difficulty thinking, stupor or coma, seizures, chest pain, unexplained nausea or vomiting, and stroke-like symptoms.  Patients should also be counseled not to use MAOIs with alcohol, and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (506, 7329, 'Linezolid', 'Foods that contain large amounts of tyramine may precipitate a hypertensive crisis in patients treated with monoamine oxidase inhibitors (MAOIs).  The mechanism is inhibition of MAO-A, the enzyme responsible for metabolizing exogenous amines such as tyramine in the gut and preventing them from being absorbed intact.  Once absorbed, tyramine is metabolized to octopamine, a substance that is believed to displace norepinephrine from storage granules.', 'Tyrosine-rich foods', 'Major', 'In general, patients treated with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should avoid consumption of products that contain large amounts of amines and protein foods in which aging or breakdown of protein is used to increase flavor.  These foods include cheese (particularly strong, aged or processed cheeses), sour cream, wine (particularly red wine), champagne, beer, pickled herring, anchovies, caviar, shrimp paste, liver (particularly chicken liver), dry sausage, salamis, figs, raisins, bananas, avocados, chocolate, soy sauce, bean curd, sauerkraut, yogurt, papaya products, meat tenderizers, fava bean pods, protein extracts, yeast extracts, and dietary supplements.  Caffeine may also precipitate hypertensive crisis so its intake should be minimized as well.  At least 14 days should elapse following discontinuation of MAOI therapy before these foods may be consumed.  Specially designed reference materials and dietary consultation are recommended so that an appropriate and safe diet can be planned.  Patients should be advised to promptly seek medical attention if they experience potential signs and symptoms of a hypertensive crisis such as severe headache, visual disturbances, difficulty thinking, stupor or coma, seizures, chest pain, unexplained nausea or vomiting, and stroke-like symptoms.  Patients should also be counseled not to use MAOIs with alcohol, and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (507, 7330, 'Linezolid', 'Foods that contain large amounts of tyramine may precipitate a hypertensive crisis in patients treated with monoamine oxidase inhibitors (MAOIs).  The mechanism is inhibition of MAO-A, the enzyme responsible for metabolizing exogenous amines such as tyramine in the gut and preventing them from being absorbed intact.  Once absorbed, tyramine is metabolized to octopamine, a substance that is believed to displace norepinephrine from storage granules.', 'Tyrosine-rich foods', 'Major', 'In general, patients treated with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should avoid consumption of products that contain large amounts of amines and protein foods in which aging or breakdown of protein is used to increase flavor.  These foods include cheese (particularly strong, aged or processed cheeses), sour cream, wine (particularly red wine), champagne, beer, pickled herring, anchovies, caviar, shrimp paste, liver (particularly chicken liver), dry sausage, salamis, figs, raisins, bananas, avocados, chocolate, soy sauce, bean curd, sauerkraut, yogurt, papaya products, meat tenderizers, fava bean pods, protein extracts, yeast extracts, and dietary supplements.  Caffeine may also precipitate hypertensive crisis so its intake should be minimized as well.  At least 14 days should elapse following discontinuation of MAOI therapy before these foods may be consumed.  Specially designed reference materials and dietary consultation are recommended so that an appropriate and safe diet can be planned.  Patients should be advised to promptly seek medical attention if they experience potential signs and symptoms of a hypertensive crisis such as severe headache, visual disturbances, difficulty thinking, stupor or coma, seizures, chest pain, unexplained nausea or vomiting, and stroke-like symptoms.  Patients should also be counseled not to use MAOIs with alcohol, and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (508, 12965, 'Linezolid', 'Foods that contain large amounts of tyramine may precipitate a hypertensive crisis in patients treated with monoamine oxidase inhibitors (MAOIs).  The mechanism is inhibition of MAO-A, the enzyme responsible for metabolizing exogenous amines such as tyramine in the gut and preventing them from being absorbed intact.  Once absorbed, tyramine is metabolized to octopamine, a substance that is believed to displace norepinephrine from storage granules.', 'Tyrosine-rich foods', 'Major', 'In general, patients treated with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should avoid consumption of products that contain large amounts of amines and protein foods in which aging or breakdown of protein is used to increase flavor.  These foods include cheese (particularly strong, aged or processed cheeses), sour cream, wine (particularly red wine), champagne, beer, pickled herring, anchovies, caviar, shrimp paste, liver (particularly chicken liver), dry sausage, salamis, figs, raisins, bananas, avocados, chocolate, soy sauce, bean curd, sauerkraut, yogurt, papaya products, meat tenderizers, fava bean pods, protein extracts, yeast extracts, and dietary supplements.  Caffeine may also precipitate hypertensive crisis so its intake should be minimized as well.  At least 14 days should elapse following discontinuation of MAOI therapy before these foods may be consumed.  Specially designed reference materials and dietary consultation are recommended so that an appropriate and safe diet can be planned.  Patients should be advised to promptly seek medical attention if they experience potential signs and symptoms of a hypertensive crisis such as severe headache, visual disturbances, difficulty thinking, stupor or coma, seizures, chest pain, unexplained nausea or vomiting, and stroke-like symptoms.  Patients should also be counseled not to use MAOIs with alcohol, and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (509, 13118, 'Linezolid', 'Foods that contain large amounts of tyramine may precipitate a hypertensive crisis in patients treated with monoamine oxidase inhibitors (MAOIs).  The mechanism is inhibition of MAO-A, the enzyme responsible for metabolizing exogenous amines such as tyramine in the gut and preventing them from being absorbed intact.  Once absorbed, tyramine is metabolized to octopamine, a substance that is believed to displace norepinephrine from storage granules.', 'Tyrosine-rich foods', 'Major', 'In general, patients treated with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should avoid consumption of products that contain large amounts of amines and protein foods in which aging or breakdown of protein is used to increase flavor.  These foods include cheese (particularly strong, aged or processed cheeses), sour cream, wine (particularly red wine), champagne, beer, pickled herring, anchovies, caviar, shrimp paste, liver (particularly chicken liver), dry sausage, salamis, figs, raisins, bananas, avocados, chocolate, soy sauce, bean curd, sauerkraut, yogurt, papaya products, meat tenderizers, fava bean pods, protein extracts, yeast extracts, and dietary supplements.  Caffeine may also precipitate hypertensive crisis so its intake should be minimized as well.  At least 14 days should elapse following discontinuation of MAOI therapy before these foods may be consumed.  Specially designed reference materials and dietary consultation are recommended so that an appropriate and safe diet can be planned.  Patients should be advised to promptly seek medical attention if they experience potential signs and symptoms of a hypertensive crisis such as severe headache, visual disturbances, difficulty thinking, stupor or coma, seizures, chest pain, unexplained nausea or vomiting, and stroke-like symptoms.  Patients should also be counseled not to use MAOIs with alcohol, and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (510, 13322, 'Linezolid', 'Foods that contain large amounts of tyramine may precipitate a hypertensive crisis in patients treated with monoamine oxidase inhibitors (MAOIs).  The mechanism is inhibition of MAO-A, the enzyme responsible for metabolizing exogenous amines such as tyramine in the gut and preventing them from being absorbed intact.  Once absorbed, tyramine is metabolized to octopamine, a substance that is believed to displace norepinephrine from storage granules.', 'Tyrosine-rich foods', 'Major', 'In general, patients treated with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should avoid consumption of products that contain large amounts of amines and protein foods in which aging or breakdown of protein is used to increase flavor.  These foods include cheese (particularly strong, aged or processed cheeses), sour cream, wine (particularly red wine), champagne, beer, pickled herring, anchovies, caviar, shrimp paste, liver (particularly chicken liver), dry sausage, salamis, figs, raisins, bananas, avocados, chocolate, soy sauce, bean curd, sauerkraut, yogurt, papaya products, meat tenderizers, fava bean pods, protein extracts, yeast extracts, and dietary supplements.  Caffeine may also precipitate hypertensive crisis so its intake should be minimized as well.  At least 14 days should elapse following discontinuation of MAOI therapy before these foods may be consumed.  Specially designed reference materials and dietary consultation are recommended so that an appropriate and safe diet can be planned.  Patients should be advised to promptly seek medical attention if they experience potential signs and symptoms of a hypertensive crisis such as severe headache, visual disturbances, difficulty thinking, stupor or coma, seizures, chest pain, unexplained nausea or vomiting, and stroke-like symptoms.  Patients should also be counseled not to use MAOIs with alcohol, and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (511, 14745, 'Linezolid', 'Foods that contain large amounts of tyramine may precipitate a hypertensive crisis in patients treated with monoamine oxidase inhibitors (MAOIs).  The mechanism is inhibition of MAO-A, the enzyme responsible for metabolizing exogenous amines such as tyramine in the gut and preventing them from being absorbed intact.  Once absorbed, tyramine is metabolized to octopamine, a substance that is believed to displace norepinephrine from storage granules.', 'Tyrosine-rich foods', 'Major', 'In general, patients treated with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should avoid consumption of products that contain large amounts of amines and protein foods in which aging or breakdown of protein is used to increase flavor.  These foods include cheese (particularly strong, aged or processed cheeses), sour cream, wine (particularly red wine), champagne, beer, pickled herring, anchovies, caviar, shrimp paste, liver (particularly chicken liver), dry sausage, salamis, figs, raisins, bananas, avocados, chocolate, soy sauce, bean curd, sauerkraut, yogurt, papaya products, meat tenderizers, fava bean pods, protein extracts, yeast extracts, and dietary supplements.  Caffeine may also precipitate hypertensive crisis so its intake should be minimized as well.  At least 14 days should elapse following discontinuation of MAOI therapy before these foods may be consumed.  Specially designed reference materials and dietary consultation are recommended so that an appropriate and safe diet can be planned.  Patients should be advised to promptly seek medical attention if they experience potential signs and symptoms of a hypertensive crisis such as severe headache, visual disturbances, difficulty thinking, stupor or coma, seizures, chest pain, unexplained nausea or vomiting, and stroke-like symptoms.  Patients should also be counseled not to use MAOIs with alcohol, and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (512, 14747, 'Linezolid', 'Foods that contain large amounts of tyramine may precipitate a hypertensive crisis in patients treated with monoamine oxidase inhibitors (MAOIs).  The mechanism is inhibition of MAO-A, the enzyme responsible for metabolizing exogenous amines such as tyramine in the gut and preventing them from being absorbed intact.  Once absorbed, tyramine is metabolized to octopamine, a substance that is believed to displace norepinephrine from storage granules.', 'Tyrosine-rich foods', 'Major', 'In general, patients treated with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should avoid consumption of products that contain large amounts of amines and protein foods in which aging or breakdown of protein is used to increase flavor.  These foods include cheese (particularly strong, aged or processed cheeses), sour cream, wine (particularly red wine), champagne, beer, pickled herring, anchovies, caviar, shrimp paste, liver (particularly chicken liver), dry sausage, salamis, figs, raisins, bananas, avocados, chocolate, soy sauce, bean curd, sauerkraut, yogurt, papaya products, meat tenderizers, fava bean pods, protein extracts, yeast extracts, and dietary supplements.  Caffeine may also precipitate hypertensive crisis so its intake should be minimized as well.  At least 14 days should elapse following discontinuation of MAOI therapy before these foods may be consumed.  Specially designed reference materials and dietary consultation are recommended so that an appropriate and safe diet can be planned.  Patients should be advised to promptly seek medical attention if they experience potential signs and symptoms of a hypertensive crisis such as severe headache, visual disturbances, difficulty thinking, stupor or coma, seizures, chest pain, unexplained nausea or vomiting, and stroke-like symptoms.  Patients should also be counseled not to use MAOIs with alcohol, and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (513, 14748, 'Linezolid', 'Foods that contain large amounts of tyramine may precipitate a hypertensive crisis in patients treated with monoamine oxidase inhibitors (MAOIs).  The mechanism is inhibition of MAO-A, the enzyme responsible for metabolizing exogenous amines such as tyramine in the gut and preventing them from being absorbed intact.  Once absorbed, tyramine is metabolized to octopamine, a substance that is believed to displace norepinephrine from storage granules.', 'Tyrosine-rich foods', 'Major', 'In general, patients treated with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should avoid consumption of products that contain large amounts of amines and protein foods in which aging or breakdown of protein is used to increase flavor.  These foods include cheese (particularly strong, aged or processed cheeses), sour cream, wine (particularly red wine), champagne, beer, pickled herring, anchovies, caviar, shrimp paste, liver (particularly chicken liver), dry sausage, salamis, figs, raisins, bananas, avocados, chocolate, soy sauce, bean curd, sauerkraut, yogurt, papaya products, meat tenderizers, fava bean pods, protein extracts, yeast extracts, and dietary supplements.  Caffeine may also precipitate hypertensive crisis so its intake should be minimized as well.  At least 14 days should elapse following discontinuation of MAOI therapy before these foods may be consumed.  Specially designed reference materials and dietary consultation are recommended so that an appropriate and safe diet can be planned.  Patients should be advised to promptly seek medical attention if they experience potential signs and symptoms of a hypertensive crisis such as severe headache, visual disturbances, difficulty thinking, stupor or coma, seizures, chest pain, unexplained nausea or vomiting, and stroke-like symptoms.  Patients should also be counseled not to use MAOIs with alcohol, and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (514, 14879, 'Linezolid', 'Foods that contain large amounts of tyramine may precipitate a hypertensive crisis in patients treated with monoamine oxidase inhibitors (MAOIs).  The mechanism is inhibition of MAO-A, the enzyme responsible for metabolizing exogenous amines such as tyramine in the gut and preventing them from being absorbed intact.  Once absorbed, tyramine is metabolized to octopamine, a substance that is believed to displace norepinephrine from storage granules.', 'Tyrosine-rich foods', 'Major', 'In general, patients treated with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should avoid consumption of products that contain large amounts of amines and protein foods in which aging or breakdown of protein is used to increase flavor.  These foods include cheese (particularly strong, aged or processed cheeses), sour cream, wine (particularly red wine), champagne, beer, pickled herring, anchovies, caviar, shrimp paste, liver (particularly chicken liver), dry sausage, salamis, figs, raisins, bananas, avocados, chocolate, soy sauce, bean curd, sauerkraut, yogurt, papaya products, meat tenderizers, fava bean pods, protein extracts, yeast extracts, and dietary supplements.  Caffeine may also precipitate hypertensive crisis so its intake should be minimized as well.  At least 14 days should elapse following discontinuation of MAOI therapy before these foods may be consumed.  Specially designed reference materials and dietary consultation are recommended so that an appropriate and safe diet can be planned.  Patients should be advised to promptly seek medical attention if they experience potential signs and symptoms of a hypertensive crisis such as severe headache, visual disturbances, difficulty thinking, stupor or coma, seizures, chest pain, unexplained nausea or vomiting, and stroke-like symptoms.  Patients should also be counseled not to use MAOIs with alcohol, and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (515, 17141, 'Linezolid', 'Foods that contain large amounts of tyramine may precipitate a hypertensive crisis in patients treated with monoamine oxidase inhibitors (MAOIs).  The mechanism is inhibition of MAO-A, the enzyme responsible for metabolizing exogenous amines such as tyramine in the gut and preventing them from being absorbed intact.  Once absorbed, tyramine is metabolized to octopamine, a substance that is believed to displace norepinephrine from storage granules.', 'Tyrosine-rich foods', 'Major', 'In general, patients treated with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should avoid consumption of products that contain large amounts of amines and protein foods in which aging or breakdown of protein is used to increase flavor.  These foods include cheese (particularly strong, aged or processed cheeses), sour cream, wine (particularly red wine), champagne, beer, pickled herring, anchovies, caviar, shrimp paste, liver (particularly chicken liver), dry sausage, salamis, figs, raisins, bananas, avocados, chocolate, soy sauce, bean curd, sauerkraut, yogurt, papaya products, meat tenderizers, fava bean pods, protein extracts, yeast extracts, and dietary supplements.  Caffeine may also precipitate hypertensive crisis so its intake should be minimized as well.  At least 14 days should elapse following discontinuation of MAOI therapy before these foods may be consumed.  Specially designed reference materials and dietary consultation are recommended so that an appropriate and safe diet can be planned.  Patients should be advised to promptly seek medical attention if they experience potential signs and symptoms of a hypertensive crisis such as severe headache, visual disturbances, difficulty thinking, stupor or coma, seizures, chest pain, unexplained nausea or vomiting, and stroke-like symptoms.  Patients should also be counseled not to use MAOIs with alcohol, and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (516, 17142, 'Linezolid', 'Foods that contain large amounts of tyramine may precipitate a hypertensive crisis in patients treated with monoamine oxidase inhibitors (MAOIs).  The mechanism is inhibition of MAO-A, the enzyme responsible for metabolizing exogenous amines such as tyramine in the gut and preventing them from being absorbed intact.  Once absorbed, tyramine is metabolized to octopamine, a substance that is believed to displace norepinephrine from storage granules.', 'Tyrosine-rich foods', 'Major', 'In general, patients treated with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should avoid consumption of products that contain large amounts of amines and protein foods in which aging or breakdown of protein is used to increase flavor.  These foods include cheese (particularly strong, aged or processed cheeses), sour cream, wine (particularly red wine), champagne, beer, pickled herring, anchovies, caviar, shrimp paste, liver (particularly chicken liver), dry sausage, salamis, figs, raisins, bananas, avocados, chocolate, soy sauce, bean curd, sauerkraut, yogurt, papaya products, meat tenderizers, fava bean pods, protein extracts, yeast extracts, and dietary supplements.  Caffeine may also precipitate hypertensive crisis so its intake should be minimized as well.  At least 14 days should elapse following discontinuation of MAOI therapy before these foods may be consumed.  Specially designed reference materials and dietary consultation are recommended so that an appropriate and safe diet can be planned.  Patients should be advised to promptly seek medical attention if they experience potential signs and symptoms of a hypertensive crisis such as severe headache, visual disturbances, difficulty thinking, stupor or coma, seizures, chest pain, unexplained nausea or vomiting, and stroke-like symptoms.  Patients should also be counseled not to use MAOIs with alcohol, and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (517, 21121, 'Linezolid', 'Foods that contain large amounts of tyramine may precipitate a hypertensive crisis in patients treated with monoamine oxidase inhibitors (MAOIs).  The mechanism is inhibition of MAO-A, the enzyme responsible for metabolizing exogenous amines such as tyramine in the gut and preventing them from being absorbed intact.  Once absorbed, tyramine is metabolized to octopamine, a substance that is believed to displace norepinephrine from storage granules.', 'Tyrosine-rich foods', 'Major', 'In general, patients treated with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should avoid consumption of products that contain large amounts of amines and protein foods in which aging or breakdown of protein is used to increase flavor.  These foods include cheese (particularly strong, aged or processed cheeses), sour cream, wine (particularly red wine), champagne, beer, pickled herring, anchovies, caviar, shrimp paste, liver (particularly chicken liver), dry sausage, salamis, figs, raisins, bananas, avocados, chocolate, soy sauce, bean curd, sauerkraut, yogurt, papaya products, meat tenderizers, fava bean pods, protein extracts, yeast extracts, and dietary supplements.  Caffeine may also precipitate hypertensive crisis so its intake should be minimized as well.  At least 14 days should elapse following discontinuation of MAOI therapy before these foods may be consumed.  Specially designed reference materials and dietary consultation are recommended so that an appropriate and safe diet can be planned.  Patients should be advised to promptly seek medical attention if they experience potential signs and symptoms of a hypertensive crisis such as severe headache, visual disturbances, difficulty thinking, stupor or coma, seizures, chest pain, unexplained nausea or vomiting, and stroke-like symptoms.  Patients should also be counseled not to use MAOIs with alcohol, and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (518, 21122, 'Linezolid', 'Foods that contain large amounts of tyramine may precipitate a hypertensive crisis in patients treated with monoamine oxidase inhibitors (MAOIs).  The mechanism is inhibition of MAO-A, the enzyme responsible for metabolizing exogenous amines such as tyramine in the gut and preventing them from being absorbed intact.  Once absorbed, tyramine is metabolized to octopamine, a substance that is believed to displace norepinephrine from storage granules.', 'Tyrosine-rich foods', 'Major', 'In general, patients treated with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should avoid consumption of products that contain large amounts of amines and protein foods in which aging or breakdown of protein is used to increase flavor.  These foods include cheese (particularly strong, aged or processed cheeses), sour cream, wine (particularly red wine), champagne, beer, pickled herring, anchovies, caviar, shrimp paste, liver (particularly chicken liver), dry sausage, salamis, figs, raisins, bananas, avocados, chocolate, soy sauce, bean curd, sauerkraut, yogurt, papaya products, meat tenderizers, fava bean pods, protein extracts, yeast extracts, and dietary supplements.  Caffeine may also precipitate hypertensive crisis so its intake should be minimized as well.  At least 14 days should elapse following discontinuation of MAOI therapy before these foods may be consumed.  Specially designed reference materials and dietary consultation are recommended so that an appropriate and safe diet can be planned.  Patients should be advised to promptly seek medical attention if they experience potential signs and symptoms of a hypertensive crisis such as severe headache, visual disturbances, difficulty thinking, stupor or coma, seizures, chest pain, unexplained nausea or vomiting, and stroke-like symptoms.  Patients should also be counseled not to use MAOIs with alcohol, and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (519, 21848, 'Linezolid', 'Foods that contain large amounts of tyramine may precipitate a hypertensive crisis in patients treated with monoamine oxidase inhibitors (MAOIs).  The mechanism is inhibition of MAO-A, the enzyme responsible for metabolizing exogenous amines such as tyramine in the gut and preventing them from being absorbed intact.  Once absorbed, tyramine is metabolized to octopamine, a substance that is believed to displace norepinephrine from storage granules.', 'Tyrosine-rich foods', 'Major', 'In general, patients treated with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should avoid consumption of products that contain large amounts of amines and protein foods in which aging or breakdown of protein is used to increase flavor.  These foods include cheese (particularly strong, aged or processed cheeses), sour cream, wine (particularly red wine), champagne, beer, pickled herring, anchovies, caviar, shrimp paste, liver (particularly chicken liver), dry sausage, salamis, figs, raisins, bananas, avocados, chocolate, soy sauce, bean curd, sauerkraut, yogurt, papaya products, meat tenderizers, fava bean pods, protein extracts, yeast extracts, and dietary supplements.  Caffeine may also precipitate hypertensive crisis so its intake should be minimized as well.  At least 14 days should elapse following discontinuation of MAOI therapy before these foods may be consumed.  Specially designed reference materials and dietary consultation are recommended so that an appropriate and safe diet can be planned.  Patients should be advised to promptly seek medical attention if they experience potential signs and symptoms of a hypertensive crisis such as severe headache, visual disturbances, difficulty thinking, stupor or coma, seizures, chest pain, unexplained nausea or vomiting, and stroke-like symptoms.  Patients should also be counseled not to use MAOIs with alcohol, and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (520, 21849, 'Linezolid', 'Foods that contain large amounts of tyramine may precipitate a hypertensive crisis in patients treated with monoamine oxidase inhibitors (MAOIs).  The mechanism is inhibition of MAO-A, the enzyme responsible for metabolizing exogenous amines such as tyramine in the gut and preventing them from being absorbed intact.  Once absorbed, tyramine is metabolized to octopamine, a substance that is believed to displace norepinephrine from storage granules.', 'Tyrosine-rich foods', 'Major', 'In general, patients treated with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should avoid consumption of products that contain large amounts of amines and protein foods in which aging or breakdown of protein is used to increase flavor.  These foods include cheese (particularly strong, aged or processed cheeses), sour cream, wine (particularly red wine), champagne, beer, pickled herring, anchovies, caviar, shrimp paste, liver (particularly chicken liver), dry sausage, salamis, figs, raisins, bananas, avocados, chocolate, soy sauce, bean curd, sauerkraut, yogurt, papaya products, meat tenderizers, fava bean pods, protein extracts, yeast extracts, and dietary supplements.  Caffeine may also precipitate hypertensive crisis so its intake should be minimized as well.  At least 14 days should elapse following discontinuation of MAOI therapy before these foods may be consumed.  Specially designed reference materials and dietary consultation are recommended so that an appropriate and safe diet can be planned.  Patients should be advised to promptly seek medical attention if they experience potential signs and symptoms of a hypertensive crisis such as severe headache, visual disturbances, difficulty thinking, stupor or coma, seizures, chest pain, unexplained nausea or vomiting, and stroke-like symptoms.  Patients should also be counseled not to use MAOIs with alcohol, and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (521, 21850, 'Linezolid', 'Foods that contain large amounts of tyramine may precipitate a hypertensive crisis in patients treated with monoamine oxidase inhibitors (MAOIs).  The mechanism is inhibition of MAO-A, the enzyme responsible for metabolizing exogenous amines such as tyramine in the gut and preventing them from being absorbed intact.  Once absorbed, tyramine is metabolized to octopamine, a substance that is believed to displace norepinephrine from storage granules.', 'Tyrosine-rich foods', 'Major', 'In general, patients treated with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should avoid consumption of products that contain large amounts of amines and protein foods in which aging or breakdown of protein is used to increase flavor.  These foods include cheese (particularly strong, aged or processed cheeses), sour cream, wine (particularly red wine), champagne, beer, pickled herring, anchovies, caviar, shrimp paste, liver (particularly chicken liver), dry sausage, salamis, figs, raisins, bananas, avocados, chocolate, soy sauce, bean curd, sauerkraut, yogurt, papaya products, meat tenderizers, fava bean pods, protein extracts, yeast extracts, and dietary supplements.  Caffeine may also precipitate hypertensive crisis so its intake should be minimized as well.  At least 14 days should elapse following discontinuation of MAOI therapy before these foods may be consumed.  Specially designed reference materials and dietary consultation are recommended so that an appropriate and safe diet can be planned.  Patients should be advised to promptly seek medical attention if they experience potential signs and symptoms of a hypertensive crisis such as severe headache, visual disturbances, difficulty thinking, stupor or coma, seizures, chest pain, unexplained nausea or vomiting, and stroke-like symptoms.  Patients should also be counseled not to use MAOIs with alcohol, and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (522, 21851, 'Linezolid', 'Foods that contain large amounts of tyramine may precipitate a hypertensive crisis in patients treated with monoamine oxidase inhibitors (MAOIs).  The mechanism is inhibition of MAO-A, the enzyme responsible for metabolizing exogenous amines such as tyramine in the gut and preventing them from being absorbed intact.  Once absorbed, tyramine is metabolized to octopamine, a substance that is believed to displace norepinephrine from storage granules.', 'Tyrosine-rich foods', 'Major', 'In general, patients treated with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should avoid consumption of products that contain large amounts of amines and protein foods in which aging or breakdown of protein is used to increase flavor.  These foods include cheese (particularly strong, aged or processed cheeses), sour cream, wine (particularly red wine), champagne, beer, pickled herring, anchovies, caviar, shrimp paste, liver (particularly chicken liver), dry sausage, salamis, figs, raisins, bananas, avocados, chocolate, soy sauce, bean curd, sauerkraut, yogurt, papaya products, meat tenderizers, fava bean pods, protein extracts, yeast extracts, and dietary supplements.  Caffeine may also precipitate hypertensive crisis so its intake should be minimized as well.  At least 14 days should elapse following discontinuation of MAOI therapy before these foods may be consumed.  Specially designed reference materials and dietary consultation are recommended so that an appropriate and safe diet can be planned.  Patients should be advised to promptly seek medical attention if they experience potential signs and symptoms of a hypertensive crisis such as severe headache, visual disturbances, difficulty thinking, stupor or coma, seizures, chest pain, unexplained nausea or vomiting, and stroke-like symptoms.  Patients should also be counseled not to use MAOIs with alcohol, and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (523, 24390, 'Linezolid', 'Foods that contain large amounts of tyramine may precipitate a hypertensive crisis in patients treated with monoamine oxidase inhibitors (MAOIs).  The mechanism is inhibition of MAO-A, the enzyme responsible for metabolizing exogenous amines such as tyramine in the gut and preventing them from being absorbed intact.  Once absorbed, tyramine is metabolized to octopamine, a substance that is believed to displace norepinephrine from storage granules.', 'Tyrosine-rich foods', 'Major', 'In general, patients treated with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should avoid consumption of products that contain large amounts of amines and protein foods in which aging or breakdown of protein is used to increase flavor.  These foods include cheese (particularly strong, aged or processed cheeses), sour cream, wine (particularly red wine), champagne, beer, pickled herring, anchovies, caviar, shrimp paste, liver (particularly chicken liver), dry sausage, salamis, figs, raisins, bananas, avocados, chocolate, soy sauce, bean curd, sauerkraut, yogurt, papaya products, meat tenderizers, fava bean pods, protein extracts, yeast extracts, and dietary supplements.  Caffeine may also precipitate hypertensive crisis so its intake should be minimized as well.  At least 14 days should elapse following discontinuation of MAOI therapy before these foods may be consumed.  Specially designed reference materials and dietary consultation are recommended so that an appropriate and safe diet can be planned.  Patients should be advised to promptly seek medical attention if they experience potential signs and symptoms of a hypertensive crisis such as severe headache, visual disturbances, difficulty thinking, stupor or coma, seizures, chest pain, unexplained nausea or vomiting, and stroke-like symptoms.  Patients should also be counseled not to use MAOIs with alcohol, and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (524, 24391, 'Linezolid', 'Foods that contain large amounts of tyramine may precipitate a hypertensive crisis in patients treated with monoamine oxidase inhibitors (MAOIs).  The mechanism is inhibition of MAO-A, the enzyme responsible for metabolizing exogenous amines such as tyramine in the gut and preventing them from being absorbed intact.  Once absorbed, tyramine is metabolized to octopamine, a substance that is believed to displace norepinephrine from storage granules.', 'Tyrosine-rich foods', 'Major', 'In general, patients treated with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should avoid consumption of products that contain large amounts of amines and protein foods in which aging or breakdown of protein is used to increase flavor.  These foods include cheese (particularly strong, aged or processed cheeses), sour cream, wine (particularly red wine), champagne, beer, pickled herring, anchovies, caviar, shrimp paste, liver (particularly chicken liver), dry sausage, salamis, figs, raisins, bananas, avocados, chocolate, soy sauce, bean curd, sauerkraut, yogurt, papaya products, meat tenderizers, fava bean pods, protein extracts, yeast extracts, and dietary supplements.  Caffeine may also precipitate hypertensive crisis so its intake should be minimized as well.  At least 14 days should elapse following discontinuation of MAOI therapy before these foods may be consumed.  Specially designed reference materials and dietary consultation are recommended so that an appropriate and safe diet can be planned.  Patients should be advised to promptly seek medical attention if they experience potential signs and symptoms of a hypertensive crisis such as severe headache, visual disturbances, difficulty thinking, stupor or coma, seizures, chest pain, unexplained nausea or vomiting, and stroke-like symptoms.  Patients should also be counseled not to use MAOIs with alcohol, and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (525, 25918, 'Linezolid', 'Foods that contain large amounts of tyramine may precipitate a hypertensive crisis in patients treated with monoamine oxidase inhibitors (MAOIs).  The mechanism is inhibition of MAO-A, the enzyme responsible for metabolizing exogenous amines such as tyramine in the gut and preventing them from being absorbed intact.  Once absorbed, tyramine is metabolized to octopamine, a substance that is believed to displace norepinephrine from storage granules.', 'Tyrosine-rich foods', 'Major', 'In general, patients treated with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should avoid consumption of products that contain large amounts of amines and protein foods in which aging or breakdown of protein is used to increase flavor.  These foods include cheese (particularly strong, aged or processed cheeses), sour cream, wine (particularly red wine), champagne, beer, pickled herring, anchovies, caviar, shrimp paste, liver (particularly chicken liver), dry sausage, salamis, figs, raisins, bananas, avocados, chocolate, soy sauce, bean curd, sauerkraut, yogurt, papaya products, meat tenderizers, fava bean pods, protein extracts, yeast extracts, and dietary supplements.  Caffeine may also precipitate hypertensive crisis so its intake should be minimized as well.  At least 14 days should elapse following discontinuation of MAOI therapy before these foods may be consumed.  Specially designed reference materials and dietary consultation are recommended so that an appropriate and safe diet can be planned.  Patients should be advised to promptly seek medical attention if they experience potential signs and symptoms of a hypertensive crisis such as severe headache, visual disturbances, difficulty thinking, stupor or coma, seizures, chest pain, unexplained nausea or vomiting, and stroke-like symptoms.  Patients should also be counseled not to use MAOIs with alcohol, and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (526, 29354, 'Linezolid', 'Foods that contain large amounts of tyramine may precipitate a hypertensive crisis in patients treated with monoamine oxidase inhibitors (MAOIs).  The mechanism is inhibition of MAO-A, the enzyme responsible for metabolizing exogenous amines such as tyramine in the gut and preventing them from being absorbed intact.  Once absorbed, tyramine is metabolized to octopamine, a substance that is believed to displace norepinephrine from storage granules.', 'Tyrosine-rich foods', 'Major', 'In general, patients treated with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should avoid consumption of products that contain large amounts of amines and protein foods in which aging or breakdown of protein is used to increase flavor.  These foods include cheese (particularly strong, aged or processed cheeses), sour cream, wine (particularly red wine), champagne, beer, pickled herring, anchovies, caviar, shrimp paste, liver (particularly chicken liver), dry sausage, salamis, figs, raisins, bananas, avocados, chocolate, soy sauce, bean curd, sauerkraut, yogurt, papaya products, meat tenderizers, fava bean pods, protein extracts, yeast extracts, and dietary supplements.  Caffeine may also precipitate hypertensive crisis so its intake should be minimized as well.  At least 14 days should elapse following discontinuation of MAOI therapy before these foods may be consumed.  Specially designed reference materials and dietary consultation are recommended so that an appropriate and safe diet can be planned.  Patients should be advised to promptly seek medical attention if they experience potential signs and symptoms of a hypertensive crisis such as severe headache, visual disturbances, difficulty thinking, stupor or coma, seizures, chest pain, unexplained nausea or vomiting, and stroke-like symptoms.  Patients should also be counseled not to use MAOIs with alcohol, and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (527, 29606, 'Linezolid', 'Foods that contain large amounts of tyramine may precipitate a hypertensive crisis in patients treated with monoamine oxidase inhibitors (MAOIs).  The mechanism is inhibition of MAO-A, the enzyme responsible for metabolizing exogenous amines such as tyramine in the gut and preventing them from being absorbed intact.  Once absorbed, tyramine is metabolized to octopamine, a substance that is believed to displace norepinephrine from storage granules.', 'Tyrosine-rich foods', 'Major', 'In general, patients treated with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should avoid consumption of products that contain large amounts of amines and protein foods in which aging or breakdown of protein is used to increase flavor.  These foods include cheese (particularly strong, aged or processed cheeses), sour cream, wine (particularly red wine), champagne, beer, pickled herring, anchovies, caviar, shrimp paste, liver (particularly chicken liver), dry sausage, salamis, figs, raisins, bananas, avocados, chocolate, soy sauce, bean curd, sauerkraut, yogurt, papaya products, meat tenderizers, fava bean pods, protein extracts, yeast extracts, and dietary supplements.  Caffeine may also precipitate hypertensive crisis so its intake should be minimized as well.  At least 14 days should elapse following discontinuation of MAOI therapy before these foods may be consumed.  Specially designed reference materials and dietary consultation are recommended so that an appropriate and safe diet can be planned.  Patients should be advised to promptly seek medical attention if they experience potential signs and symptoms of a hypertensive crisis such as severe headache, visual disturbances, difficulty thinking, stupor or coma, seizures, chest pain, unexplained nausea or vomiting, and stroke-like symptoms.  Patients should also be counseled not to use MAOIs with alcohol, and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (528, 29607, 'Linezolid', 'Foods that contain large amounts of tyramine may precipitate a hypertensive crisis in patients treated with monoamine oxidase inhibitors (MAOIs).  The mechanism is inhibition of MAO-A, the enzyme responsible for metabolizing exogenous amines such as tyramine in the gut and preventing them from being absorbed intact.  Once absorbed, tyramine is metabolized to octopamine, a substance that is believed to displace norepinephrine from storage granules.', 'Tyrosine-rich foods', 'Major', 'In general, patients treated with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should avoid consumption of products that contain large amounts of amines and protein foods in which aging or breakdown of protein is used to increase flavor.  These foods include cheese (particularly strong, aged or processed cheeses), sour cream, wine (particularly red wine), champagne, beer, pickled herring, anchovies, caviar, shrimp paste, liver (particularly chicken liver), dry sausage, salamis, figs, raisins, bananas, avocados, chocolate, soy sauce, bean curd, sauerkraut, yogurt, papaya products, meat tenderizers, fava bean pods, protein extracts, yeast extracts, and dietary supplements.  Caffeine may also precipitate hypertensive crisis so its intake should be minimized as well.  At least 14 days should elapse following discontinuation of MAOI therapy before these foods may be consumed.  Specially designed reference materials and dietary consultation are recommended so that an appropriate and safe diet can be planned.  Patients should be advised to promptly seek medical attention if they experience potential signs and symptoms of a hypertensive crisis such as severe headache, visual disturbances, difficulty thinking, stupor or coma, seizures, chest pain, unexplained nausea or vomiting, and stroke-like symptoms.  Patients should also be counseled not to use MAOIs with alcohol, and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (529, 29608, 'Linezolid', 'Foods that contain large amounts of tyramine may precipitate a hypertensive crisis in patients treated with monoamine oxidase inhibitors (MAOIs).  The mechanism is inhibition of MAO-A, the enzyme responsible for metabolizing exogenous amines such as tyramine in the gut and preventing them from being absorbed intact.  Once absorbed, tyramine is metabolized to octopamine, a substance that is believed to displace norepinephrine from storage granules.', 'Tyrosine-rich foods', 'Major', 'In general, patients treated with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should avoid consumption of products that contain large amounts of amines and protein foods in which aging or breakdown of protein is used to increase flavor.  These foods include cheese (particularly strong, aged or processed cheeses), sour cream, wine (particularly red wine), champagne, beer, pickled herring, anchovies, caviar, shrimp paste, liver (particularly chicken liver), dry sausage, salamis, figs, raisins, bananas, avocados, chocolate, soy sauce, bean curd, sauerkraut, yogurt, papaya products, meat tenderizers, fava bean pods, protein extracts, yeast extracts, and dietary supplements.  Caffeine may also precipitate hypertensive crisis so its intake should be minimized as well.  At least 14 days should elapse following discontinuation of MAOI therapy before these foods may be consumed.  Specially designed reference materials and dietary consultation are recommended so that an appropriate and safe diet can be planned.  Patients should be advised to promptly seek medical attention if they experience potential signs and symptoms of a hypertensive crisis such as severe headache, visual disturbances, difficulty thinking, stupor or coma, seizures, chest pain, unexplained nausea or vomiting, and stroke-like symptoms.  Patients should also be counseled not to use MAOIs with alcohol, and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (530, 30068, 'Linezolid', 'Foods that contain large amounts of tyramine may precipitate a hypertensive crisis in patients treated with monoamine oxidase inhibitors (MAOIs).  The mechanism is inhibition of MAO-A, the enzyme responsible for metabolizing exogenous amines such as tyramine in the gut and preventing them from being absorbed intact.  Once absorbed, tyramine is metabolized to octopamine, a substance that is believed to displace norepinephrine from storage granules.', 'Tyrosine-rich foods', 'Major', 'In general, patients treated with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should avoid consumption of products that contain large amounts of amines and protein foods in which aging or breakdown of protein is used to increase flavor.  These foods include cheese (particularly strong, aged or processed cheeses), sour cream, wine (particularly red wine), champagne, beer, pickled herring, anchovies, caviar, shrimp paste, liver (particularly chicken liver), dry sausage, salamis, figs, raisins, bananas, avocados, chocolate, soy sauce, bean curd, sauerkraut, yogurt, papaya products, meat tenderizers, fava bean pods, protein extracts, yeast extracts, and dietary supplements.  Caffeine may also precipitate hypertensive crisis so its intake should be minimized as well.  At least 14 days should elapse following discontinuation of MAOI therapy before these foods may be consumed.  Specially designed reference materials and dietary consultation are recommended so that an appropriate and safe diet can be planned.  Patients should be advised to promptly seek medical attention if they experience potential signs and symptoms of a hypertensive crisis such as severe headache, visual disturbances, difficulty thinking, stupor or coma, seizures, chest pain, unexplained nausea or vomiting, and stroke-like symptoms.  Patients should also be counseled not to use MAOIs with alcohol, and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (531, 32064, 'Linezolid', 'Foods that contain large amounts of tyramine may precipitate a hypertensive crisis in patients treated with monoamine oxidase inhibitors (MAOIs).  The mechanism is inhibition of MAO-A, the enzyme responsible for metabolizing exogenous amines such as tyramine in the gut and preventing them from being absorbed intact.  Once absorbed, tyramine is metabolized to octopamine, a substance that is believed to displace norepinephrine from storage granules.', 'Tyrosine-rich foods', 'Major', 'In general, patients treated with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should avoid consumption of products that contain large amounts of amines and protein foods in which aging or breakdown of protein is used to increase flavor.  These foods include cheese (particularly strong, aged or processed cheeses), sour cream, wine (particularly red wine), champagne, beer, pickled herring, anchovies, caviar, shrimp paste, liver (particularly chicken liver), dry sausage, salamis, figs, raisins, bananas, avocados, chocolate, soy sauce, bean curd, sauerkraut, yogurt, papaya products, meat tenderizers, fava bean pods, protein extracts, yeast extracts, and dietary supplements.  Caffeine may also precipitate hypertensive crisis so its intake should be minimized as well.  At least 14 days should elapse following discontinuation of MAOI therapy before these foods may be consumed.  Specially designed reference materials and dietary consultation are recommended so that an appropriate and safe diet can be planned.  Patients should be advised to promptly seek medical attention if they experience potential signs and symptoms of a hypertensive crisis such as severe headache, visual disturbances, difficulty thinking, stupor or coma, seizures, chest pain, unexplained nausea or vomiting, and stroke-like symptoms.  Patients should also be counseled not to use MAOIs with alcohol, and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (532, 32789, 'Linezolid', 'Foods that contain large amounts of tyramine may precipitate a hypertensive crisis in patients treated with monoamine oxidase inhibitors (MAOIs).  The mechanism is inhibition of MAO-A, the enzyme responsible for metabolizing exogenous amines such as tyramine in the gut and preventing them from being absorbed intact.  Once absorbed, tyramine is metabolized to octopamine, a substance that is believed to displace norepinephrine from storage granules.', 'Tyrosine-rich foods', 'Major', 'In general, patients treated with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should avoid consumption of products that contain large amounts of amines and protein foods in which aging or breakdown of protein is used to increase flavor.  These foods include cheese (particularly strong, aged or processed cheeses), sour cream, wine (particularly red wine), champagne, beer, pickled herring, anchovies, caviar, shrimp paste, liver (particularly chicken liver), dry sausage, salamis, figs, raisins, bananas, avocados, chocolate, soy sauce, bean curd, sauerkraut, yogurt, papaya products, meat tenderizers, fava bean pods, protein extracts, yeast extracts, and dietary supplements.  Caffeine may also precipitate hypertensive crisis so its intake should be minimized as well.  At least 14 days should elapse following discontinuation of MAOI therapy before these foods may be consumed.  Specially designed reference materials and dietary consultation are recommended so that an appropriate and safe diet can be planned.  Patients should be advised to promptly seek medical attention if they experience potential signs and symptoms of a hypertensive crisis such as severe headache, visual disturbances, difficulty thinking, stupor or coma, seizures, chest pain, unexplained nausea or vomiting, and stroke-like symptoms.  Patients should also be counseled not to use MAOIs with alcohol, and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (533, 0, 'Lomitapide', 'Administration of lomitapide with food may increase the risk of common gastrointestinal adverse reactions such as diarrhea, nausea, vomiting, dyspepsia, abdominal pain or discomfort, abdominal distension, constipation, and flatulence.  Absorption of concomitant oral medications may be affected in patients who develop diarrhea or vomiting.', 'food', 'Major', 'Lomitapide should be taken once daily with a glass of water, without food, at least 2 hours after the evening meal.  Strict adherence to a low-fat diet (<20% of total calories from fat) and gradual dosage titration may also help to reduce gastrointestinal intolerance.  Patients should avoid consumption of grapefruit, grapefruit juice, and any supplement containing grapefruit extract during treatment with lomitapide.  Since alcohol may increase levels of hepatic fat and induce or exacerbate liver injury, the manufacturer recommends that patients taking lomitapide not consume more than one alcoholic drink per day.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (534, 5593, 'Acarbose', 'Alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Hypoglycemia most frequently occurs during acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.  Episodes of hypoglycemia may last for 8 to 12 hours after ethanol ingestion.  By contrast, chronic alcohol abuse can cause impaired glucose tolerance and hyperglycemia.  Moderate alcohol consumption generally does not affect blood glucose levels in patients with well controlled diabetes.  A disulfiram-like reaction (e.g., flushing, headache, and nausea) to alcohol has been reported frequently with the use of chlorpropamide and very rarely with other sulfonylureas.', 'alcohol', 'Moderate', 'Patients with diabetes should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Patients with well controlled diabetes should limit their alcohol intake to one drink daily for women and two drinks daily for men (1 drink = 5 oz wine, 12 oz beer, or 1.5 oz distilled spirits) in conjunction with their normal meal plan.  Alcohol should not be consumed on an empty stomach or following exercise.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (535, 24143, 'Acarbose', 'Alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Hypoglycemia most frequently occurs during acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.  Episodes of hypoglycemia may last for 8 to 12 hours after ethanol ingestion.  By contrast, chronic alcohol abuse can cause impaired glucose tolerance and hyperglycemia.  Moderate alcohol consumption generally does not affect blood glucose levels in patients with well controlled diabetes.  A disulfiram-like reaction (e.g., flushing, headache, and nausea) to alcohol has been reported frequently with the use of chlorpropamide and very rarely with other sulfonylureas.', 'alcohol', 'Moderate', 'Patients with diabetes should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Patients with well controlled diabetes should limit their alcohol intake to one drink daily for women and two drinks daily for men (1 drink = 5 oz wine, 12 oz beer, or 1.5 oz distilled spirits) in conjunction with their normal meal plan.  Alcohol should not be consumed on an empty stomach or following exercise.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (536, 8332, 'Apomorphine', 'Alcohol and apomorphine may have additive hypotensive and sedative effects.  Coadministration of 0.6 or 0.3 g/kg of ethanol with apomorphine in healthy subjects resulted in greater decreases in blood pressure compared to apomorphine alone.', 'alcohol', 'Moderate', 'Patients should be advised to avoid consumption of alcohol during apomorphine treatment.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (537, 22989, 'Apomorphine', 'Alcohol and apomorphine may have additive hypotensive and sedative effects.  Coadministration of 0.6 or 0.3 g/kg of ethanol with apomorphine in healthy subjects resulted in greater decreases in blood pressure compared to apomorphine alone.', 'alcohol', 'Moderate', 'Patients should be advised to avoid consumption of alcohol during apomorphine treatment.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (538, 23054, 'Apomorphine', 'Alcohol and apomorphine may have additive hypotensive and sedative effects.  Coadministration of 0.6 or 0.3 g/kg of ethanol with apomorphine in healthy subjects resulted in greater decreases in blood pressure compared to apomorphine alone.', 'alcohol', 'Moderate', 'Patients should be advised to avoid consumption of alcohol during apomorphine treatment.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (539, 17400, 'Lofexidine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (540, 7568, 'Lovastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.  ', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (541, 10128, 'Lovastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.  ', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (542, 16270, 'Lovastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.  ', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (543, 16271, 'Lovastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.  ', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (544, 16272, 'Lovastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.  ', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (545, 21861, 'Lovastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.  ', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (546, 21862, 'Lovastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.  ', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (547, 7568, 'Lovastatin', 'Coadministration with grapefruit juice may significantly increase the plasma concentrations of lovastatin and simvastatin and their active acid metabolites.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Major', 'Patients receiving therapy with lovastatin, simvastatin, or red yeast rice (which contains lovastatin) should be advised to avoid the consumption of grapefruit and grapefruit juice.  Fluvastatin, pravastatin, pitavastatin, and rosuvastatin are metabolized by other enzymes and may be preferable alternatives in some individuals.  All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  Also, patients should either refrain from the use of oat bran and pectin, or separate the administration times by at least 2 to 4 hours if concurrent use cannot be avoided.  Caution may be advisable when coadministered with green tea or green tea extracts.  Dosing reduction of the statin and/or limiting consumption of green tea and green tea products may be required if an interaction is suspected.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (548, 10128, 'Lovastatin', 'Coadministration with grapefruit juice may significantly increase the plasma concentrations of lovastatin and simvastatin and their active acid metabolites.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Major', 'Patients receiving therapy with lovastatin, simvastatin, or red yeast rice (which contains lovastatin) should be advised to avoid the consumption of grapefruit and grapefruit juice.  Fluvastatin, pravastatin, pitavastatin, and rosuvastatin are metabolized by other enzymes and may be preferable alternatives in some individuals.  All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  Also, patients should either refrain from the use of oat bran and pectin, or separate the administration times by at least 2 to 4 hours if concurrent use cannot be avoided.  Caution may be advisable when coadministered with green tea or green tea extracts.  Dosing reduction of the statin and/or limiting consumption of green tea and green tea products may be required if an interaction is suspected.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (549, 16270, 'Lovastatin', 'Coadministration with grapefruit juice may significantly increase the plasma concentrations of lovastatin and simvastatin and their active acid metabolites.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Major', 'Patients receiving therapy with lovastatin, simvastatin, or red yeast rice (which contains lovastatin) should be advised to avoid the consumption of grapefruit and grapefruit juice.  Fluvastatin, pravastatin, pitavastatin, and rosuvastatin are metabolized by other enzymes and may be preferable alternatives in some individuals.  All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  Also, patients should either refrain from the use of oat bran and pectin, or separate the administration times by at least 2 to 4 hours if concurrent use cannot be avoided.  Caution may be advisable when coadministered with green tea or green tea extracts.  Dosing reduction of the statin and/or limiting consumption of green tea and green tea products may be required if an interaction is suspected.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (550, 16271, 'Lovastatin', 'Coadministration with grapefruit juice may significantly increase the plasma concentrations of lovastatin and simvastatin and their active acid metabolites.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Major', 'Patients receiving therapy with lovastatin, simvastatin, or red yeast rice (which contains lovastatin) should be advised to avoid the consumption of grapefruit and grapefruit juice.  Fluvastatin, pravastatin, pitavastatin, and rosuvastatin are metabolized by other enzymes and may be preferable alternatives in some individuals.  All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  Also, patients should either refrain from the use of oat bran and pectin, or separate the administration times by at least 2 to 4 hours if concurrent use cannot be avoided.  Caution may be advisable when coadministered with green tea or green tea extracts.  Dosing reduction of the statin and/or limiting consumption of green tea and green tea products may be required if an interaction is suspected.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (551, 16272, 'Lovastatin', 'Coadministration with grapefruit juice may significantly increase the plasma concentrations of lovastatin and simvastatin and their active acid metabolites.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Major', 'Patients receiving therapy with lovastatin, simvastatin, or red yeast rice (which contains lovastatin) should be advised to avoid the consumption of grapefruit and grapefruit juice.  Fluvastatin, pravastatin, pitavastatin, and rosuvastatin are metabolized by other enzymes and may be preferable alternatives in some individuals.  All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  Also, patients should either refrain from the use of oat bran and pectin, or separate the administration times by at least 2 to 4 hours if concurrent use cannot be avoided.  Caution may be advisable when coadministered with green tea or green tea extracts.  Dosing reduction of the statin and/or limiting consumption of green tea and green tea products may be required if an interaction is suspected.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (552, 21861, 'Lovastatin', 'Coadministration with grapefruit juice may significantly increase the plasma concentrations of lovastatin and simvastatin and their active acid metabolites.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Major', 'Patients receiving therapy with lovastatin, simvastatin, or red yeast rice (which contains lovastatin) should be advised to avoid the consumption of grapefruit and grapefruit juice.  Fluvastatin, pravastatin, pitavastatin, and rosuvastatin are metabolized by other enzymes and may be preferable alternatives in some individuals.  All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  Also, patients should either refrain from the use of oat bran and pectin, or separate the administration times by at least 2 to 4 hours if concurrent use cannot be avoided.  Caution may be advisable when coadministered with green tea or green tea extracts.  Dosing reduction of the statin and/or limiting consumption of green tea and green tea products may be required if an interaction is suspected.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (553, 21862, 'Lovastatin', 'Coadministration with grapefruit juice may significantly increase the plasma concentrations of lovastatin and simvastatin and their active acid metabolites.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Major', 'Patients receiving therapy with lovastatin, simvastatin, or red yeast rice (which contains lovastatin) should be advised to avoid the consumption of grapefruit and grapefruit juice.  Fluvastatin, pravastatin, pitavastatin, and rosuvastatin are metabolized by other enzymes and may be preferable alternatives in some individuals.  All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  Also, patients should either refrain from the use of oat bran and pectin, or separate the administration times by at least 2 to 4 hours if concurrent use cannot be avoided.  Caution may be advisable when coadministered with green tea or green tea extracts.  Dosing reduction of the statin and/or limiting consumption of green tea and green tea products may be required if an interaction is suspected.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (554, 7568, 'Lovastatin', 'Coadministration with grapefruit juice may significantly increase the plasma concentrations of lovastatin and simvastatin and their active acid metabolites.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'green tea', 'Major', 'Caution may be advisable when coadministered with green tea or green tea extracts.  Dosing reduction of the statin and/or limiting consumption of green tea and green tea products may be required if an interaction is suspected.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (555, 10128, 'Lovastatin', 'Coadministration with grapefruit juice may significantly increase the plasma concentrations of lovastatin and simvastatin and their active acid metabolites.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'green tea', 'Major', 'Caution may be advisable when coadministered with green tea or green tea extracts.  Dosing reduction of the statin and/or limiting consumption of green tea and green tea products may be required if an interaction is suspected.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (556, 16270, 'Lovastatin', 'Coadministration with grapefruit juice may significantly increase the plasma concentrations of lovastatin and simvastatin and their active acid metabolites.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'green tea', 'Major', 'Caution may be advisable when coadministered with green tea or green tea extracts.  Dosing reduction of the statin and/or limiting consumption of green tea and green tea products may be required if an interaction is suspected.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (557, 16271, 'Lovastatin', 'Coadministration with grapefruit juice may significantly increase the plasma concentrations of lovastatin and simvastatin and their active acid metabolites.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'green tea', 'Major', 'Caution may be advisable when coadministered with green tea or green tea extracts.  Dosing reduction of the statin and/or limiting consumption of green tea and green tea products may be required if an interaction is suspected.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (558, 16272, 'Lovastatin', 'Coadministration with grapefruit juice may significantly increase the plasma concentrations of lovastatin and simvastatin and their active acid metabolites.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'green tea', 'Major', 'Caution may be advisable when coadministered with green tea or green tea extracts.  Dosing reduction of the statin and/or limiting consumption of green tea and green tea products may be required if an interaction is suspected.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (559, 21861, 'Lovastatin', 'Coadministration with grapefruit juice may significantly increase the plasma concentrations of lovastatin and simvastatin and their active acid metabolites.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'green tea', 'Major', 'Caution may be advisable when coadministered with green tea or green tea extracts.  Dosing reduction of the statin and/or limiting consumption of green tea and green tea products may be required if an interaction is suspected.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (560, 21862, 'Lovastatin', 'Coadministration with grapefruit juice may significantly increase the plasma concentrations of lovastatin and simvastatin and their active acid metabolites.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'green tea', 'Major', 'Caution may be advisable when coadministered with green tea or green tea extracts.  Dosing reduction of the statin and/or limiting consumption of green tea and green tea products may be required if an interaction is suspected.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (561, 616, 'Losartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (562, 617, 'Losartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (563, 618, 'Losartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (564, 3133, 'Losartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (565, 3134, 'Losartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (566, 6776, 'Losartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (567, 6777, 'Losartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (568, 7547, 'Losartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (569, 7553, 'Losartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (570, 21241, 'Losartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (571, 22049, 'Losartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (572, 22050, 'Losartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (573, 22054, 'Losartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (574, 22056, 'Losartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (575, 22057, 'Losartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (576, 22064, 'Losartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (577, 22065, 'Losartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (578, 22066, 'Losartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (579, 22084, 'Losartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (580, 22085, 'Losartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (581, 25862, 'Losartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (582, 26503, 'Losartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (583, 616, 'Losartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).  ARBs can promote hyperkalemia through inhibition of angiotensin II-induced aldosterone secretion.  Patients with diabetes, heart failure, dehydration, or renal insufficiency have a greater risk of developing hyperkalemia.', 'Food High in Potassium', 'Moderate', 'Patients who regularly consume grapefruits and grapefruit juice should be monitored for altered efficacy of losartan.  Grapefruits and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (584, 617, 'Losartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).  ARBs can promote hyperkalemia through inhibition of angiotensin II-induced aldosterone secretion.  Patients with diabetes, heart failure, dehydration, or renal insufficiency have a greater risk of developing hyperkalemia.', 'Food High in Potassium', 'Moderate', 'Patients who regularly consume grapefruits and grapefruit juice should be monitored for altered efficacy of losartan.  Grapefruits and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (585, 618, 'Losartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).  ARBs can promote hyperkalemia through inhibition of angiotensin II-induced aldosterone secretion.  Patients with diabetes, heart failure, dehydration, or renal insufficiency have a greater risk of developing hyperkalemia.', 'Food High in Potassium', 'Moderate', 'Patients who regularly consume grapefruits and grapefruit juice should be monitored for altered efficacy of losartan.  Grapefruits and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (586, 3133, 'Losartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).  ARBs can promote hyperkalemia through inhibition of angiotensin II-induced aldosterone secretion.  Patients with diabetes, heart failure, dehydration, or renal insufficiency have a greater risk of developing hyperkalemia.', 'Food High in Potassium', 'Moderate', 'Patients who regularly consume grapefruits and grapefruit juice should be monitored for altered efficacy of losartan.  Grapefruits and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (587, 3134, 'Losartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).  ARBs can promote hyperkalemia through inhibition of angiotensin II-induced aldosterone secretion.  Patients with diabetes, heart failure, dehydration, or renal insufficiency have a greater risk of developing hyperkalemia.', 'Food High in Potassium', 'Moderate', 'Patients who regularly consume grapefruits and grapefruit juice should be monitored for altered efficacy of losartan.  Grapefruits and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (588, 6776, 'Losartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).  ARBs can promote hyperkalemia through inhibition of angiotensin II-induced aldosterone secretion.  Patients with diabetes, heart failure, dehydration, or renal insufficiency have a greater risk of developing hyperkalemia.', 'Food High in Potassium', 'Moderate', 'Patients who regularly consume grapefruits and grapefruit juice should be monitored for altered efficacy of losartan.  Grapefruits and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (589, 6777, 'Losartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).  ARBs can promote hyperkalemia through inhibition of angiotensin II-induced aldosterone secretion.  Patients with diabetes, heart failure, dehydration, or renal insufficiency have a greater risk of developing hyperkalemia.', 'Food High in Potassium', 'Moderate', 'Patients who regularly consume grapefruits and grapefruit juice should be monitored for altered efficacy of losartan.  Grapefruits and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (590, 7547, 'Losartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).  ARBs can promote hyperkalemia through inhibition of angiotensin II-induced aldosterone secretion.  Patients with diabetes, heart failure, dehydration, or renal insufficiency have a greater risk of developing hyperkalemia.', 'Food High in Potassium', 'Moderate', 'Patients who regularly consume grapefruits and grapefruit juice should be monitored for altered efficacy of losartan.  Grapefruits and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (591, 7553, 'Losartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).  ARBs can promote hyperkalemia through inhibition of angiotensin II-induced aldosterone secretion.  Patients with diabetes, heart failure, dehydration, or renal insufficiency have a greater risk of developing hyperkalemia.', 'Food High in Potassium', 'Moderate', 'Patients who regularly consume grapefruits and grapefruit juice should be monitored for altered efficacy of losartan.  Grapefruits and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (592, 21241, 'Losartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).  ARBs can promote hyperkalemia through inhibition of angiotensin II-induced aldosterone secretion.  Patients with diabetes, heart failure, dehydration, or renal insufficiency have a greater risk of developing hyperkalemia.', 'Food High in Potassium', 'Moderate', 'Patients who regularly consume grapefruits and grapefruit juice should be monitored for altered efficacy of losartan.  Grapefruits and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (593, 22049, 'Losartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).  ARBs can promote hyperkalemia through inhibition of angiotensin II-induced aldosterone secretion.  Patients with diabetes, heart failure, dehydration, or renal insufficiency have a greater risk of developing hyperkalemia.', 'Food High in Potassium', 'Moderate', 'Patients who regularly consume grapefruits and grapefruit juice should be monitored for altered efficacy of losartan.  Grapefruits and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (594, 22050, 'Losartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).  ARBs can promote hyperkalemia through inhibition of angiotensin II-induced aldosterone secretion.  Patients with diabetes, heart failure, dehydration, or renal insufficiency have a greater risk of developing hyperkalemia.', 'Food High in Potassium', 'Moderate', 'Patients who regularly consume grapefruits and grapefruit juice should be monitored for altered efficacy of losartan.  Grapefruits and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (595, 22054, 'Losartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).  ARBs can promote hyperkalemia through inhibition of angiotensin II-induced aldosterone secretion.  Patients with diabetes, heart failure, dehydration, or renal insufficiency have a greater risk of developing hyperkalemia.', 'Food High in Potassium', 'Moderate', 'Patients who regularly consume grapefruits and grapefruit juice should be monitored for altered efficacy of losartan.  Grapefruits and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (596, 22056, 'Losartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).  ARBs can promote hyperkalemia through inhibition of angiotensin II-induced aldosterone secretion.  Patients with diabetes, heart failure, dehydration, or renal insufficiency have a greater risk of developing hyperkalemia.', 'Food High in Potassium', 'Moderate', 'Patients who regularly consume grapefruits and grapefruit juice should be monitored for altered efficacy of losartan.  Grapefruits and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (597, 22057, 'Losartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).  ARBs can promote hyperkalemia through inhibition of angiotensin II-induced aldosterone secretion.  Patients with diabetes, heart failure, dehydration, or renal insufficiency have a greater risk of developing hyperkalemia.', 'Food High in Potassium', 'Moderate', 'Patients who regularly consume grapefruits and grapefruit juice should be monitored for altered efficacy of losartan.  Grapefruits and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (598, 22064, 'Losartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).  ARBs can promote hyperkalemia through inhibition of angiotensin II-induced aldosterone secretion.  Patients with diabetes, heart failure, dehydration, or renal insufficiency have a greater risk of developing hyperkalemia.', 'Food High in Potassium', 'Moderate', 'Patients who regularly consume grapefruits and grapefruit juice should be monitored for altered efficacy of losartan.  Grapefruits and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (599, 22065, 'Losartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).  ARBs can promote hyperkalemia through inhibition of angiotensin II-induced aldosterone secretion.  Patients with diabetes, heart failure, dehydration, or renal insufficiency have a greater risk of developing hyperkalemia.', 'Food High in Potassium', 'Moderate', 'Patients who regularly consume grapefruits and grapefruit juice should be monitored for altered efficacy of losartan.  Grapefruits and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (600, 22066, 'Losartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).  ARBs can promote hyperkalemia through inhibition of angiotensin II-induced aldosterone secretion.  Patients with diabetes, heart failure, dehydration, or renal insufficiency have a greater risk of developing hyperkalemia.', 'Food High in Potassium', 'Moderate', 'Patients who regularly consume grapefruits and grapefruit juice should be monitored for altered efficacy of losartan.  Grapefruits and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (601, 22084, 'Losartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).  ARBs can promote hyperkalemia through inhibition of angiotensin II-induced aldosterone secretion.  Patients with diabetes, heart failure, dehydration, or renal insufficiency have a greater risk of developing hyperkalemia.', 'Food High in Potassium', 'Moderate', 'Patients who regularly consume grapefruits and grapefruit juice should be monitored for altered efficacy of losartan.  Grapefruits and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (602, 22085, 'Losartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).  ARBs can promote hyperkalemia through inhibition of angiotensin II-induced aldosterone secretion.  Patients with diabetes, heart failure, dehydration, or renal insufficiency have a greater risk of developing hyperkalemia.', 'Food High in Potassium', 'Moderate', 'Patients who regularly consume grapefruits and grapefruit juice should be monitored for altered efficacy of losartan.  Grapefruits and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (603, 25862, 'Losartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).  ARBs can promote hyperkalemia through inhibition of angiotensin II-induced aldosterone secretion.  Patients with diabetes, heart failure, dehydration, or renal insufficiency have a greater risk of developing hyperkalemia.', 'Food High in Potassium', 'Moderate', 'Patients who regularly consume grapefruits and grapefruit juice should be monitored for altered efficacy of losartan.  Grapefruits and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (604, 26503, 'Losartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).  ARBs can promote hyperkalemia through inhibition of angiotensin II-induced aldosterone secretion.  Patients with diabetes, heart failure, dehydration, or renal insufficiency have a greater risk of developing hyperkalemia.', 'Food High in Potassium', 'Moderate', 'Patients who regularly consume grapefruits and grapefruit juice should be monitored for altered efficacy of losartan.  Grapefruits and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (605, 11849, 'Lorlatinib', 'Grapefruit and grapefruit juice may significantly increase the plasma concentrations of lorlatinib.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall induced by certain compounds present in grapefruit.  Because grapefruit juice inhibits primarily intestinal rather than hepatic CYP450 3A4, the magnitude of interaction is greatest for those drugs that undergo significant presystemic metabolism by CYP450 3A4 (i.e., drugs with low oral bioavailability).  In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands.', 'grapefruit juice', 'Major', 'Patients treated with lorlatinib should avoid consumption of grapefruit, grapefruit juice, and any supplement containing grapefruit extract.  If coadministration is unavoidable, some authorities recommend reducing the initial dosage of lorlatinib from 100 mg orally once daily to 75 mg orally once daily.  In patients who have had a dosage reduction to 75 mg orally once daily due to adverse reactions, the lorlatinib dosage should be further reduced to 50 mg orally once daily upon initiation of a potent CYP450 3A4 inhibitor.  After 3 plasma half-lives following discontinuation of the potent CYP450 3A4 inhibitor, the lorlatinib dosage may be increased to that used prior to initiation of the inhibitor.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (606, 13897, 'Lorlatinib', 'Grapefruit and grapefruit juice may significantly increase the plasma concentrations of lorlatinib.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall induced by certain compounds present in grapefruit.  Because grapefruit juice inhibits primarily intestinal rather than hepatic CYP450 3A4, the magnitude of interaction is greatest for those drugs that undergo significant presystemic metabolism by CYP450 3A4 (i.e., drugs with low oral bioavailability).  In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands.', 'grapefruit juice', 'Major', 'Patients treated with lorlatinib should avoid consumption of grapefruit, grapefruit juice, and any supplement containing grapefruit extract.  If coadministration is unavoidable, some authorities recommend reducing the initial dosage of lorlatinib from 100 mg orally once daily to 75 mg orally once daily.  In patients who have had a dosage reduction to 75 mg orally once daily due to adverse reactions, the lorlatinib dosage should be further reduced to 50 mg orally once daily upon initiation of a potent CYP450 3A4 inhibitor.  After 3 plasma half-lives following discontinuation of the potent CYP450 3A4 inhibitor, the lorlatinib dosage may be increased to that used prior to initiation of the inhibitor.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (607, 22082, 'Loxapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (608, 22083, 'Loxapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (609, 0, 'Lumateperone', 'Alcohol may potentiate some of the pharmacologic effects of central nervous system (CNS)-active agents.  Use in combination may result in additive CNS depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (610, 0, 'Lumateperone', 'Grapefruit and grapefruit juice may increase the plasma concentrations of lumateperone.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  Inhibition of hepatic CYP', 'grapefruit juice', 'Moderate', 'Lumateperone should be administered with food.  Coadministration of grapefruit or grapefruit juice with lumateperone should be avoided.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (611, 9850, 'Lurasidone', 'Grapefruit juice may significantly increase the plasma concentrations of lurasidone.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Major', 'Patients treated with lurasidone should avoid consumption of grapefruit and grapefruit juice as well as alcohol.  Lurasidone should be taken with food (at least 350 calories).', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (612, 10106, 'Lurasidone', 'Grapefruit juice may significantly increase the plasma concentrations of lurasidone.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Major', 'Patients treated with lurasidone should avoid consumption of grapefruit and grapefruit juice as well as alcohol.  Lurasidone should be taken with food (at least 350 calories).', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (613, 28600, 'Lurasidone', 'Grapefruit juice may significantly increase the plasma concentrations of lurasidone.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Major', 'Patients treated with lurasidone should avoid consumption of grapefruit and grapefruit juice as well as alcohol.  Lurasidone should be taken with food (at least 350 calories).', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (614, 30460, 'Lurasidone', 'Grapefruit juice may significantly increase the plasma concentrations of lurasidone.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Major', 'Patients treated with lurasidone should avoid consumption of grapefruit and grapefruit juice as well as alcohol.  Lurasidone should be taken with food (at least 350 calories).', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (615, 30461, 'Lurasidone', 'Grapefruit juice may significantly increase the plasma concentrations of lurasidone.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Major', 'Patients treated with lurasidone should avoid consumption of grapefruit and grapefruit juice as well as alcohol.  Lurasidone should be taken with food (at least 350 calories).', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (616, 31523, 'Lurasidone', 'Grapefruit juice may significantly increase the plasma concentrations of lurasidone.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Major', 'Patients treated with lurasidone should avoid consumption of grapefruit and grapefruit juice as well as alcohol.  Lurasidone should be taken with food (at least 350 calories).', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (617, 0, 'Lurbinectedin', 'Coadministration with inhibitors of CYP450 3A4 such as grapefruit juice may increase the plasma concentrations of lurbinectedin, which may increase the incidence and severity of adverse reactions, such as myelosuppression and hepatotoxicity.', 'grapefruit juice', 'Moderate', 'The manufacturer recommends avoiding eating or drinking grapefruit or products that contain grapefruit juice during treatment with lurbenectedin.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (618, 0, 'Macimorelin', 'Food reduces the oral bioavailability of macimorelin.  According to the product labeling, administration with a liquid meal decreased macimorelin peak plasma concentration (Cmax) and systemic exposure (AUC) by 55% and 49%, respectively, compared to administration under fasting conditions (i.e., for at least 8 hours).', 'food', 'Moderate', 'Macimorelin should be administered after fasting for at least 8 hours.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (619, 0, 'Maraviroc', 'Administration with food may reduce the bioavailability of maraviroc.  According to the product labeling, coadministration of a 300 mg dose of maraviroc with a high-fat breakfast reduced maraviroc peak plasma concentration (Cmax) and systemic exposure (AUC) by 33% in healthy volunteers.', 'high-fat foods', 'Minor', 'No food restrictions were used in the clinical studies that demonstrated the safety and efficacy of maraviroc.  Therefore, maraviroc can be taken with or without food at the recommended dosage.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (620, 0, 'Maprotiline', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (621, 8617, 'Meclizine', 'Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be increased with the combination.  The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system.', 'alcohol', 'Moderate', 'Alcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (622, 22430, 'Meclizine', 'Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be increased with the combination.  The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system.', 'alcohol', 'Moderate', 'Alcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (623, 24890, 'Meclofenamic acid', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (624, 7659, 'Mefenamic acid', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (625, 18838, 'Mefenamic acid', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (626, 22457, 'Mefenamic acid', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (627, 22458, 'Mefenamic acid', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (628, 25061, 'Mefenamic acid', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (629, 25063, 'Mefenamic acid', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (630, 25064, 'Mefenamic acid', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (631, 25065, 'Mefenamic acid', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (632, 14317, 'Mefloquine', 'Food enhances the oral absorption and bioavailability of mefloquine.  The proposed mechanism is increased drug solubility in the presence of food.', 'high-fat foods', 'Moderate', 'To ensure maximal oral absorption, mefloquine should be administered immediately after a meal with at least 8 ounces of water.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (633, 1646, 'Melatonin', 'Oral caffeine may significantly increase the bioavailability of melatonin.  The proposed mechanism is inhibition of CYP450 1A2 first-pass metabolism.', 'coffee', 'Moderate', 'Caution and monitoring are recommended if melatonin is used with inhibitors of CYP450 1A2 like caffeine or inducers of CYP450 1A2 like cigarette smoking.  Consumption of alcohol should be avoided when taking melatonin.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (634, 3594, 'Melatonin', 'Oral caffeine may significantly increase the bioavailability of melatonin.  The proposed mechanism is inhibition of CYP450 1A2 first-pass metabolism.', 'coffee', 'Moderate', 'Caution and monitoring are recommended if melatonin is used with inhibitors of CYP450 1A2 like caffeine or inducers of CYP450 1A2 like cigarette smoking.  Consumption of alcohol should be avoided when taking melatonin.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (635, 3764, 'Melatonin', 'Oral caffeine may significantly increase the bioavailability of melatonin.  The proposed mechanism is inhibition of CYP450 1A2 first-pass metabolism.', 'coffee', 'Moderate', 'Caution and monitoring are recommended if melatonin is used with inhibitors of CYP450 1A2 like caffeine or inducers of CYP450 1A2 like cigarette smoking.  Consumption of alcohol should be avoided when taking melatonin.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (636, 4860, 'Melatonin', 'Oral caffeine may significantly increase the bioavailability of melatonin.  The proposed mechanism is inhibition of CYP450 1A2 first-pass metabolism.', 'coffee', 'Moderate', 'Caution and monitoring are recommended if melatonin is used with inhibitors of CYP450 1A2 like caffeine or inducers of CYP450 1A2 like cigarette smoking.  Consumption of alcohol should be avoided when taking melatonin.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (637, 4948, 'Melatonin', 'Oral caffeine may significantly increase the bioavailability of melatonin.  The proposed mechanism is inhibition of CYP450 1A2 first-pass metabolism.', 'coffee', 'Moderate', 'Caution and monitoring are recommended if melatonin is used with inhibitors of CYP450 1A2 like caffeine or inducers of CYP450 1A2 like cigarette smoking.  Consumption of alcohol should be avoided when taking melatonin.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (638, 7117, 'Melatonin', 'Oral caffeine may significantly increase the bioavailability of melatonin.  The proposed mechanism is inhibition of CYP450 1A2 first-pass metabolism.', 'coffee', 'Moderate', 'Caution and monitoring are recommended if melatonin is used with inhibitors of CYP450 1A2 like caffeine or inducers of CYP450 1A2 like cigarette smoking.  Consumption of alcohol should be avoided when taking melatonin.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (639, 7118, 'Melatonin', 'Oral caffeine may significantly increase the bioavailability of melatonin.  The proposed mechanism is inhibition of CYP450 1A2 first-pass metabolism.', 'coffee', 'Moderate', 'Caution and monitoring are recommended if melatonin is used with inhibitors of CYP450 1A2 like caffeine or inducers of CYP450 1A2 like cigarette smoking.  Consumption of alcohol should be avoided when taking melatonin.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (640, 7120, 'Melatonin', 'Oral caffeine may significantly increase the bioavailability of melatonin.  The proposed mechanism is inhibition of CYP450 1A2 first-pass metabolism.', 'coffee', 'Moderate', 'Caution and monitoring are recommended if melatonin is used with inhibitors of CYP450 1A2 like caffeine or inducers of CYP450 1A2 like cigarette smoking.  Consumption of alcohol should be avoided when taking melatonin.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (641, 7171, 'Melatonin', 'Oral caffeine may significantly increase the bioavailability of melatonin.  The proposed mechanism is inhibition of CYP450 1A2 first-pass metabolism.', 'coffee', 'Moderate', 'Caution and monitoring are recommended if melatonin is used with inhibitors of CYP450 1A2 like caffeine or inducers of CYP450 1A2 like cigarette smoking.  Consumption of alcohol should be avoided when taking melatonin.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (642, 10877, 'Melatonin', 'Oral caffeine may significantly increase the bioavailability of melatonin.  The proposed mechanism is inhibition of CYP450 1A2 first-pass metabolism.', 'coffee', 'Moderate', 'Caution and monitoring are recommended if melatonin is used with inhibitors of CYP450 1A2 like caffeine or inducers of CYP450 1A2 like cigarette smoking.  Consumption of alcohol should be avoided when taking melatonin.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (643, 13638, 'Melatonin', 'Oral caffeine may significantly increase the bioavailability of melatonin.  The proposed mechanism is inhibition of CYP450 1A2 first-pass metabolism.', 'coffee', 'Moderate', 'Caution and monitoring are recommended if melatonin is used with inhibitors of CYP450 1A2 like caffeine or inducers of CYP450 1A2 like cigarette smoking.  Consumption of alcohol should be avoided when taking melatonin.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (644, 13930, 'Melatonin', 'Oral caffeine may significantly increase the bioavailability of melatonin.  The proposed mechanism is inhibition of CYP450 1A2 first-pass metabolism.', 'coffee', 'Moderate', 'Caution and monitoring are recommended if melatonin is used with inhibitors of CYP450 1A2 like caffeine or inducers of CYP450 1A2 like cigarette smoking.  Consumption of alcohol should be avoided when taking melatonin.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (645, 15145, 'Melatonin', 'Oral caffeine may significantly increase the bioavailability of melatonin.  The proposed mechanism is inhibition of CYP450 1A2 first-pass metabolism.', 'coffee', 'Moderate', 'Caution and monitoring are recommended if melatonin is used with inhibitors of CYP450 1A2 like caffeine or inducers of CYP450 1A2 like cigarette smoking.  Consumption of alcohol should be avoided when taking melatonin.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (646, 15978, 'Melatonin', 'Oral caffeine may significantly increase the bioavailability of melatonin.  The proposed mechanism is inhibition of CYP450 1A2 first-pass metabolism.', 'coffee', 'Moderate', 'Caution and monitoring are recommended if melatonin is used with inhibitors of CYP450 1A2 like caffeine or inducers of CYP450 1A2 like cigarette smoking.  Consumption of alcohol should be avoided when taking melatonin.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (647, 22495, 'Melatonin', 'Oral caffeine may significantly increase the bioavailability of melatonin.  The proposed mechanism is inhibition of CYP450 1A2 first-pass metabolism.', 'coffee', 'Moderate', 'Caution and monitoring are recommended if melatonin is used with inhibitors of CYP450 1A2 like caffeine or inducers of CYP450 1A2 like cigarette smoking.  Consumption of alcohol should be avoided when taking melatonin.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (648, 23958, 'Melatonin', 'Oral caffeine may significantly increase the bioavailability of melatonin.  The proposed mechanism is inhibition of CYP450 1A2 first-pass metabolism.', 'coffee', 'Moderate', 'Caution and monitoring are recommended if melatonin is used with inhibitors of CYP450 1A2 like caffeine or inducers of CYP450 1A2 like cigarette smoking.  Consumption of alcohol should be avoided when taking melatonin.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (649, 30427, 'Melatonin', 'Oral caffeine may significantly increase the bioavailability of melatonin.  The proposed mechanism is inhibition of CYP450 1A2 first-pass metabolism.', 'coffee', 'Moderate', 'Caution and monitoring are recommended if melatonin is used with inhibitors of CYP450 1A2 like caffeine or inducers of CYP450 1A2 like cigarette smoking.  Consumption of alcohol should be avoided when taking melatonin.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (650, 30889, 'Melatonin', 'Oral caffeine may significantly increase the bioavailability of melatonin.  The proposed mechanism is inhibition of CYP450 1A2 first-pass metabolism.', 'coffee', 'Moderate', 'Caution and monitoring are recommended if melatonin is used with inhibitors of CYP450 1A2 like caffeine or inducers of CYP450 1A2 like cigarette smoking.  Consumption of alcohol should be avoided when taking melatonin.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (651, 30902, 'Melatonin', 'Oral caffeine may significantly increase the bioavailability of melatonin.  The proposed mechanism is inhibition of CYP450 1A2 first-pass metabolism.', 'coffee', 'Moderate', 'Caution and monitoring are recommended if melatonin is used with inhibitors of CYP450 1A2 like caffeine or inducers of CYP450 1A2 like cigarette smoking.  Consumption of alcohol should be avoided when taking melatonin.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (652, 32093, 'Melatonin', 'Oral caffeine may significantly increase the bioavailability of melatonin.  The proposed mechanism is inhibition of CYP450 1A2 first-pass metabolism.', 'coffee', 'Moderate', 'Caution and monitoring are recommended if melatonin is used with inhibitors of CYP450 1A2 like caffeine or inducers of CYP450 1A2 like cigarette smoking.  Consumption of alcohol should be avoided when taking melatonin.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (653, 32164, 'Melatonin', 'Oral caffeine may significantly increase the bioavailability of melatonin.  The proposed mechanism is inhibition of CYP450 1A2 first-pass metabolism.', 'coffee', 'Moderate', 'Caution and monitoring are recommended if melatonin is used with inhibitors of CYP450 1A2 like caffeine or inducers of CYP450 1A2 like cigarette smoking.  Consumption of alcohol should be avoided when taking melatonin.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (654, 1646, 'Melatonin', 'Oral caffeine may significantly increase the bioavailability of melatonin.  The proposed mechanism is inhibition of CYP450 1A2 first-pass metabolism.', 'cigarette', 'Moderate', 'Caution and monitoring are recommended if melatonin is used with inhibitors of CYP450 1A2 like caffeine or inducers of CYP450 1A2 like cigarette smoking.  Consumption of alcohol should be avoided when taking melatonin.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (655, 3594, 'Melatonin', 'Oral caffeine may significantly increase the bioavailability of melatonin.  The proposed mechanism is inhibition of CYP450 1A2 first-pass metabolism.', 'cigarette', 'Moderate', 'Caution and monitoring are recommended if melatonin is used with inhibitors of CYP450 1A2 like caffeine or inducers of CYP450 1A2 like cigarette smoking.  Consumption of alcohol should be avoided when taking melatonin.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (656, 3764, 'Melatonin', 'Oral caffeine may significantly increase the bioavailability of melatonin.  The proposed mechanism is inhibition of CYP450 1A2 first-pass metabolism.', 'cigarette', 'Moderate', 'Caution and monitoring are recommended if melatonin is used with inhibitors of CYP450 1A2 like caffeine or inducers of CYP450 1A2 like cigarette smoking.  Consumption of alcohol should be avoided when taking melatonin.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (657, 4860, 'Melatonin', 'Oral caffeine may significantly increase the bioavailability of melatonin.  The proposed mechanism is inhibition of CYP450 1A2 first-pass metabolism.', 'cigarette', 'Moderate', 'Caution and monitoring are recommended if melatonin is used with inhibitors of CYP450 1A2 like caffeine or inducers of CYP450 1A2 like cigarette smoking.  Consumption of alcohol should be avoided when taking melatonin.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (658, 4948, 'Melatonin', 'Oral caffeine may significantly increase the bioavailability of melatonin.  The proposed mechanism is inhibition of CYP450 1A2 first-pass metabolism.', 'cigarette', 'Moderate', 'Caution and monitoring are recommended if melatonin is used with inhibitors of CYP450 1A2 like caffeine or inducers of CYP450 1A2 like cigarette smoking.  Consumption of alcohol should be avoided when taking melatonin.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (659, 7117, 'Melatonin', 'Oral caffeine may significantly increase the bioavailability of melatonin.  The proposed mechanism is inhibition of CYP450 1A2 first-pass metabolism.', 'cigarette', 'Moderate', 'Caution and monitoring are recommended if melatonin is used with inhibitors of CYP450 1A2 like caffeine or inducers of CYP450 1A2 like cigarette smoking.  Consumption of alcohol should be avoided when taking melatonin.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (660, 7118, 'Melatonin', 'Oral caffeine may significantly increase the bioavailability of melatonin.  The proposed mechanism is inhibition of CYP450 1A2 first-pass metabolism.', 'cigarette', 'Moderate', 'Caution and monitoring are recommended if melatonin is used with inhibitors of CYP450 1A2 like caffeine or inducers of CYP450 1A2 like cigarette smoking.  Consumption of alcohol should be avoided when taking melatonin.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (661, 7120, 'Melatonin', 'Oral caffeine may significantly increase the bioavailability of melatonin.  The proposed mechanism is inhibition of CYP450 1A2 first-pass metabolism.', 'cigarette', 'Moderate', 'Caution and monitoring are recommended if melatonin is used with inhibitors of CYP450 1A2 like caffeine or inducers of CYP450 1A2 like cigarette smoking.  Consumption of alcohol should be avoided when taking melatonin.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (662, 7171, 'Melatonin', 'Oral caffeine may significantly increase the bioavailability of melatonin.  The proposed mechanism is inhibition of CYP450 1A2 first-pass metabolism.', 'cigarette', 'Moderate', 'Caution and monitoring are recommended if melatonin is used with inhibitors of CYP450 1A2 like caffeine or inducers of CYP450 1A2 like cigarette smoking.  Consumption of alcohol should be avoided when taking melatonin.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (663, 10877, 'Melatonin', 'Oral caffeine may significantly increase the bioavailability of melatonin.  The proposed mechanism is inhibition of CYP450 1A2 first-pass metabolism.', 'cigarette', 'Moderate', 'Caution and monitoring are recommended if melatonin is used with inhibitors of CYP450 1A2 like caffeine or inducers of CYP450 1A2 like cigarette smoking.  Consumption of alcohol should be avoided when taking melatonin.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (664, 13638, 'Melatonin', 'Oral caffeine may significantly increase the bioavailability of melatonin.  The proposed mechanism is inhibition of CYP450 1A2 first-pass metabolism.', 'cigarette', 'Moderate', 'Caution and monitoring are recommended if melatonin is used with inhibitors of CYP450 1A2 like caffeine or inducers of CYP450 1A2 like cigarette smoking.  Consumption of alcohol should be avoided when taking melatonin.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (665, 13930, 'Melatonin', 'Oral caffeine may significantly increase the bioavailability of melatonin.  The proposed mechanism is inhibition of CYP450 1A2 first-pass metabolism.', 'cigarette', 'Moderate', 'Caution and monitoring are recommended if melatonin is used with inhibitors of CYP450 1A2 like caffeine or inducers of CYP450 1A2 like cigarette smoking.  Consumption of alcohol should be avoided when taking melatonin.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (666, 15145, 'Melatonin', 'Oral caffeine may significantly increase the bioavailability of melatonin.  The proposed mechanism is inhibition of CYP450 1A2 first-pass metabolism.', 'cigarette', 'Moderate', 'Caution and monitoring are recommended if melatonin is used with inhibitors of CYP450 1A2 like caffeine or inducers of CYP450 1A2 like cigarette smoking.  Consumption of alcohol should be avoided when taking melatonin.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (667, 15978, 'Melatonin', 'Oral caffeine may significantly increase the bioavailability of melatonin.  The proposed mechanism is inhibition of CYP450 1A2 first-pass metabolism.', 'cigarette', 'Moderate', 'Caution and monitoring are recommended if melatonin is used with inhibitors of CYP450 1A2 like caffeine or inducers of CYP450 1A2 like cigarette smoking.  Consumption of alcohol should be avoided when taking melatonin.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (668, 22495, 'Melatonin', 'Oral caffeine may significantly increase the bioavailability of melatonin.  The proposed mechanism is inhibition of CYP450 1A2 first-pass metabolism.', 'cigarette', 'Moderate', 'Caution and monitoring are recommended if melatonin is used with inhibitors of CYP450 1A2 like caffeine or inducers of CYP450 1A2 like cigarette smoking.  Consumption of alcohol should be avoided when taking melatonin.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (669, 23958, 'Melatonin', 'Oral caffeine may significantly increase the bioavailability of melatonin.  The proposed mechanism is inhibition of CYP450 1A2 first-pass metabolism.', 'cigarette', 'Moderate', 'Caution and monitoring are recommended if melatonin is used with inhibitors of CYP450 1A2 like caffeine or inducers of CYP450 1A2 like cigarette smoking.  Consumption of alcohol should be avoided when taking melatonin.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (670, 30427, 'Melatonin', 'Oral caffeine may significantly increase the bioavailability of melatonin.  The proposed mechanism is inhibition of CYP450 1A2 first-pass metabolism.', 'cigarette', 'Moderate', 'Caution and monitoring are recommended if melatonin is used with inhibitors of CYP450 1A2 like caffeine or inducers of CYP450 1A2 like cigarette smoking.  Consumption of alcohol should be avoided when taking melatonin.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (671, 30889, 'Melatonin', 'Oral caffeine may significantly increase the bioavailability of melatonin.  The proposed mechanism is inhibition of CYP450 1A2 first-pass metabolism.', 'cigarette', 'Moderate', 'Caution and monitoring are recommended if melatonin is used with inhibitors of CYP450 1A2 like caffeine or inducers of CYP450 1A2 like cigarette smoking.  Consumption of alcohol should be avoided when taking melatonin.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (672, 30902, 'Melatonin', 'Oral caffeine may significantly increase the bioavailability of melatonin.  The proposed mechanism is inhibition of CYP450 1A2 first-pass metabolism.', 'cigarette', 'Moderate', 'Caution and monitoring are recommended if melatonin is used with inhibitors of CYP450 1A2 like caffeine or inducers of CYP450 1A2 like cigarette smoking.  Consumption of alcohol should be avoided when taking melatonin.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (673, 32093, 'Melatonin', 'Oral caffeine may significantly increase the bioavailability of melatonin.  The proposed mechanism is inhibition of CYP450 1A2 first-pass metabolism.', 'cigarette', 'Moderate', 'Caution and monitoring are recommended if melatonin is used with inhibitors of CYP450 1A2 like caffeine or inducers of CYP450 1A2 like cigarette smoking.  Consumption of alcohol should be avoided when taking melatonin.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (674, 32164, 'Melatonin', 'Oral caffeine may significantly increase the bioavailability of melatonin.  The proposed mechanism is inhibition of CYP450 1A2 first-pass metabolism.', 'cigarette', 'Moderate', 'Caution and monitoring are recommended if melatonin is used with inhibitors of CYP450 1A2 like caffeine or inducers of CYP450 1A2 like cigarette smoking.  Consumption of alcohol should be avoided when taking melatonin.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (675, 786, 'Meloxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (676, 788, 'Meloxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (677, 789, 'Meloxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (678, 790, 'Meloxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (679, 7832, 'Meloxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (680, 7833, 'Meloxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (681, 7835, 'Meloxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (682, 7905, 'Meloxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (683, 7906, 'Meloxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (684, 7909, 'Meloxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (685, 7912, 'Meloxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (686, 7913, 'Meloxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (687, 7917, 'Meloxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (688, 7918, 'Meloxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (689, 8107, 'Meloxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (690, 8109, 'Meloxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (691, 8110, 'Meloxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (692, 8111, 'Meloxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (693, 8258, 'Meloxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (694, 8263, 'Meloxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (695, 8265, 'Meloxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (696, 8372, 'Meloxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (697, 8373, 'Meloxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (698, 14230, 'Meloxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (699, 14435, 'Meloxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (700, 22443, 'Meloxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (701, 22504, 'Meloxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (702, 22509, 'Meloxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (703, 22511, 'Meloxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (704, 22864, 'Meloxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (705, 22866, 'Meloxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (706, 22878, 'Meloxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (707, 22879, 'Meloxicam', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (708, 0, 'Mesoridazine', 'Concurrent use of ethanol and phenothiazines may result in additive CNS depression and psychomotor impairment.  Also, ethanol may precipitate dystonic reactions in patients who are taking phenothiazines.', 'alcohol', 'Moderate', 'Patients should be advised to avoid alcohol during phenothiazine therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (709, 22745, 'Meprobamate', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (710, 0, 'Mepenzolate', 'Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be increased with the combination.  The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system.', 'alcohol', 'Moderate', 'Alcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (711, 25505, 'Mercaptopurine', 'Limited data suggest that food may decrease the oral bioavailability of 6-mercaptopurine (6-MP).', 'food', 'Moderate', 'Until more information is available regarding the effect of food on 6-MP absorption, it may be advisable to take 6-MP on an empty stomach 1 hour before or 2 hours after a meal.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (712, 0, 'Metamfetamine', 'Alcohol may potentiate the central nervous system and cardiovascular effects of centrally-acting appetite suppressants.', 'alcohol', 'Moderate', 'Concomitant use of centrally-acting appetite suppressants and alcohol should be avoided if possible, especially in patients with a history of cardiovascular disease.  Patients should be counselled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (713, 0, 'Meperidine', 'Ethanol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics.', 'alcohol', 'Moderate', 'Concomitant use of opioid analgesics with ethanol should be avoided.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (714, 8073, 'Metaxalone', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (715, 26426, 'Metaxalone', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (716, 614, 'Metformin', 'Alcohol can potentiate the effect of metformin on lactate metabolism and increase the risk of lactic acidosis.  In addition, alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Although hypoglycemia rarely occurs during treatment with metformin alone, the risk may increase with acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.', 'alcohol', 'Major', 'Metformin should be taken with meals, and excessive alcohol intake should be avoided during treatment.  Diabetes patients in general should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Alcohol should not be consumed on an empty stomach or following exercise, as it may increase the risk of hypoglycemia.  Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon).  With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias.  Metformin should be withdrawn promptly if lactic acidosis is suspected.  Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis.  Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (717, 2576, 'Metformin', 'Alcohol can potentiate the effect of metformin on lactate metabolism and increase the risk of lactic acidosis.  In addition, alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Although hypoglycemia rarely occurs during treatment with metformin alone, the risk may increase with acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.', 'alcohol', 'Major', 'Metformin should be taken with meals, and excessive alcohol intake should be avoided during treatment.  Diabetes patients in general should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Alcohol should not be consumed on an empty stomach or following exercise, as it may increase the risk of hypoglycemia.  Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon).  With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias.  Metformin should be withdrawn promptly if lactic acidosis is suspected.  Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis.  Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (718, 2577, 'Metformin', 'Alcohol can potentiate the effect of metformin on lactate metabolism and increase the risk of lactic acidosis.  In addition, alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Although hypoglycemia rarely occurs during treatment with metformin alone, the risk may increase with acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.', 'alcohol', 'Major', 'Metformin should be taken with meals, and excessive alcohol intake should be avoided during treatment.  Diabetes patients in general should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Alcohol should not be consumed on an empty stomach or following exercise, as it may increase the risk of hypoglycemia.  Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon).  With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias.  Metformin should be withdrawn promptly if lactic acidosis is suspected.  Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis.  Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (719, 2578, 'Metformin', 'Alcohol can potentiate the effect of metformin on lactate metabolism and increase the risk of lactic acidosis.  In addition, alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Although hypoglycemia rarely occurs during treatment with metformin alone, the risk may increase with acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.', 'alcohol', 'Major', 'Metformin should be taken with meals, and excessive alcohol intake should be avoided during treatment.  Diabetes patients in general should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Alcohol should not be consumed on an empty stomach or following exercise, as it may increase the risk of hypoglycemia.  Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon).  With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias.  Metformin should be withdrawn promptly if lactic acidosis is suspected.  Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis.  Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (720, 2579, 'Metformin', 'Alcohol can potentiate the effect of metformin on lactate metabolism and increase the risk of lactic acidosis.  In addition, alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Although hypoglycemia rarely occurs during treatment with metformin alone, the risk may increase with acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.', 'alcohol', 'Major', 'Metformin should be taken with meals, and excessive alcohol intake should be avoided during treatment.  Diabetes patients in general should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Alcohol should not be consumed on an empty stomach or following exercise, as it may increase the risk of hypoglycemia.  Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon).  With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias.  Metformin should be withdrawn promptly if lactic acidosis is suspected.  Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis.  Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (721, 3606, 'Metformin', 'Alcohol can potentiate the effect of metformin on lactate metabolism and increase the risk of lactic acidosis.  In addition, alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Although hypoglycemia rarely occurs during treatment with metformin alone, the risk may increase with acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.', 'alcohol', 'Major', 'Metformin should be taken with meals, and excessive alcohol intake should be avoided during treatment.  Diabetes patients in general should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Alcohol should not be consumed on an empty stomach or following exercise, as it may increase the risk of hypoglycemia.  Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon).  With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias.  Metformin should be withdrawn promptly if lactic acidosis is suspected.  Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis.  Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (722, 3607, 'Metformin', 'Alcohol can potentiate the effect of metformin on lactate metabolism and increase the risk of lactic acidosis.  In addition, alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Although hypoglycemia rarely occurs during treatment with metformin alone, the risk may increase with acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.', 'alcohol', 'Major', 'Metformin should be taken with meals, and excessive alcohol intake should be avoided during treatment.  Diabetes patients in general should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Alcohol should not be consumed on an empty stomach or following exercise, as it may increase the risk of hypoglycemia.  Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon).  With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias.  Metformin should be withdrawn promptly if lactic acidosis is suspected.  Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis.  Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (723, 3608, 'Metformin', 'Alcohol can potentiate the effect of metformin on lactate metabolism and increase the risk of lactic acidosis.  In addition, alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Although hypoglycemia rarely occurs during treatment with metformin alone, the risk may increase with acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.', 'alcohol', 'Major', 'Metformin should be taken with meals, and excessive alcohol intake should be avoided during treatment.  Diabetes patients in general should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Alcohol should not be consumed on an empty stomach or following exercise, as it may increase the risk of hypoglycemia.  Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon).  With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias.  Metformin should be withdrawn promptly if lactic acidosis is suspected.  Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis.  Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (724, 4684, 'Metformin', 'Alcohol can potentiate the effect of metformin on lactate metabolism and increase the risk of lactic acidosis.  In addition, alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Although hypoglycemia rarely occurs during treatment with metformin alone, the risk may increase with acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.', 'alcohol', 'Major', 'Metformin should be taken with meals, and excessive alcohol intake should be avoided during treatment.  Diabetes patients in general should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Alcohol should not be consumed on an empty stomach or following exercise, as it may increase the risk of hypoglycemia.  Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon).  With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias.  Metformin should be withdrawn promptly if lactic acidosis is suspected.  Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis.  Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (725, 5600, 'Metformin', 'Alcohol can potentiate the effect of metformin on lactate metabolism and increase the risk of lactic acidosis.  In addition, alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Although hypoglycemia rarely occurs during treatment with metformin alone, the risk may increase with acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.', 'alcohol', 'Major', 'Metformin should be taken with meals, and excessive alcohol intake should be avoided during treatment.  Diabetes patients in general should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Alcohol should not be consumed on an empty stomach or following exercise, as it may increase the risk of hypoglycemia.  Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon).  With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias.  Metformin should be withdrawn promptly if lactic acidosis is suspected.  Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis.  Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (726, 5601, 'Metformin', 'Alcohol can potentiate the effect of metformin on lactate metabolism and increase the risk of lactic acidosis.  In addition, alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Although hypoglycemia rarely occurs during treatment with metformin alone, the risk may increase with acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.', 'alcohol', 'Major', 'Metformin should be taken with meals, and excessive alcohol intake should be avoided during treatment.  Diabetes patients in general should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Alcohol should not be consumed on an empty stomach or following exercise, as it may increase the risk of hypoglycemia.  Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon).  With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias.  Metformin should be withdrawn promptly if lactic acidosis is suspected.  Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis.  Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (727, 5607, 'Metformin', 'Alcohol can potentiate the effect of metformin on lactate metabolism and increase the risk of lactic acidosis.  In addition, alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Although hypoglycemia rarely occurs during treatment with metformin alone, the risk may increase with acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.', 'alcohol', 'Major', 'Metformin should be taken with meals, and excessive alcohol intake should be avoided during treatment.  Diabetes patients in general should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Alcohol should not be consumed on an empty stomach or following exercise, as it may increase the risk of hypoglycemia.  Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon).  With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias.  Metformin should be withdrawn promptly if lactic acidosis is suspected.  Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis.  Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (728, 5608, 'Metformin', 'Alcohol can potentiate the effect of metformin on lactate metabolism and increase the risk of lactic acidosis.  In addition, alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Although hypoglycemia rarely occurs during treatment with metformin alone, the risk may increase with acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.', 'alcohol', 'Major', 'Metformin should be taken with meals, and excessive alcohol intake should be avoided during treatment.  Diabetes patients in general should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Alcohol should not be consumed on an empty stomach or following exercise, as it may increase the risk of hypoglycemia.  Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon).  With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias.  Metformin should be withdrawn promptly if lactic acidosis is suspected.  Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis.  Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (729, 5609, 'Metformin', 'Alcohol can potentiate the effect of metformin on lactate metabolism and increase the risk of lactic acidosis.  In addition, alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Although hypoglycemia rarely occurs during treatment with metformin alone, the risk may increase with acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.', 'alcohol', 'Major', 'Metformin should be taken with meals, and excessive alcohol intake should be avoided during treatment.  Diabetes patients in general should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Alcohol should not be consumed on an empty stomach or following exercise, as it may increase the risk of hypoglycemia.  Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon).  With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias.  Metformin should be withdrawn promptly if lactic acidosis is suspected.  Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis.  Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (730, 5610, 'Metformin', 'Alcohol can potentiate the effect of metformin on lactate metabolism and increase the risk of lactic acidosis.  In addition, alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Although hypoglycemia rarely occurs during treatment with metformin alone, the risk may increase with acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.', 'alcohol', 'Major', 'Metformin should be taken with meals, and excessive alcohol intake should be avoided during treatment.  Diabetes patients in general should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Alcohol should not be consumed on an empty stomach or following exercise, as it may increase the risk of hypoglycemia.  Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon).  With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias.  Metformin should be withdrawn promptly if lactic acidosis is suspected.  Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis.  Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (731, 8006, 'Metformin', 'Alcohol can potentiate the effect of metformin on lactate metabolism and increase the risk of lactic acidosis.  In addition, alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Although hypoglycemia rarely occurs during treatment with metformin alone, the risk may increase with acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.', 'alcohol', 'Major', 'Metformin should be taken with meals, and excessive alcohol intake should be avoided during treatment.  Diabetes patients in general should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Alcohol should not be consumed on an empty stomach or following exercise, as it may increase the risk of hypoglycemia.  Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon).  With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias.  Metformin should be withdrawn promptly if lactic acidosis is suspected.  Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis.  Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (732, 8082, 'Metformin', 'Alcohol can potentiate the effect of metformin on lactate metabolism and increase the risk of lactic acidosis.  In addition, alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Although hypoglycemia rarely occurs during treatment with metformin alone, the risk may increase with acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.', 'alcohol', 'Major', 'Metformin should be taken with meals, and excessive alcohol intake should be avoided during treatment.  Diabetes patients in general should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Alcohol should not be consumed on an empty stomach or following exercise, as it may increase the risk of hypoglycemia.  Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon).  With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias.  Metformin should be withdrawn promptly if lactic acidosis is suspected.  Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis.  Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (733, 13130, 'Metformin', 'Alcohol can potentiate the effect of metformin on lactate metabolism and increase the risk of lactic acidosis.  In addition, alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Although hypoglycemia rarely occurs during treatment with metformin alone, the risk may increase with acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.', 'alcohol', 'Major', 'Metformin should be taken with meals, and excessive alcohol intake should be avoided during treatment.  Diabetes patients in general should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Alcohol should not be consumed on an empty stomach or following exercise, as it may increase the risk of hypoglycemia.  Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon).  With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias.  Metformin should be withdrawn promptly if lactic acidosis is suspected.  Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis.  Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (734, 13692, 'Metformin', 'Alcohol can potentiate the effect of metformin on lactate metabolism and increase the risk of lactic acidosis.  In addition, alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Although hypoglycemia rarely occurs during treatment with metformin alone, the risk may increase with acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.', 'alcohol', 'Major', 'Metformin should be taken with meals, and excessive alcohol intake should be avoided during treatment.  Diabetes patients in general should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Alcohol should not be consumed on an empty stomach or following exercise, as it may increase the risk of hypoglycemia.  Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon).  With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias.  Metformin should be withdrawn promptly if lactic acidosis is suspected.  Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis.  Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (735, 14125, 'Metformin', 'Alcohol can potentiate the effect of metformin on lactate metabolism and increase the risk of lactic acidosis.  In addition, alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Although hypoglycemia rarely occurs during treatment with metformin alone, the risk may increase with acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.', 'alcohol', 'Major', 'Metformin should be taken with meals, and excessive alcohol intake should be avoided during treatment.  Diabetes patients in general should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Alcohol should not be consumed on an empty stomach or following exercise, as it may increase the risk of hypoglycemia.  Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon).  With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias.  Metformin should be withdrawn promptly if lactic acidosis is suspected.  Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis.  Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (736, 16319, 'Metformin', 'Alcohol can potentiate the effect of metformin on lactate metabolism and increase the risk of lactic acidosis.  In addition, alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Although hypoglycemia rarely occurs during treatment with metformin alone, the risk may increase with acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.', 'alcohol', 'Major', 'Metformin should be taken with meals, and excessive alcohol intake should be avoided during treatment.  Diabetes patients in general should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Alcohol should not be consumed on an empty stomach or following exercise, as it may increase the risk of hypoglycemia.  Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon).  With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias.  Metformin should be withdrawn promptly if lactic acidosis is suspected.  Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis.  Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (737, 17997, 'Metformin', 'Alcohol can potentiate the effect of metformin on lactate metabolism and increase the risk of lactic acidosis.  In addition, alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Although hypoglycemia rarely occurs during treatment with metformin alone, the risk may increase with acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.', 'alcohol', 'Major', 'Metformin should be taken with meals, and excessive alcohol intake should be avoided during treatment.  Diabetes patients in general should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Alcohol should not be consumed on an empty stomach or following exercise, as it may increase the risk of hypoglycemia.  Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon).  With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias.  Metformin should be withdrawn promptly if lactic acidosis is suspected.  Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis.  Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (738, 21147, 'Metformin', 'Alcohol can potentiate the effect of metformin on lactate metabolism and increase the risk of lactic acidosis.  In addition, alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Although hypoglycemia rarely occurs during treatment with metformin alone, the risk may increase with acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.', 'alcohol', 'Major', 'Metformin should be taken with meals, and excessive alcohol intake should be avoided during treatment.  Diabetes patients in general should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Alcohol should not be consumed on an empty stomach or following exercise, as it may increase the risk of hypoglycemia.  Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon).  With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias.  Metformin should be withdrawn promptly if lactic acidosis is suspected.  Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis.  Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (739, 22409, 'Metformin', 'Alcohol can potentiate the effect of metformin on lactate metabolism and increase the risk of lactic acidosis.  In addition, alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Although hypoglycemia rarely occurs during treatment with metformin alone, the risk may increase with acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.', 'alcohol', 'Major', 'Metformin should be taken with meals, and excessive alcohol intake should be avoided during treatment.  Diabetes patients in general should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Alcohol should not be consumed on an empty stomach or following exercise, as it may increase the risk of hypoglycemia.  Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon).  With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias.  Metformin should be withdrawn promptly if lactic acidosis is suspected.  Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis.  Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (740, 22485, 'Metformin', 'Alcohol can potentiate the effect of metformin on lactate metabolism and increase the risk of lactic acidosis.  In addition, alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Although hypoglycemia rarely occurs during treatment with metformin alone, the risk may increase with acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.', 'alcohol', 'Major', 'Metformin should be taken with meals, and excessive alcohol intake should be avoided during treatment.  Diabetes patients in general should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Alcohol should not be consumed on an empty stomach or following exercise, as it may increase the risk of hypoglycemia.  Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon).  With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias.  Metformin should be withdrawn promptly if lactic acidosis is suspected.  Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis.  Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (741, 22574, 'Metformin', 'Alcohol can potentiate the effect of metformin on lactate metabolism and increase the risk of lactic acidosis.  In addition, alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Although hypoglycemia rarely occurs during treatment with metformin alone, the risk may increase with acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.', 'alcohol', 'Major', 'Metformin should be taken with meals, and excessive alcohol intake should be avoided during treatment.  Diabetes patients in general should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Alcohol should not be consumed on an empty stomach or following exercise, as it may increase the risk of hypoglycemia.  Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon).  With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias.  Metformin should be withdrawn promptly if lactic acidosis is suspected.  Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis.  Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (742, 22575, 'Metformin', 'Alcohol can potentiate the effect of metformin on lactate metabolism and increase the risk of lactic acidosis.  In addition, alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Although hypoglycemia rarely occurs during treatment with metformin alone, the risk may increase with acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.', 'alcohol', 'Major', 'Metformin should be taken with meals, and excessive alcohol intake should be avoided during treatment.  Diabetes patients in general should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Alcohol should not be consumed on an empty stomach or following exercise, as it may increase the risk of hypoglycemia.  Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon).  With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias.  Metformin should be withdrawn promptly if lactic acidosis is suspected.  Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis.  Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (743, 22635, 'Metformin', 'Alcohol can potentiate the effect of metformin on lactate metabolism and increase the risk of lactic acidosis.  In addition, alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Although hypoglycemia rarely occurs during treatment with metformin alone, the risk may increase with acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.', 'alcohol', 'Major', 'Metformin should be taken with meals, and excessive alcohol intake should be avoided during treatment.  Diabetes patients in general should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Alcohol should not be consumed on an empty stomach or following exercise, as it may increase the risk of hypoglycemia.  Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon).  With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias.  Metformin should be withdrawn promptly if lactic acidosis is suspected.  Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis.  Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (744, 33194, 'Metformin', 'Alcohol can potentiate the effect of metformin on lactate metabolism and increase the risk of lactic acidosis.  In addition, alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Although hypoglycemia rarely occurs during treatment with metformin alone, the risk may increase with acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.', 'alcohol', 'Major', 'Metformin should be taken with meals, and excessive alcohol intake should be avoided during treatment.  Diabetes patients in general should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Alcohol should not be consumed on an empty stomach or following exercise, as it may increase the risk of hypoglycemia.  Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon).  With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias.  Metformin should be withdrawn promptly if lactic acidosis is suspected.  Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis.  Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (745, 33195, 'Metformin', 'Alcohol can potentiate the effect of metformin on lactate metabolism and increase the risk of lactic acidosis.  In addition, alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Although hypoglycemia rarely occurs during treatment with metformin alone, the risk may increase with acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.', 'alcohol', 'Major', 'Metformin should be taken with meals, and excessive alcohol intake should be avoided during treatment.  Diabetes patients in general should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Alcohol should not be consumed on an empty stomach or following exercise, as it may increase the risk of hypoglycemia.  Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon).  With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias.  Metformin should be withdrawn promptly if lactic acidosis is suspected.  Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis.  Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (746, 33196, 'Metformin', 'Alcohol can potentiate the effect of metformin on lactate metabolism and increase the risk of lactic acidosis.  In addition, alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Although hypoglycemia rarely occurs during treatment with metformin alone, the risk may increase with acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.', 'alcohol', 'Major', 'Metformin should be taken with meals, and excessive alcohol intake should be avoided during treatment.  Diabetes patients in general should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Alcohol should not be consumed on an empty stomach or following exercise, as it may increase the risk of hypoglycemia.  Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon).  With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias.  Metformin should be withdrawn promptly if lactic acidosis is suspected.  Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis.  Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (747, 0, 'Methadone', 'Ethanol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Moderate', 'Concomitant use of opioid analgesics with ethanol should be avoided.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (748, 0, 'Methadone', 'Coadministration with grapefruit juice may increase the plasma concentrations of methadone.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Moderate', 'Given the interindividual variability in the pharmacokinetics of methadone, a more significant interaction with grapefruit juice in certain patients cannot be ruled out.  Patients treated with methadone should preferably avoid or limit the consumption of grapefruit juice, particularly during the induction of maintenance treatment.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (749, 0, 'Methohexital', 'Concurrent acute use of barbiturates and ethanol may result in additive CNS effects,  including impaired coordination, sedation, and death.  Tolerance of these agents may occur with chronic use.  The mechanism is related to inhibition of microsomal enzymes acutely and induction of hepatic microsomal enzymes chronically.', 'alcohol', 'Major', 'The combination of ethanol and barbiturates should be avoided.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (750, 8642, 'Methoxsalen', 'The ingestion of foods containing photosensitizing components (e.g., limes, figs, parsley, parsnips, rue (Ruta graveolens), mustard, carrots and celery) may increase the risk of photosensitivity and severe burning during methoxsalen therapy.', 'foods containing photosensitizing components', 'Moderate', 'Patients who are undergoing PUVA treatment and taking methoxsalen should be advised to avoid eating large quantities of these foods.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (751, 11875, 'Methoxsalen', 'The ingestion of foods containing photosensitizing components (e.g., limes, figs, parsley, parsnips, rue (Ruta graveolens), mustard, carrots and celery) may increase the risk of photosensitivity and severe burning during methoxsalen therapy.', 'foods containing photosensitizing components', 'Moderate', 'Patients who are undergoing PUVA treatment and taking methoxsalen should be advised to avoid eating large quantities of these foods.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (752, 23373, 'Methoxsalen', 'The ingestion of foods containing photosensitizing components (e.g., limes, figs, parsley, parsnips, rue (Ruta graveolens), mustard, carrots and celery) may increase the risk of photosensitivity and severe burning during methoxsalen therapy.', 'foods containing photosensitizing components', 'Moderate', 'Patients who are undergoing PUVA treatment and taking methoxsalen should be advised to avoid eating large quantities of these foods.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (753, 28696, 'Methoxsalen', 'The ingestion of foods containing photosensitizing components (e.g., limes, figs, parsley, parsnips, rue (Ruta graveolens), mustard, carrots and celery) may increase the risk of photosensitivity and severe burning during methoxsalen therapy.', 'foods containing photosensitizing components', 'Moderate', 'Patients who are undergoing PUVA treatment and taking methoxsalen should be advised to avoid eating large quantities of these foods.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (754, 566, 'Methocarbamol', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (755, 8088, 'Methocarbamol', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (756, 19132, 'Methocarbamol', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (757, 22639, 'Methocarbamol', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (758, 5019, 'Methotrexate', 'Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.  Methotrexate, especially at higher dosages or during prolonged treatment, has been associated with severe hepatotoxicity including acute hepatitis, chronic fibrosis, cirrhosis, and fatal liver failure.', 'alcohol', 'Moderate', 'The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate.  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (759, 8089, 'Methotrexate', 'Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.  Methotrexate, especially at higher dosages or during prolonged treatment, has been associated with severe hepatotoxicity including acute hepatitis, chronic fibrosis, cirrhosis, and fatal liver failure.', 'alcohol', 'Moderate', 'The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate.  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (760, 11930, 'Methotrexate', 'Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.  Methotrexate, especially at higher dosages or during prolonged treatment, has been associated with severe hepatotoxicity including acute hepatitis, chronic fibrosis, cirrhosis, and fatal liver failure.', 'alcohol', 'Moderate', 'The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate.  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (761, 14338, 'Methotrexate', 'Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.  Methotrexate, especially at higher dosages or during prolonged treatment, has been associated with severe hepatotoxicity including acute hepatitis, chronic fibrosis, cirrhosis, and fatal liver failure.', 'alcohol', 'Moderate', 'The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate.  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (762, 14594, 'Methotrexate', 'Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.  Methotrexate, especially at higher dosages or during prolonged treatment, has been associated with severe hepatotoxicity including acute hepatitis, chronic fibrosis, cirrhosis, and fatal liver failure.', 'alcohol', 'Moderate', 'The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate.  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (763, 18291, 'Methotrexate', 'Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.  Methotrexate, especially at higher dosages or during prolonged treatment, has been associated with severe hepatotoxicity including acute hepatitis, chronic fibrosis, cirrhosis, and fatal liver failure.', 'alcohol', 'Moderate', 'The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate.  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (764, 22641, 'Methotrexate', 'Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.  Methotrexate, especially at higher dosages or during prolonged treatment, has been associated with severe hepatotoxicity including acute hepatitis, chronic fibrosis, cirrhosis, and fatal liver failure.', 'alcohol', 'Moderate', 'The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate.  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (765, 22644, 'Methotrexate', 'Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.  Methotrexate, especially at higher dosages or during prolonged treatment, has been associated with severe hepatotoxicity including acute hepatitis, chronic fibrosis, cirrhosis, and fatal liver failure.', 'alcohol', 'Moderate', 'The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate.  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (766, 22645, 'Methotrexate', 'Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.  Methotrexate, especially at higher dosages or during prolonged treatment, has been associated with severe hepatotoxicity including acute hepatitis, chronic fibrosis, cirrhosis, and fatal liver failure.', 'alcohol', 'Moderate', 'The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate.  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (767, 22647, 'Methotrexate', 'Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.  Methotrexate, especially at higher dosages or during prolonged treatment, has been associated with severe hepatotoxicity including acute hepatitis, chronic fibrosis, cirrhosis, and fatal liver failure.', 'alcohol', 'Moderate', 'The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate.  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (768, 22648, 'Methotrexate', 'Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.  Methotrexate, especially at higher dosages or during prolonged treatment, has been associated with severe hepatotoxicity including acute hepatitis, chronic fibrosis, cirrhosis, and fatal liver failure.', 'alcohol', 'Moderate', 'The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate.  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (769, 22649, 'Methotrexate', 'Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.  Methotrexate, especially at higher dosages or during prolonged treatment, has been associated with severe hepatotoxicity including acute hepatitis, chronic fibrosis, cirrhosis, and fatal liver failure.', 'alcohol', 'Moderate', 'The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate.  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (770, 22650, 'Methotrexate', 'Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.  Methotrexate, especially at higher dosages or during prolonged treatment, has been associated with severe hepatotoxicity including acute hepatitis, chronic fibrosis, cirrhosis, and fatal liver failure.', 'alcohol', 'Moderate', 'The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate.  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (771, 22651, 'Methotrexate', 'Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.  Methotrexate, especially at higher dosages or during prolonged treatment, has been associated with severe hepatotoxicity including acute hepatitis, chronic fibrosis, cirrhosis, and fatal liver failure.', 'alcohol', 'Moderate', 'The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate.  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (772, 22652, 'Methotrexate', 'Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.  Methotrexate, especially at higher dosages or during prolonged treatment, has been associated with severe hepatotoxicity including acute hepatitis, chronic fibrosis, cirrhosis, and fatal liver failure.', 'alcohol', 'Moderate', 'The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate.  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (773, 22653, 'Methotrexate', 'Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.  Methotrexate, especially at higher dosages or during prolonged treatment, has been associated with severe hepatotoxicity including acute hepatitis, chronic fibrosis, cirrhosis, and fatal liver failure.', 'alcohol', 'Moderate', 'The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate.  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (774, 22654, 'Methotrexate', 'Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.  Methotrexate, especially at higher dosages or during prolonged treatment, has been associated with severe hepatotoxicity including acute hepatitis, chronic fibrosis, cirrhosis, and fatal liver failure.', 'alcohol', 'Moderate', 'The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate.  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (775, 22655, 'Methotrexate', 'Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.  Methotrexate, especially at higher dosages or during prolonged treatment, has been associated with severe hepatotoxicity including acute hepatitis, chronic fibrosis, cirrhosis, and fatal liver failure.', 'alcohol', 'Moderate', 'The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate.  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (776, 22657, 'Methotrexate', 'Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.  Methotrexate, especially at higher dosages or during prolonged treatment, has been associated with severe hepatotoxicity including acute hepatitis, chronic fibrosis, cirrhosis, and fatal liver failure.', 'alcohol', 'Moderate', 'The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate.  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (777, 22786, 'Methotrexate', 'Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.  Methotrexate, especially at higher dosages or during prolonged treatment, has been associated with severe hepatotoxicity including acute hepatitis, chronic fibrosis, cirrhosis, and fatal liver failure.', 'alcohol', 'Moderate', 'The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate.  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (778, 23055, 'Methotrexate', 'Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.  Methotrexate, especially at higher dosages or during prolonged treatment, has been associated with severe hepatotoxicity including acute hepatitis, chronic fibrosis, cirrhosis, and fatal liver failure.', 'alcohol', 'Moderate', 'The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate.  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (779, 23056, 'Methotrexate', 'Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.  Methotrexate, especially at higher dosages or during prolonged treatment, has been associated with severe hepatotoxicity including acute hepatitis, chronic fibrosis, cirrhosis, and fatal liver failure.', 'alcohol', 'Moderate', 'The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate.  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (780, 28776, 'Methotrexate', 'Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.  Methotrexate, especially at higher dosages or during prolonged treatment, has been associated with severe hepatotoxicity including acute hepatitis, chronic fibrosis, cirrhosis, and fatal liver failure.', 'alcohol', 'Moderate', 'The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate.  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (781, 28778, 'Methotrexate', 'Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.  Methotrexate, especially at higher dosages or during prolonged treatment, has been associated with severe hepatotoxicity including acute hepatitis, chronic fibrosis, cirrhosis, and fatal liver failure.', 'alcohol', 'Moderate', 'The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate.  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (782, 28779, 'Methotrexate', 'Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.  Methotrexate, especially at higher dosages or during prolonged treatment, has been associated with severe hepatotoxicity including acute hepatitis, chronic fibrosis, cirrhosis, and fatal liver failure.', 'alcohol', 'Moderate', 'The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate.  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (783, 32982, 'Methotrexate', 'Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.  Methotrexate, especially at higher dosages or during prolonged treatment, has been associated with severe hepatotoxicity including acute hepatitis, chronic fibrosis, cirrhosis, and fatal liver failure.', 'alcohol', 'Moderate', 'The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate.  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (784, 32983, 'Methotrexate', 'Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.  Methotrexate, especially at higher dosages or during prolonged treatment, has been associated with severe hepatotoxicity including acute hepatitis, chronic fibrosis, cirrhosis, and fatal liver failure.', 'alcohol', 'Moderate', 'The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate.  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (785, 33198, 'Methotrexate', 'Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.  Methotrexate, especially at higher dosages or during prolonged treatment, has been associated with severe hepatotoxicity including acute hepatitis, chronic fibrosis, cirrhosis, and fatal liver failure.', 'alcohol', 'Moderate', 'The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate.  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (786, 5019, 'Methotrexate', 'Limited data suggest that consumption of greater than 180 mg/day of caffeine may interfere with the efficacy of methotrexate (MTX) in patients with rheumatoid arthritis.  The exact mechanism of interaction is unknown but may be related to the antagonistic effect of caffeine on adenosine receptors, as anti-inflammatory properties of MTX is thought to result from the accumulation of adenosine.', 'coffee', 'Moderate', 'Until further information is available, the potential for interaction should be considered in patients who consume substantial amounts of caffeine and caffeine-containing foods and are prescribed methotrexate for rheumatoid arthritis.  It may be appropriate to limit caffeine intake if an interaction is suspected in cases of treatment failure.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (787, 8089, 'Methotrexate', 'Limited data suggest that consumption of greater than 180 mg/day of caffeine may interfere with the efficacy of methotrexate (MTX) in patients with rheumatoid arthritis.  The exact mechanism of interaction is unknown but may be related to the antagonistic effect of caffeine on adenosine receptors, as anti-inflammatory properties of MTX is thought to result from the accumulation of adenosine.', 'coffee', 'Moderate', 'Until further information is available, the potential for interaction should be considered in patients who consume substantial amounts of caffeine and caffeine-containing foods and are prescribed methotrexate for rheumatoid arthritis.  It may be appropriate to limit caffeine intake if an interaction is suspected in cases of treatment failure.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (788, 11930, 'Methotrexate', 'Limited data suggest that consumption of greater than 180 mg/day of caffeine may interfere with the efficacy of methotrexate (MTX) in patients with rheumatoid arthritis.  The exact mechanism of interaction is unknown but may be related to the antagonistic effect of caffeine on adenosine receptors, as anti-inflammatory properties of MTX is thought to result from the accumulation of adenosine.', 'coffee', 'Moderate', 'Until further information is available, the potential for interaction should be considered in patients who consume substantial amounts of caffeine and caffeine-containing foods and are prescribed methotrexate for rheumatoid arthritis.  It may be appropriate to limit caffeine intake if an interaction is suspected in cases of treatment failure.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (789, 14338, 'Methotrexate', 'Limited data suggest that consumption of greater than 180 mg/day of caffeine may interfere with the efficacy of methotrexate (MTX) in patients with rheumatoid arthritis.  The exact mechanism of interaction is unknown but may be related to the antagonistic effect of caffeine on adenosine receptors, as anti-inflammatory properties of MTX is thought to result from the accumulation of adenosine.', 'coffee', 'Moderate', 'Until further information is available, the potential for interaction should be considered in patients who consume substantial amounts of caffeine and caffeine-containing foods and are prescribed methotrexate for rheumatoid arthritis.  It may be appropriate to limit caffeine intake if an interaction is suspected in cases of treatment failure.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (790, 14594, 'Methotrexate', 'Limited data suggest that consumption of greater than 180 mg/day of caffeine may interfere with the efficacy of methotrexate (MTX) in patients with rheumatoid arthritis.  The exact mechanism of interaction is unknown but may be related to the antagonistic effect of caffeine on adenosine receptors, as anti-inflammatory properties of MTX is thought to result from the accumulation of adenosine.', 'coffee', 'Moderate', 'Until further information is available, the potential for interaction should be considered in patients who consume substantial amounts of caffeine and caffeine-containing foods and are prescribed methotrexate for rheumatoid arthritis.  It may be appropriate to limit caffeine intake if an interaction is suspected in cases of treatment failure.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (791, 18291, 'Methotrexate', 'Limited data suggest that consumption of greater than 180 mg/day of caffeine may interfere with the efficacy of methotrexate (MTX) in patients with rheumatoid arthritis.  The exact mechanism of interaction is unknown but may be related to the antagonistic effect of caffeine on adenosine receptors, as anti-inflammatory properties of MTX is thought to result from the accumulation of adenosine.', 'coffee', 'Moderate', 'Until further information is available, the potential for interaction should be considered in patients who consume substantial amounts of caffeine and caffeine-containing foods and are prescribed methotrexate for rheumatoid arthritis.  It may be appropriate to limit caffeine intake if an interaction is suspected in cases of treatment failure.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (792, 22641, 'Methotrexate', 'Limited data suggest that consumption of greater than 180 mg/day of caffeine may interfere with the efficacy of methotrexate (MTX) in patients with rheumatoid arthritis.  The exact mechanism of interaction is unknown but may be related to the antagonistic effect of caffeine on adenosine receptors, as anti-inflammatory properties of MTX is thought to result from the accumulation of adenosine.', 'coffee', 'Moderate', 'Until further information is available, the potential for interaction should be considered in patients who consume substantial amounts of caffeine and caffeine-containing foods and are prescribed methotrexate for rheumatoid arthritis.  It may be appropriate to limit caffeine intake if an interaction is suspected in cases of treatment failure.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (793, 22644, 'Methotrexate', 'Limited data suggest that consumption of greater than 180 mg/day of caffeine may interfere with the efficacy of methotrexate (MTX) in patients with rheumatoid arthritis.  The exact mechanism of interaction is unknown but may be related to the antagonistic effect of caffeine on adenosine receptors, as anti-inflammatory properties of MTX is thought to result from the accumulation of adenosine.', 'coffee', 'Moderate', 'Until further information is available, the potential for interaction should be considered in patients who consume substantial amounts of caffeine and caffeine-containing foods and are prescribed methotrexate for rheumatoid arthritis.  It may be appropriate to limit caffeine intake if an interaction is suspected in cases of treatment failure.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (794, 22645, 'Methotrexate', 'Limited data suggest that consumption of greater than 180 mg/day of caffeine may interfere with the efficacy of methotrexate (MTX) in patients with rheumatoid arthritis.  The exact mechanism of interaction is unknown but may be related to the antagonistic effect of caffeine on adenosine receptors, as anti-inflammatory properties of MTX is thought to result from the accumulation of adenosine.', 'coffee', 'Moderate', 'Until further information is available, the potential for interaction should be considered in patients who consume substantial amounts of caffeine and caffeine-containing foods and are prescribed methotrexate for rheumatoid arthritis.  It may be appropriate to limit caffeine intake if an interaction is suspected in cases of treatment failure.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (795, 22647, 'Methotrexate', 'Limited data suggest that consumption of greater than 180 mg/day of caffeine may interfere with the efficacy of methotrexate (MTX) in patients with rheumatoid arthritis.  The exact mechanism of interaction is unknown but may be related to the antagonistic effect of caffeine on adenosine receptors, as anti-inflammatory properties of MTX is thought to result from the accumulation of adenosine.', 'coffee', 'Moderate', 'Until further information is available, the potential for interaction should be considered in patients who consume substantial amounts of caffeine and caffeine-containing foods and are prescribed methotrexate for rheumatoid arthritis.  It may be appropriate to limit caffeine intake if an interaction is suspected in cases of treatment failure.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (796, 22648, 'Methotrexate', 'Limited data suggest that consumption of greater than 180 mg/day of caffeine may interfere with the efficacy of methotrexate (MTX) in patients with rheumatoid arthritis.  The exact mechanism of interaction is unknown but may be related to the antagonistic effect of caffeine on adenosine receptors, as anti-inflammatory properties of MTX is thought to result from the accumulation of adenosine.', 'coffee', 'Moderate', 'Until further information is available, the potential for interaction should be considered in patients who consume substantial amounts of caffeine and caffeine-containing foods and are prescribed methotrexate for rheumatoid arthritis.  It may be appropriate to limit caffeine intake if an interaction is suspected in cases of treatment failure.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (797, 22649, 'Methotrexate', 'Limited data suggest that consumption of greater than 180 mg/day of caffeine may interfere with the efficacy of methotrexate (MTX) in patients with rheumatoid arthritis.  The exact mechanism of interaction is unknown but may be related to the antagonistic effect of caffeine on adenosine receptors, as anti-inflammatory properties of MTX is thought to result from the accumulation of adenosine.', 'coffee', 'Moderate', 'Until further information is available, the potential for interaction should be considered in patients who consume substantial amounts of caffeine and caffeine-containing foods and are prescribed methotrexate for rheumatoid arthritis.  It may be appropriate to limit caffeine intake if an interaction is suspected in cases of treatment failure.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (798, 22650, 'Methotrexate', 'Limited data suggest that consumption of greater than 180 mg/day of caffeine may interfere with the efficacy of methotrexate (MTX) in patients with rheumatoid arthritis.  The exact mechanism of interaction is unknown but may be related to the antagonistic effect of caffeine on adenosine receptors, as anti-inflammatory properties of MTX is thought to result from the accumulation of adenosine.', 'coffee', 'Moderate', 'Until further information is available, the potential for interaction should be considered in patients who consume substantial amounts of caffeine and caffeine-containing foods and are prescribed methotrexate for rheumatoid arthritis.  It may be appropriate to limit caffeine intake if an interaction is suspected in cases of treatment failure.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (799, 22651, 'Methotrexate', 'Limited data suggest that consumption of greater than 180 mg/day of caffeine may interfere with the efficacy of methotrexate (MTX) in patients with rheumatoid arthritis.  The exact mechanism of interaction is unknown but may be related to the antagonistic effect of caffeine on adenosine receptors, as anti-inflammatory properties of MTX is thought to result from the accumulation of adenosine.', 'coffee', 'Moderate', 'Until further information is available, the potential for interaction should be considered in patients who consume substantial amounts of caffeine and caffeine-containing foods and are prescribed methotrexate for rheumatoid arthritis.  It may be appropriate to limit caffeine intake if an interaction is suspected in cases of treatment failure.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (800, 22652, 'Methotrexate', 'Limited data suggest that consumption of greater than 180 mg/day of caffeine may interfere with the efficacy of methotrexate (MTX) in patients with rheumatoid arthritis.  The exact mechanism of interaction is unknown but may be related to the antagonistic effect of caffeine on adenosine receptors, as anti-inflammatory properties of MTX is thought to result from the accumulation of adenosine.', 'coffee', 'Moderate', 'Until further information is available, the potential for interaction should be considered in patients who consume substantial amounts of caffeine and caffeine-containing foods and are prescribed methotrexate for rheumatoid arthritis.  It may be appropriate to limit caffeine intake if an interaction is suspected in cases of treatment failure.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (801, 22653, 'Methotrexate', 'Limited data suggest that consumption of greater than 180 mg/day of caffeine may interfere with the efficacy of methotrexate (MTX) in patients with rheumatoid arthritis.  The exact mechanism of interaction is unknown but may be related to the antagonistic effect of caffeine on adenosine receptors, as anti-inflammatory properties of MTX is thought to result from the accumulation of adenosine.', 'coffee', 'Moderate', 'Until further information is available, the potential for interaction should be considered in patients who consume substantial amounts of caffeine and caffeine-containing foods and are prescribed methotrexate for rheumatoid arthritis.  It may be appropriate to limit caffeine intake if an interaction is suspected in cases of treatment failure.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (802, 22654, 'Methotrexate', 'Limited data suggest that consumption of greater than 180 mg/day of caffeine may interfere with the efficacy of methotrexate (MTX) in patients with rheumatoid arthritis.  The exact mechanism of interaction is unknown but may be related to the antagonistic effect of caffeine on adenosine receptors, as anti-inflammatory properties of MTX is thought to result from the accumulation of adenosine.', 'coffee', 'Moderate', 'Until further information is available, the potential for interaction should be considered in patients who consume substantial amounts of caffeine and caffeine-containing foods and are prescribed methotrexate for rheumatoid arthritis.  It may be appropriate to limit caffeine intake if an interaction is suspected in cases of treatment failure.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (803, 22655, 'Methotrexate', 'Limited data suggest that consumption of greater than 180 mg/day of caffeine may interfere with the efficacy of methotrexate (MTX) in patients with rheumatoid arthritis.  The exact mechanism of interaction is unknown but may be related to the antagonistic effect of caffeine on adenosine receptors, as anti-inflammatory properties of MTX is thought to result from the accumulation of adenosine.', 'coffee', 'Moderate', 'Until further information is available, the potential for interaction should be considered in patients who consume substantial amounts of caffeine and caffeine-containing foods and are prescribed methotrexate for rheumatoid arthritis.  It may be appropriate to limit caffeine intake if an interaction is suspected in cases of treatment failure.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (804, 22657, 'Methotrexate', 'Limited data suggest that consumption of greater than 180 mg/day of caffeine may interfere with the efficacy of methotrexate (MTX) in patients with rheumatoid arthritis.  The exact mechanism of interaction is unknown but may be related to the antagonistic effect of caffeine on adenosine receptors, as anti-inflammatory properties of MTX is thought to result from the accumulation of adenosine.', 'coffee', 'Moderate', 'Until further information is available, the potential for interaction should be considered in patients who consume substantial amounts of caffeine and caffeine-containing foods and are prescribed methotrexate for rheumatoid arthritis.  It may be appropriate to limit caffeine intake if an interaction is suspected in cases of treatment failure.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (805, 22786, 'Methotrexate', 'Limited data suggest that consumption of greater than 180 mg/day of caffeine may interfere with the efficacy of methotrexate (MTX) in patients with rheumatoid arthritis.  The exact mechanism of interaction is unknown but may be related to the antagonistic effect of caffeine on adenosine receptors, as anti-inflammatory properties of MTX is thought to result from the accumulation of adenosine.', 'coffee', 'Moderate', 'Until further information is available, the potential for interaction should be considered in patients who consume substantial amounts of caffeine and caffeine-containing foods and are prescribed methotrexate for rheumatoid arthritis.  It may be appropriate to limit caffeine intake if an interaction is suspected in cases of treatment failure.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (806, 23055, 'Methotrexate', 'Limited data suggest that consumption of greater than 180 mg/day of caffeine may interfere with the efficacy of methotrexate (MTX) in patients with rheumatoid arthritis.  The exact mechanism of interaction is unknown but may be related to the antagonistic effect of caffeine on adenosine receptors, as anti-inflammatory properties of MTX is thought to result from the accumulation of adenosine.', 'coffee', 'Moderate', 'Until further information is available, the potential for interaction should be considered in patients who consume substantial amounts of caffeine and caffeine-containing foods and are prescribed methotrexate for rheumatoid arthritis.  It may be appropriate to limit caffeine intake if an interaction is suspected in cases of treatment failure.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (807, 23056, 'Methotrexate', 'Limited data suggest that consumption of greater than 180 mg/day of caffeine may interfere with the efficacy of methotrexate (MTX) in patients with rheumatoid arthritis.  The exact mechanism of interaction is unknown but may be related to the antagonistic effect of caffeine on adenosine receptors, as anti-inflammatory properties of MTX is thought to result from the accumulation of adenosine.', 'coffee', 'Moderate', 'Until further information is available, the potential for interaction should be considered in patients who consume substantial amounts of caffeine and caffeine-containing foods and are prescribed methotrexate for rheumatoid arthritis.  It may be appropriate to limit caffeine intake if an interaction is suspected in cases of treatment failure.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (808, 28776, 'Methotrexate', 'Limited data suggest that consumption of greater than 180 mg/day of caffeine may interfere with the efficacy of methotrexate (MTX) in patients with rheumatoid arthritis.  The exact mechanism of interaction is unknown but may be related to the antagonistic effect of caffeine on adenosine receptors, as anti-inflammatory properties of MTX is thought to result from the accumulation of adenosine.', 'coffee', 'Moderate', 'Until further information is available, the potential for interaction should be considered in patients who consume substantial amounts of caffeine and caffeine-containing foods and are prescribed methotrexate for rheumatoid arthritis.  It may be appropriate to limit caffeine intake if an interaction is suspected in cases of treatment failure.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (809, 28778, 'Methotrexate', 'Limited data suggest that consumption of greater than 180 mg/day of caffeine may interfere with the efficacy of methotrexate (MTX) in patients with rheumatoid arthritis.  The exact mechanism of interaction is unknown but may be related to the antagonistic effect of caffeine on adenosine receptors, as anti-inflammatory properties of MTX is thought to result from the accumulation of adenosine.', 'coffee', 'Moderate', 'Until further information is available, the potential for interaction should be considered in patients who consume substantial amounts of caffeine and caffeine-containing foods and are prescribed methotrexate for rheumatoid arthritis.  It may be appropriate to limit caffeine intake if an interaction is suspected in cases of treatment failure.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (810, 28779, 'Methotrexate', 'Limited data suggest that consumption of greater than 180 mg/day of caffeine may interfere with the efficacy of methotrexate (MTX) in patients with rheumatoid arthritis.  The exact mechanism of interaction is unknown but may be related to the antagonistic effect of caffeine on adenosine receptors, as anti-inflammatory properties of MTX is thought to result from the accumulation of adenosine.', 'coffee', 'Moderate', 'Until further information is available, the potential for interaction should be considered in patients who consume substantial amounts of caffeine and caffeine-containing foods and are prescribed methotrexate for rheumatoid arthritis.  It may be appropriate to limit caffeine intake if an interaction is suspected in cases of treatment failure.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (811, 32982, 'Methotrexate', 'Limited data suggest that consumption of greater than 180 mg/day of caffeine may interfere with the efficacy of methotrexate (MTX) in patients with rheumatoid arthritis.  The exact mechanism of interaction is unknown but may be related to the antagonistic effect of caffeine on adenosine receptors, as anti-inflammatory properties of MTX is thought to result from the accumulation of adenosine.', 'coffee', 'Moderate', 'Until further information is available, the potential for interaction should be considered in patients who consume substantial amounts of caffeine and caffeine-containing foods and are prescribed methotrexate for rheumatoid arthritis.  It may be appropriate to limit caffeine intake if an interaction is suspected in cases of treatment failure.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (812, 32983, 'Methotrexate', 'Limited data suggest that consumption of greater than 180 mg/day of caffeine may interfere with the efficacy of methotrexate (MTX) in patients with rheumatoid arthritis.  The exact mechanism of interaction is unknown but may be related to the antagonistic effect of caffeine on adenosine receptors, as anti-inflammatory properties of MTX is thought to result from the accumulation of adenosine.', 'coffee', 'Moderate', 'Until further information is available, the potential for interaction should be considered in patients who consume substantial amounts of caffeine and caffeine-containing foods and are prescribed methotrexate for rheumatoid arthritis.  It may be appropriate to limit caffeine intake if an interaction is suspected in cases of treatment failure.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (813, 33198, 'Methotrexate', 'Limited data suggest that consumption of greater than 180 mg/day of caffeine may interfere with the efficacy of methotrexate (MTX) in patients with rheumatoid arthritis.  The exact mechanism of interaction is unknown but may be related to the antagonistic effect of caffeine on adenosine receptors, as anti-inflammatory properties of MTX is thought to result from the accumulation of adenosine.', 'coffee', 'Moderate', 'Until further information is available, the potential for interaction should be considered in patients who consume substantial amounts of caffeine and caffeine-containing foods and are prescribed methotrexate for rheumatoid arthritis.  It may be appropriate to limit caffeine intake if an interaction is suspected in cases of treatment failure.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (814, 17, 'Aripiprazole', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (815, 18, 'Aripiprazole', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (816, 20, 'Aripiprazole', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (817, 21, 'Aripiprazole', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (818, 22, 'Aripiprazole', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (819, 204, 'Aripiprazole', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (820, 205, 'Aripiprazole', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (821, 925, 'Aripiprazole', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (822, 927, 'Aripiprazole', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (823, 940, 'Aripiprazole', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (824, 943, 'Aripiprazole', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (825, 946, 'Aripiprazole', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (826, 948, 'Aripiprazole', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (827, 950, 'Aripiprazole', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (828, 952, 'Aripiprazole', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (829, 1766, 'Aripiprazole', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (830, 3339, 'Aripiprazole', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (831, 10222, 'Aripiprazole', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (832, 14308, 'Aripiprazole', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (833, 14309, 'Aripiprazole', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (834, 14310, 'Aripiprazole', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (835, 14311, 'Aripiprazole', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (836, 14392, 'Aripiprazole', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (837, 14393, 'Aripiprazole', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (838, 14394, 'Aripiprazole', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (839, 14400, 'Aripiprazole', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (840, 14401, 'Aripiprazole', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (841, 14404, 'Aripiprazole', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (842, 25140, 'Aripiprazole', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (843, 26610, 'Aripiprazole', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (844, 26614, 'Aripiprazole', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (845, 26615, 'Aripiprazole', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (846, 26616, 'Aripiprazole', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (847, 26617, 'Aripiprazole', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (848, 26618, 'Aripiprazole', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (849, 26619, 'Aripiprazole', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (850, 31991, 'Aripiprazole', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (851, 32347, 'Aripiprazole', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (852, 32440, 'Aripiprazole', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (853, 32441, 'Aripiprazole', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (854, 14411, 'Armodafinil', 'Administration with food may delay the absorption of modafinil (the racemate) and armodafinil (the R-enantiomer) without significantly affecting their overall bioavailability.', 'food', 'Minor', 'Armodafinil should be administered on an empty stomach, at least 2 hours after or 1 hour before a meal.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (855, 14412, 'Armodafinil', 'Administration with food may delay the absorption of modafinil (the racemate) and armodafinil (the R-enantiomer) without significantly affecting their overall bioavailability.', 'food', 'Minor', 'Armodafinil should be administered on an empty stomach, at least 2 hours after or 1 hour before a meal.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (856, 14413, 'Armodafinil', 'Administration with food may delay the absorption of modafinil (the racemate) and armodafinil (the R-enantiomer) without significantly affecting their overall bioavailability.', 'food', 'Minor', 'Armodafinil should be administered on an empty stomach, at least 2 hours after or 1 hour before a meal.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (857, 14414, 'Armodafinil', 'Administration with food may delay the absorption of modafinil (the racemate) and armodafinil (the R-enantiomer) without significantly affecting their overall bioavailability.', 'food', 'Minor', 'Armodafinil should be administered on an empty stomach, at least 2 hours after or 1 hour before a meal.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (858, 14415, 'Armodafinil', 'Administration with food may delay the absorption of modafinil (the racemate) and armodafinil (the R-enantiomer) without significantly affecting their overall bioavailability.', 'food', 'Minor', 'Armodafinil should be administered on an empty stomach, at least 2 hours after or 1 hour before a meal.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (859, 14416, 'Armodafinil', 'Administration with food may delay the absorption of modafinil (the racemate) and armodafinil (the R-enantiomer) without significantly affecting their overall bioavailability.', 'food', 'Minor', 'Armodafinil should be administered on an empty stomach, at least 2 hours after or 1 hour before a meal.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (860, 29614, 'Armodafinil', 'Administration with food may delay the absorption of modafinil (the racemate) and armodafinil (the R-enantiomer) without significantly affecting their overall bioavailability.', 'food', 'Minor', 'Armodafinil should be administered on an empty stomach, at least 2 hours after or 1 hour before a meal.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (861, 29615, 'Armodafinil', 'Administration with food may delay the absorption of modafinil (the racemate) and armodafinil (the R-enantiomer) without significantly affecting their overall bioavailability.', 'food', 'Minor', 'Armodafinil should be administered on an empty stomach, at least 2 hours after or 1 hour before a meal.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (862, 0, 'Methscopolamine', 'Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be increased with the combination.  The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system.', 'alcohol', 'Moderate', 'Alcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (863, 0, 'Methsuximide', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (864, 2971, 'Methylphenidate', 'Alcohol may exacerbate the adverse central nervous system effects of psychoactive drugs, including methylphenidate.', 'alcohol', 'Moderate', 'Patients treated with methylphenidate should be advised to avoid alcohol or medications that contain alcohol.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (865, 2972, 'Methylphenidate', 'Alcohol may exacerbate the adverse central nervous system effects of psychoactive drugs, including methylphenidate.', 'alcohol', 'Moderate', 'Patients treated with methylphenidate should be advised to avoid alcohol or medications that contain alcohol.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (866, 12975, 'Methylphenidate', 'Alcohol may exacerbate the adverse central nervous system effects of psychoactive drugs, including methylphenidate.', 'alcohol', 'Moderate', 'Patients treated with methylphenidate should be advised to avoid alcohol or medications that contain alcohol.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (867, 3423, 'Methylprednisolone', 'Grapefruit juice may increase the plasma concentrations of orally administered drugs that are substrates of the CYP450 3A4 isoenzyme.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  Because grapefruit juice inhibits primarily intestinal rather than hepatic CYP450 3A4, the magnitude of interaction is greatest for those drugs that undergo significant presystemic metabolism by CYP450 3A4 (i.e., drugs with low oral bioavailability).  In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands.  Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition.  Pharmacokinetic interactions involving grapefruit juice are also subject to a high degree of interpatient variability, thus the extent to which a given patient may be affected is difficult to predict.', 'grapefruit juice', 'Moderate', 'Patients who regularly consume grapefruit or grapefruit juice should be monitored for adverse effects and altered plasma concentrations of drugs that undergo significant presystemic metabolism by CYP450 3A4.  Grapefruit and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact with these drugs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (868, 12369, 'Methylprednisolone', 'Grapefruit juice may increase the plasma concentrations of orally administered drugs that are substrates of the CYP450 3A4 isoenzyme.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  Because grapefruit juice inhibits primarily intestinal rather than hepatic CYP450 3A4, the magnitude of interaction is greatest for those drugs that undergo significant presystemic metabolism by CYP450 3A4 (i.e., drugs with low oral bioavailability).  In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands.  Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition.  Pharmacokinetic interactions involving grapefruit juice are also subject to a high degree of interpatient variability, thus the extent to which a given patient may be affected is difficult to predict.', 'grapefruit juice', 'Moderate', 'Patients who regularly consume grapefruit or grapefruit juice should be monitored for adverse effects and altered plasma concentrations of drugs that undergo significant presystemic metabolism by CYP450 3A4.  Grapefruit and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact with these drugs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (869, 18476, 'Methylprednisolone', 'Grapefruit juice may increase the plasma concentrations of orally administered drugs that are substrates of the CYP450 3A4 isoenzyme.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  Because grapefruit juice inhibits primarily intestinal rather than hepatic CYP450 3A4, the magnitude of interaction is greatest for those drugs that undergo significant presystemic metabolism by CYP450 3A4 (i.e., drugs with low oral bioavailability).  In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands.  Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition.  Pharmacokinetic interactions involving grapefruit juice are also subject to a high degree of interpatient variability, thus the extent to which a given patient may be affected is difficult to predict.', 'grapefruit juice', 'Moderate', 'Patients who regularly consume grapefruit or grapefruit juice should be monitored for adverse effects and altered plasma concentrations of drugs that undergo significant presystemic metabolism by CYP450 3A4.  Grapefruit and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact with these drugs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (870, 22157, 'Methylprednisolone', 'Grapefruit juice may increase the plasma concentrations of orally administered drugs that are substrates of the CYP450 3A4 isoenzyme.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  Because grapefruit juice inhibits primarily intestinal rather than hepatic CYP450 3A4, the magnitude of interaction is greatest for those drugs that undergo significant presystemic metabolism by CYP450 3A4 (i.e., drugs with low oral bioavailability).  In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands.  Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition.  Pharmacokinetic interactions involving grapefruit juice are also subject to a high degree of interpatient variability, thus the extent to which a given patient may be affected is difficult to predict.', 'grapefruit juice', 'Moderate', 'Patients who regularly consume grapefruit or grapefruit juice should be monitored for adverse effects and altered plasma concentrations of drugs that undergo significant presystemic metabolism by CYP450 3A4.  Grapefruit and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact with these drugs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (871, 22660, 'Methylprednisolone', 'Grapefruit juice may increase the plasma concentrations of orally administered drugs that are substrates of the CYP450 3A4 isoenzyme.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  Because grapefruit juice inhibits primarily intestinal rather than hepatic CYP450 3A4, the magnitude of interaction is greatest for those drugs that undergo significant presystemic metabolism by CYP450 3A4 (i.e., drugs with low oral bioavailability).  In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands.  Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition.  Pharmacokinetic interactions involving grapefruit juice are also subject to a high degree of interpatient variability, thus the extent to which a given patient may be affected is difficult to predict.', 'grapefruit juice', 'Moderate', 'Patients who regularly consume grapefruit or grapefruit juice should be monitored for adverse effects and altered plasma concentrations of drugs that undergo significant presystemic metabolism by CYP450 3A4.  Grapefruit and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact with these drugs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (872, 22661, 'Methylprednisolone', 'Grapefruit juice may increase the plasma concentrations of orally administered drugs that are substrates of the CYP450 3A4 isoenzyme.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  Because grapefruit juice inhibits primarily intestinal rather than hepatic CYP450 3A4, the magnitude of interaction is greatest for those drugs that undergo significant presystemic metabolism by CYP450 3A4 (i.e., drugs with low oral bioavailability).  In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands.  Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition.  Pharmacokinetic interactions involving grapefruit juice are also subject to a high degree of interpatient variability, thus the extent to which a given patient may be affected is difficult to predict.', 'grapefruit juice', 'Moderate', 'Patients who regularly consume grapefruit or grapefruit juice should be monitored for adverse effects and altered plasma concentrations of drugs that undergo significant presystemic metabolism by CYP450 3A4.  Grapefruit and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact with these drugs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (873, 26026, 'Methylprednisolone', 'Grapefruit juice may increase the plasma concentrations of orally administered drugs that are substrates of the CYP450 3A4 isoenzyme.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  Because grapefruit juice inhibits primarily intestinal rather than hepatic CYP450 3A4, the magnitude of interaction is greatest for those drugs that undergo significant presystemic metabolism by CYP450 3A4 (i.e., drugs with low oral bioavailability).  In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands.  Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition.  Pharmacokinetic interactions involving grapefruit juice are also subject to a high degree of interpatient variability, thus the extent to which a given patient may be affected is difficult to predict.', 'grapefruit juice', 'Moderate', 'Patients who regularly consume grapefruit or grapefruit juice should be monitored for adverse effects and altered plasma concentrations of drugs that undergo significant presystemic metabolism by CYP450 3A4.  Grapefruit and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact with these drugs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (874, 28809, 'Methylprednisolone', 'Grapefruit juice may increase the plasma concentrations of orally administered drugs that are substrates of the CYP450 3A4 isoenzyme.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  Because grapefruit juice inhibits primarily intestinal rather than hepatic CYP450 3A4, the magnitude of interaction is greatest for those drugs that undergo significant presystemic metabolism by CYP450 3A4 (i.e., drugs with low oral bioavailability).  In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands.  Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition.  Pharmacokinetic interactions involving grapefruit juice are also subject to a high degree of interpatient variability, thus the extent to which a given patient may be affected is difficult to predict.', 'grapefruit juice', 'Moderate', 'Patients who regularly consume grapefruit or grapefruit juice should be monitored for adverse effects and altered plasma concentrations of drugs that undergo significant presystemic metabolism by CYP450 3A4.  Grapefruit and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact with these drugs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (875, 29754, 'Methylprednisolone', 'Grapefruit juice may increase the plasma concentrations of orally administered drugs that are substrates of the CYP450 3A4 isoenzyme.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  Because grapefruit juice inhibits primarily intestinal rather than hepatic CYP450 3A4, the magnitude of interaction is greatest for those drugs that undergo significant presystemic metabolism by CYP450 3A4 (i.e., drugs with low oral bioavailability).  In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands.  Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition.  Pharmacokinetic interactions involving grapefruit juice are also subject to a high degree of interpatient variability, thus the extent to which a given patient may be affected is difficult to predict.', 'grapefruit juice', 'Moderate', 'Patients who regularly consume grapefruit or grapefruit juice should be monitored for adverse effects and altered plasma concentrations of drugs that undergo significant presystemic metabolism by CYP450 3A4.  Grapefruit and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact with these drugs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (876, 516, 'Metoclopramide', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (877, 2797, 'Metoclopramide', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (878, 7824, 'Metoclopramide', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (879, 7825, 'Metoclopramide', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (880, 7826, 'Metoclopramide', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (881, 7827, 'Metoclopramide', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (882, 7828, 'Metoclopramide', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (883, 8097, 'Metoclopramide', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (884, 25000, 'Metoclopramide', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (885, 25001, 'Metoclopramide', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (886, 25002, 'Metoclopramide', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (887, 25257, 'Metoclopramide', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (888, 25259, 'Metoclopramide', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (889, 25261, 'Metoclopramide', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (890, 27683, 'Metoclopramide', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (891, 29582, 'Metoclopramide', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (892, 29583, 'Metoclopramide', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (893, 142, 'Methyldopa', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (894, 272, 'Methyldopa', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (895, 322, 'Methyldopa', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (896, 4254, 'Methyldopa', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (897, 8095, 'Methyldopa', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (898, 21220, 'Methyldopa', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (899, 0, 'Methylphenobarbital', 'Concurrent acute use of barbiturates and ethanol may result in additive CNS effects,  including impaired coordination, sedation, and death.  Tolerance of these agents may occur with chronic use.  The mechanism is related to inhibition of microsomal enzymes acutely and induction of hepatic microsomal enzymes chronically.', 'alcohol', 'Major', 'The combination of ethanol and barbiturates should be avoided.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (900, 8083, 'Methylergometrine', 'Grapefruit juice may increase the plasma concentrations of orally administered drugs that are substrates of the CYP450 3A4 isoenzyme.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients who regularly consume grapefruit or grapefruit juice should be monitored for adverse effects and altered plasma concentrations of drugs that undergo significant presystemic metabolism by CYP450 3A4.  Grapefruit and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact with these drugs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (901, 8084, 'Methylergometrine', 'Grapefruit juice may increase the plasma concentrations of orally administered drugs that are substrates of the CYP450 3A4 isoenzyme.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients who regularly consume grapefruit or grapefruit juice should be monitored for adverse effects and altered plasma concentrations of drugs that undergo significant presystemic metabolism by CYP450 3A4.  Grapefruit and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact with these drugs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (902, 31431, 'Methylergometrine', 'Grapefruit juice may increase the plasma concentrations of orally administered drugs that are substrates of the CYP450 3A4 isoenzyme.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients who regularly consume grapefruit or grapefruit juice should be monitored for adverse effects and altered plasma concentrations of drugs that undergo significant presystemic metabolism by CYP450 3A4.  Grapefruit and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact with these drugs.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (903, 721, 'Methylnaltrexone', 'Food may reduce the rate and extent of absorption of methylnaltrexone following oral administration.  When a single 450 mg oral dose of methylnaltrexone was administered with a high-fat breakfast (approximately 800 to 1000 calories; 60% from fat, 25% from carbohydrate, and 15% from protein) in healthy study subjects, methylnaltrexone peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 60% and 43%, respectively, while time to reach Cmax delayed by 2 hours.', 'high-fat foods', 'Moderate', 'Oral methylnaltrexone should be taken with water on an empty stomach at least 30 minutes before the first meal of the day.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (904, 3401, 'Methylnaltrexone', 'Food may reduce the rate and extent of absorption of methylnaltrexone following oral administration.  When a single 450 mg oral dose of methylnaltrexone was administered with a high-fat breakfast (approximately 800 to 1000 calories; 60% from fat, 25% from carbohydrate, and 15% from protein) in healthy study subjects, methylnaltrexone peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 60% and 43%, respectively, while time to reach Cmax delayed by 2 hours.', 'high-fat foods', 'Moderate', 'Oral methylnaltrexone should be taken with water on an empty stomach at least 30 minutes before the first meal of the day.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (905, 6738, 'Methylnaltrexone', 'Food may reduce the rate and extent of absorption of methylnaltrexone following oral administration.  When a single 450 mg oral dose of methylnaltrexone was administered with a high-fat breakfast (approximately 800 to 1000 calories; 60% from fat, 25% from carbohydrate, and 15% from protein) in healthy study subjects, methylnaltrexone peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 60% and 43%, respectively, while time to reach Cmax delayed by 2 hours.', 'high-fat foods', 'Moderate', 'Oral methylnaltrexone should be taken with water on an empty stomach at least 30 minutes before the first meal of the day.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (906, 6993, 'Methylnaltrexone', 'Food may reduce the rate and extent of absorption of methylnaltrexone following oral administration.  When a single 450 mg oral dose of methylnaltrexone was administered with a high-fat breakfast (approximately 800 to 1000 calories; 60% from fat, 25% from carbohydrate, and 15% from protein) in healthy study subjects, methylnaltrexone peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 60% and 43%, respectively, while time to reach Cmax delayed by 2 hours.', 'high-fat foods', 'Moderate', 'Oral methylnaltrexone should be taken with water on an empty stomach at least 30 minutes before the first meal of the day.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (907, 17233, 'Methylnaltrexone', 'Food may reduce the rate and extent of absorption of methylnaltrexone following oral administration.  When a single 450 mg oral dose of methylnaltrexone was administered with a high-fat breakfast (approximately 800 to 1000 calories; 60% from fat, 25% from carbohydrate, and 15% from protein) in healthy study subjects, methylnaltrexone peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 60% and 43%, respectively, while time to reach Cmax delayed by 2 hours.', 'high-fat foods', 'Moderate', 'Oral methylnaltrexone should be taken with water on an empty stomach at least 30 minutes before the first meal of the day.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (908, 25953, 'Methylnaltrexone', 'Food may reduce the rate and extent of absorption of methylnaltrexone following oral administration.  When a single 450 mg oral dose of methylnaltrexone was administered with a high-fat breakfast (approximately 800 to 1000 calories; 60% from fat, 25% from carbohydrate, and 15% from protein) in healthy study subjects, methylnaltrexone peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 60% and 43%, respectively, while time to reach Cmax delayed by 2 hours.', 'high-fat foods', 'Moderate', 'Oral methylnaltrexone should be taken with water on an empty stomach at least 30 minutes before the first meal of the day.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (909, 17239, 'Metolazone', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (910, 18087, 'Metolazone', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (911, 22666, 'Metolazone', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (912, 26084, 'Metolazone', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (913, 0, 'Acebutolol', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (914, 7520, 'Metoprolol', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (915, 7520, 'Metoprolol', 'The bioavailability of metoprolol may be enhanced by food.', 'food', 'Moderate', 'Patients may be instructed to take metoprolol at the same time each day, preferably with or immediately following meals.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (916, 690, 'Metronidazole (topical)', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Moderate', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (917, 691, 'Metronidazole (topical)', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Moderate', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (918, 692, 'Metronidazole (topical)', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Moderate', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (919, 4210, 'Metronidazole (topical)', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Moderate', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (920, 4325, 'Metronidazole (topical)', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Moderate', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (921, 4894, 'Metronidazole (topical)', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Moderate', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (922, 4903, 'Metronidazole (topical)', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Moderate', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (923, 4904, 'Metronidazole (topical)', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Moderate', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (924, 4905, 'Metronidazole (topical)', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Moderate', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (925, 4906, 'Metronidazole (topical)', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Moderate', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (926, 4930, 'Metronidazole (topical)', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Moderate', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (927, 6077, 'Metronidazole (topical)', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Moderate', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (928, 8101, 'Metronidazole (topical)', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Moderate', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (929, 8102, 'Metronidazole (topical)', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Moderate', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (930, 14075, 'Metronidazole (topical)', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Moderate', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (931, 14076, 'Metronidazole (topical)', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Moderate', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (932, 14080, 'Metronidazole (topical)', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Moderate', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (933, 15559, 'Metronidazole (topical)', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Moderate', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (934, 16787, 'Metronidazole (topical)', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Moderate', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (935, 17956, 'Metronidazole (topical)', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Moderate', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (936, 17957, 'Metronidazole (topical)', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Moderate', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (937, 18347, 'Metronidazole (topical)', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Moderate', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (938, 19075, 'Metronidazole (topical)', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Moderate', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (939, 19077, 'Metronidazole (topical)', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Moderate', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (940, 19078, 'Metronidazole (topical)', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Moderate', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (941, 19079, 'Metronidazole (topical)', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Moderate', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (942, 19085, 'Metronidazole (topical)', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Moderate', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (943, 19630, 'Metronidazole (topical)', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Moderate', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (944, 22672, 'Metronidazole (topical)', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Moderate', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (945, 22676, 'Metronidazole (topical)', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Moderate', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (946, 22677, 'Metronidazole (topical)', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Moderate', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (947, 22679, 'Metronidazole (topical)', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Moderate', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (948, 22680, 'Metronidazole (topical)', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Moderate', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (949, 26297, 'Metronidazole (topical)', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Moderate', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (950, 28488, 'Metronidazole (topical)', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Moderate', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (951, 28489, 'Metronidazole (topical)', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Moderate', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (952, 28490, 'Metronidazole (topical)', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Moderate', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (953, 28491, 'Metronidazole (topical)', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Moderate', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (954, 28492, 'Metronidazole (topical)', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Moderate', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (955, 30008, 'Metronidazole (topical)', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Moderate', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (956, 30543, 'Metronidazole (topical)', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Moderate', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (957, 33203, 'Metronidazole (topical)', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Moderate', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction and instructed to avoid alcoholic beverages and products containing alcohol or propylene glycol while using oral, intravenous, or vaginal preparations of a nitroimidazole.  Alcoholic beverages should not be consumed for up to 3 days after completion of systemic nitroimidazole therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (958, 690, 'Metronidazole', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Major', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (959, 691, 'Metronidazole', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Major', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (960, 692, 'Metronidazole', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Major', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (961, 4210, 'Metronidazole', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Major', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (962, 4325, 'Metronidazole', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Major', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (963, 4894, 'Metronidazole', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Major', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (964, 4903, 'Metronidazole', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Major', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (965, 4904, 'Metronidazole', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Major', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (966, 4905, 'Metronidazole', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Major', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (967, 4906, 'Metronidazole', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Major', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (968, 4930, 'Metronidazole', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Major', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (969, 6077, 'Metronidazole', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Major', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (970, 8101, 'Metronidazole', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Major', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (971, 8102, 'Metronidazole', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Major', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (972, 14075, 'Metronidazole', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Major', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (973, 14076, 'Metronidazole', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Major', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (974, 14080, 'Metronidazole', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Major', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (975, 15559, 'Metronidazole', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Major', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (976, 16787, 'Metronidazole', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Major', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (977, 17956, 'Metronidazole', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Major', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (978, 17957, 'Metronidazole', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Major', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (979, 18347, 'Metronidazole', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Major', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (980, 19075, 'Metronidazole', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Major', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (981, 19077, 'Metronidazole', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Major', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (982, 19078, 'Metronidazole', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Major', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (983, 19079, 'Metronidazole', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Major', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (984, 19085, 'Metronidazole', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Major', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (985, 19630, 'Metronidazole', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Major', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (986, 22672, 'Metronidazole', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Major', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (987, 22676, 'Metronidazole', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Major', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (988, 22677, 'Metronidazole', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Major', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (989, 22679, 'Metronidazole', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Major', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (990, 22680, 'Metronidazole', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Major', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (991, 26297, 'Metronidazole', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Major', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (992, 28488, 'Metronidazole', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Major', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (993, 28489, 'Metronidazole', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Major', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (994, 28490, 'Metronidazole', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Major', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (995, 28491, 'Metronidazole', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Major', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (996, 28492, 'Metronidazole', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Major', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (997, 30008, 'Metronidazole', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Major', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (998, 30543, 'Metronidazole', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Major', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (999, 33203, 'Metronidazole', 'Use of alcohol or products containing alcohol during nitroimidazole therapy may result in a disulfiram-like reaction in some patients.  There have been a few case reports involving metronidazole, although data overall are not convincing.  The presumed mechanism is inhibition of aldehyde dehydrogenase (ALDH) by metronidazole in a manner similar to disulfiram.  Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''.', 'alcohol', 'Major', 'Because clear evidence is lacking concerning the safety of ethanol use during nitroimidazole therapy, patients should be apprised of the potential for interaction.  Consumption of alcoholic beverages and products containing propylene glycol is specifically contraindicated during and for at least 3 days after completion of metronidazole and benznidazole therapy according to their product labeling.', NULL, NULL, 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1000, 0, 'Metyrosine', 'Metyrosine, when coadministered with other CNS depressants including alcoholic beverages, may lead to excessive somnolence and other forms of nervous system depression.', 'alcohol', 'Moderate', 'The patient should be informed to use caution if these agents are coadministered, especially if performing hazardous tasks such as driving or operating machinery.', NULL, NULL, 'DDInter', 0);